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ABSTRACT 
Heart failure (HF) is a pathological state indicating insufficient blood supply to the 
peripheral tissues from the heart. The pathophysiology of HF is multifactorial like cardiac 
remodeling including cardiac hypertrophy, perivascular fibrosis and apoptosis to compensate for 
the heart’s inability to pump enough blood. Cardiac hypertrophy is initially adaptive to 
hemodynamic overload; however, it chronically contributes to heart failure and sudden cardiac 
death. The extracellular regulatory factors and intracellular signaling pathways involved in the 
cardiac remodeling are not yet fully clear. 
PI3-kinase is an important intracellular kinase in organ size control. Cardiac 
overexpression of Class I PI3-kinase caused heart enlargement in transgenic mice. Autophagy as 
a dynamic process involving the degradation of damaged mitochondria prevents ROS 
overproduction which leads to the cardiac remodeling. Therefore, our aim was to study the 
relationship between PI3-kinases and Ang II-induced cardiac remodeling via an autophagy-
dependent mechanism. 
Ang II significantly increased autophagy with two distinctive phases: an increasing phase 
at low doses and a decreasing phase at high doses in cardiomyocytes. The Ang II-induced 
autophagic depression was attenuated by a Class I PI3-kinase inhibitor and potentiated by Class 
III PI3-kinase inhibitor. Besides, Ang II-induced cardiac hypertrophy and mitochondria ROS 
generation were attenuated via blockade of Class I PI3-kinase or mTOR. 
To further validate our in vitro data, we studied the role of Class I PI3-kinase in Ang II-
induced cardiac remodeling in vivo. We successfully transferred Lv-DNp85 (Class I PI3-kinase 
blockade) and Lv-GFP (control) into adult rat hearts and found that cardiac transfer of Lv-DNp85 
did not alter Ang II-induced pressor effect, but attenuated Ang II-induced cardiac hypertrophy, 
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perivascular fibrosis and cardiac dysfunction. Ang II-induced cardiac remodeling was associated 
with impaired autophagy and mitochondrial ROS overproduction, which were significantly 
attenuated by Lv-DNp85-induced blockade of Class I PI3-kinase. 
Taken together, these data suggest that Class I PI3-kinase is involved in Ang II-induced 
impairment of autophagy via Akt/mTOR pathway, leading to mitochondrial ROS overproduction 
and cardiac remodeling. These results are not only highly significant from a pathophysiological 
perspective, but also have important pharmacological implications in the control of cardiac 
hypertrophy to prevent decompensation and failure in cardiac function. 
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CHAPTER I. INTRODUCTION 
The primary function of the heart is to pump the blood into various peripheral organs and 
tissues, providing them with nutrients & oxygen, and eliminating the waste produced in those 
places. Heart failure (HF) means the cardiac output is insufficient to meet the body’s oxygen and 
nutrient demand. The consequences of heart failure are rather severe and sometimes even fatal 
including multiple organ dysfunctions such as dyspnea, edema and decreased exercise tolerance. 
The epidemiology of heart failure is quite harsh nowadays. So far, the most disappointing 
information is that there are more patients die of heart failure than all forms of cancer, and the 
nationwide number of new patients with heart failure reaches 550,000 annually based on the 
reports from American Heart Association [1, 2]. Heart failure immensely imposes a skyrocketing 
health and economic burden accompanied with the development of aging and industrialization 
process in the US and worldwide. In 2012, the published assessment of HF cost was $ 30.7 billion, 
taking up about 17.9 % of the World Bank GDP invested in health care, and it is estimated that 
this expense will reach $ 69.7 billion by 2030 [3, 4]. The growing incidence and prevalence of 
CHF globally in senior citizens over the age of 65 are the result of better clinical treatment of acute 
myocardial infarction along with the ageing population. Also, the advent of the pandemic of 
cardiovascular diseases in economically developing nations partially accounts for the incidence 
rise of CHF [5]. Therefore, heart failure, regarded as the disease of civilization, is the leading cause 
of mortality in developed countries and has a growing trend in developing countries, exerting 
major impacts on life expectancy. Since other cardiovascular diseases become more efficient to be 
dealt with, increasing numbers of patients are surviving long enough to develop heart failure, 
making this epidemic prevalent. 
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1.1. Etiology and pathophysiology of congestive heart failure 
CHF is a morbid state when the heart is no longer able to pump adequate blood to meet the 
body need in the peripheral metabolizing organs and tissues with a gradual reduction in cardiac 
performance. Factors such as anomalous cardiac structure, function, conduction or contractility 
contribute to the emergence and progression of congestive heart failure [6]. It is often reported that 
congestive heart failure (CHF) is the end stage of several cardiovascular diseases such as ischemic 
heart disease, hypertension, myocardial infarction, obesity, viral infection, and cardiomyopathy 
[7]. All of those diseases exert influences on cardiac output (CO). Cardiac output refers to the 
product of heart rate (HR) and stroke volume (typically 4~8L/min) and it is the combined outcome 
of interactions among physiological factors. Stroke volume is determined by mutual interactions 
of preload, afterload, and contractility with the value of 1mL/kg or roughly 60~100 mL in normal 
individuals [8]. Furthermore, heart rate is an intrinsic factor which could be influenced by 
autonomic, humoral, and local circumstances. The relationship of those factors is shown in Figure 
1. Disturbance of any above-mentioned physiological factor(s) may cause an imbalance in the 
circulation system and eventually lead to heart failure with diminished ejection fraction (EF) or 
impaired heart contractility. 
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Figure 1: Cardiac output determinants. Cardiac output refers to the amount of left ventricle-
ejected blood within one minute. Stroke volume predominately determines the cardiac output. 
Heart rate is an inherent component involving autonomic, humoral, and local circumstances. 
Stroke volume is principally determined by preload, afterload and contractility [9]. 
Preload is the maximum degree of myocardial fiber stretching at the end of diastolic stage 
just prior to contraction. End diastolic pressure/volume in left ventricle (LVEDP/V) is an indirect 
index of preload since it is impossible to precisely determine the length of a single myocardial 
sarcomere in the intact heart of living animals. According to the Frank-Starling mechanism, the 
contractility and stroke volume are proportional to the initial length of cardiomyocyte fiber within 
a certain range. In normal hearts, the LVEDP rises along with the LVEDV elevation, making the 
myocardium stretch as the response of cardiac output (CO) escalation. However, elevation of CO 
has a limitation as the continuous rise of preload, once higher than the upper limit, the increasing 
trend of CO is lessened due to the overstretching of cardiomyocyte fibers and the SV-LVEDP 
curve flattens out [8]. 
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Afterload is defined as the resistance to be overcome in the peripheral vascular system to 
prevent the blood ejection, and the index of afterload is the mean arterial pressure (MAP). The 
equation of σ = P∙r/h is used to define afterload, where P refers to ventricular pressure, r refers to 
the ventricular radius, and h refers to the ventricular wall thickness. When a downfall of cardiac 
output occurs, there is a reflex increase in systemic vascular system which is mediated through 
SNS outflow, catecholamine in the circulation system, and RAS. The potent vasoconstrictor 
peptide of endothelin also participates this process. Afterload is enhanced by elevating aortic 
pressure and/or systemic vascular resistance, resulting in rising end systolic volume and reduction 
of stroke volume which would reduce arteriolar tone in heart failure [8]. 
Contractility/inotropy indicates the competence of heart muscle fiber to contract into a 
certain fiber length. Inotropy alterations adjust the degree of contracting force and ventricular 
pressure development. Inotropy, regarded as a heart failure condition index, is positively 
proportional to ejection fraction [8]. 
The normal cardiac output is about 4~8 L/min; once there is a downfall of cardiac output, 
several neurohormonal systems such as renin angiotensin system [10] and sympathetic nervous 
system (SNS) are activated to keep normal heart function, leading to eventual heart structural 
abnormality if improperly treated. Those physiological alterations facilitate renal retention of Na+ 
& water as well as vasoconstriction in the peripheral vascular system, promoting the contraction 
of heart muscle. Those compensatory responses are beneficial to sustain the cardiac output and 
blood supply required in the peripheral system, whereas long-term activation of RAS and SNS is 
harmful to the cardiovascular system, resulting in pathological effects. Under such stress, the 
myocardium suffers decompensation, and a series of cardiac complications occur with harmful 
outcomes jeopardizing organs besides heart, such as kidneys, lungs, muscles and blood vessels, 
bringing about classic CHF clinical symptoms [11]. 
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Long-term cardiac hemodynamic load alters myocardial size, shape, structure, and function 
referred to as cardiac remodeling including alterations of myocardial mass, composition, volume 
and geometric dimensions from elliptical to spherical. At first, the failing heart thrives to expand 
ventricular volume, sustain greater SV and heighten CO although there is an EF reduction. 
Simultaneously, ventricular wall thickness and mass are also elevated, giving rise to enhanced 
contractility. However, as the ventricle goes on expanding with myocardium hypertrophy, 
ischemic changes happen with diastolic filling impairment, leading to the wall tension and fibrosis 
would undermine cardiac contractility ultimately. Myocardial apoptosis is the eventual 
consequence of the long-standing process of cardiac remodeling and the ventricle would lose the 
ability to contract synchronically, leading to less efficiency to eject the blood into the peripheral 
organs and tissues [9]. 
Hence, the etiology and pathophysiology of congestive heart failure are complicated and 
multifactorial, and stem from the combined interactions with a series of genetic and environmental 
factors. Knowing some basic knowledge of the underlying mechanisms behind the emergence and 
adaptive response of HF is beneficial for us to adopt pharmacological and surgical approaches to 
improve HF patients’ survival rate. 
1.2. Symptoms, preventions and therapeutic treatments of congestive heart failure 
Insufficient cardiac output and shortage of enough venous return cause the loss of 
competence for the heart to pump adequate blood and result in the heart failure symptoms with 
distinctive signs such as fluid build-up development and salt retention. Pulmonary edema, cough, 
and dyspnea in the respiratory system is the consequence of fluid accumulation. Confusion, anxiety 
and amnesia happen due to diminished oxygen supply to the central nervous system. The inability 
of the right ventricle to hold systemic venous return incurs lower extremity edema along with 
ascites. Appetite loss and nausea occur because of the switch of blood into essential organs, 
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diminishing the supply of gastrointestinal (GI) tract. The downfall of cardiac output and emergence 
of sodium & water retention also cause fatigue and limb weakness as the initial symbols of HF. 
The final stage of HF presents cardiac cachexia (malnutrition) and cyanosis (bluish skin) since 
excessive hemoglobin is denatured for oxygen deprivation [9, 11]. Proper diagnoses from above-
mentioned symptoms plus physical examination, lab tests, X-ray, and echocardiography methods 
help us to find out the etiology of HF. 
Preventive approaches for CHF mainly include lifestyle modification. For obese patients, 
they are required to lose excess weight. For those using tobacco and alcohol, it is wise to quit these 
hazardous materials. Appropriate exercise helps promote physical condition. Suitable medical 
therapies on the preceding diseases such as hypertension, hyperlipidemia, diabetes, and 
arrhythmias with strict restriction of water and sodium also slow the progress of HF. 
Once congestive heart failure is diagnosed and those preventive practices prove futile, two 
major approaches of treatment to combat this fatal disease will be adopted: 1). Decelerating the 
process as much as possible and alleviating the symptoms when in a relatively stable morbid state, 
2). Proper treatment in acute decompensatory heart failure to promote the life quality. For 
pharmacological treatment of acute heart failure, traditional positive inotropic agents of cardiac 
glycosides like digoxin are extensively used for over two centuries in order to enhance ventricular 
contracting force via promotion of myocardial function and strength, and reduction of SNS and 
RAAS activation. Nevertheless, wide usage of non-cardiac targeting reagents is more beneficial 
than the solely treatment of reinforcing heart inotropy. There are several approaches: 1). Diuretics: 
they facilitate the edema fluid and sodium excretion and ameliorate the cardiac output in failing 
heart; 2). Angiotensin-converting enzyme inhibitors (ACEI): prevention of conversion of Ang I to 
Ang II attenuates provocation of RAAS; 3). Angiotensin receptor blockers (ARBs): this kind of 
reagents successfully evades that side effects brought about by ACEI such as bradykinin-induced 
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dry cough, and act directly on the angiotensin receptors as the final downstream target of RAAS 
pathway; 4). β-receptor blockers: the heart and vasculature are protected from deleterious effects 
of SNS over-activation, and the heart rate also falls for more efficient contraction; 5). Aldosterone 
receptor antagonists: direct inhibition of RAAS; and 6. Bipyridines: Compounds of this kind 
inhibit phosphodiesterase and facilitate longer existence of cAMP which helps to strengthen the 
inotropic effect [12]. 
Besides the above-mentioned non-invasive pharmacological treatment, invasive surgical 
treatments are widely used to improve the cardiac function promptly. The surgeries consist of 
cardiac resynchronization therapy (CRT, restoration of ventricular efficiency by pacing both 
ventricles concurrently), surgical ventricular remodeling (SVR), coronary revascularization, 
ventricular assist device (VAD) implantation, and heart transplantation ultimately [9]. 
1.3. Sympathetic nervous system (SNS) and renin angiotensin aldosterone heart system 
(RAAS) in heart failure 
Sympathetic nervous system (SNS) and renin angiotensin aldosterone system (RAAS) are 
two major compensatory mechanisms activated at the initial stage of heart failure due to the 
downfall of cardiac output. Those two factors plus pro-inflammatory activation contribute to the 
cardiac remodeling process and signal transduction in maladaptive hearts [13]. From the equation 
of MAP=CO×TPR, we know that TPR is increased to maintain MAP once there is a decrease of 
CO as the negative feedback. Meanwhile, a lot of neurohormones facilitates the retention of 
sodium and water in order to magnify stroke volume through the Frank-Starling mechanism. 
The sympathetic nervous system is an essential component of the autonomic nervous 
system to mobilize energy whenever it is needed. The SNS acts on cardiovascular systems 
extensively, provokes heart rate increase and contractility, constricts resistance vessels and turns 
down venous capacitance [14]. The MAP decrease in HF patients stimulates sympathetic nervous 
 8 
system (SNS) and facilitates the secretion of catecholamines (epinephrine and norepinephrine) 
which directly elevates heart rate and cardiac contractility, while the vasoconstrictive effect of 
catecholamines in the peripheral vasculature raises SV and TPR to enhance MAP. Short-term 
activation of SNS temporarily improves cardiac output, whereas long-term dependence on SNS 
exerts destructive and detrimental consequences to heart function known as catecholamine toxicity 
as interstitial fibrosis, dysfunctional pumping, and eventually apoptosis or even necrosis [15]. 
Long-term exposure to norepinephrine causes significant apoptosis in cardiomyocytes because of 
the oxidative stress generation via reactive intermediates and free radicals generated through auto-
oxidation of catecholamines [16]. Three kinds of receptors of β1, β2, and α1 mainly mediate 
sympathetic nervous system leading to myocardial toxicity with lowered EF, arrhythmias, and 
tachycardia. Activation of β1 and α1 in peripheral vasculature prompt renin-angiotensin-
aldosterone system (RAAS), leading to vasoconstriction, sodium retention thirst which makes 
MAP augmentation [17]. 
For renin angiotensin system [10], it is activated due to both increased sympathetic 
activation and reduced renal blood flow, causing the release of renin. After the entry of renin into 
circulation system, renin converts angiotensinogen to angiotensin I (Ang I) in the liver. When 
circulating Ang I encounters pulmonary-located angiotensin converting enzyme [18], it is 
converted into angiotensin II (Ang II). It is well established that the effect of Ang II is to constrict 
the peripheral vasculature, enhance contractility, and promote the secretion of aldosterone. The 
final consequences of RAAS activation are to speed up norepinephrine release, enhance water and 
sodium reabsorption, improve contractility, and trigger vasopressin discharge [9]. Those effects of 
regulatory pathways are shown in Figure 2. 
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Figure 2: Summary of the compensatory responses of SNS and RAS activation during 
congestive heart failure. The diagram shows the reset of baroreceptor reflex with a lower 
sensitivity to arterial pressure in HF patients. Besides the displayed effect,  sympathetic discharge 
augmentation causes renin secretion producing more Ang II. Reversely, Ang II increases NE 
release by acting on sympathetic nerve endings [19]. 
1.4. Cardiac remodeling in heart failure 
The most essential inherent compensatory mechanism in heart failure is myocardial 
hypertrophy which refers to the increase of muscle mass with several key features such as 
cardiomyocyte size enlargement, heart expansion, gene expression alteration, enhanced synthesis 
of protein and contractile machinery reorganization [20]. 
Physiological hypertrophy is a reversible process with normal cardiac structure. 
Meanwhile, it is beneficial to adapt to the increased hemodynamic workload in healthy individuals 
during normal postnatal growth, exercise and pregnancy, and this enlargement of cardiomyocytes 
helps keep the heart function without the linkage to cardiac damage. The enhanced cardiac function 
enables the oxidation of fatty acid and glucose utilization [21]. 
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For pathological hypertrophy, state-related stress like hypertension, obesity and 
myocardial infarction elicits maladaptive cardiac hypertrophy in which unusual cardiac 
metabolisms, structures, and abnormal cardiac functions emerge. Normal cardiomyocytes are lost 
and replaced by fibrosis, leading to cardiac dysfunction and risk of heart failure or even sudden 
death. There are distinct structural, functional, metabolic, biochemical and molecular variations 
between physiological and pathological hypertrophy in cardiomyocytes [21]. For instance, 
elevated ANP, BNP, and β-MHC levels were observed in mice with aortic banding-induced 
pathological hypertrophy when compared with their physiological hypertrophy counterparts via 
swimming training. Meanwhile, M-mode echocardiography and interstitial fibrosis studies 
demonstrated this aortic banding-induced pathological hypertrophy severely undermined cardiac 
function which was not present in swimming training-induced physiological hypertrophy [22]. 
Hypertrophy is an inevitable stage of hypertension-induced heart failure with both 
compensatory and decompensatory manners to sustain cardiac performance. Hypertension, at the 
initial stage, causes concentric hypertrophy to compensate for the increasing hemodynamic or 
blood pressure overload with an adaptive manner. However, as this process goes on, cardiac 
hypertrophy gradually steps into eccentric type not only due to strengthened mechanical stress but 
also because of neuro-hormone secretion alteration, and this type of hypertrophy progresses into 
heart failure and ultimately cardiomyocytes death with ventricular dilation and a downfall of 
contractility [23]. Sarcastically, identical neurohormones in SNS and RAAS are attributed to 
cardiomyocytes death even though they stimulate the compensatory hypertrophy to counteract the 
initial hemodynamic stress. The exact pathways such as necrosis/oncosis, apoptosis, and 
autophagy-induced cardiomyocyte death are dependent on certain physiological circumstances 
[24]. 
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1.5. ROS and cardiac hypertrophy 
Since the heart is beating continuously, there is an indispensable need for oxygen supply 
to maintain heart function. Be that as it may, the consumption of oxygen is essential to the 
generation of ROS as byproducts. It is known that almost 5% of the oxygen is converted into ROS 
in normal tissues which attributes to the pathophysiology of heart failure [25]. ROS is the 
abbreviation of reactive oxygen species, and the major ROS are small molecules derived from 
oxygen, including oxygen radicals such as superoxide anion (O2
-•), hydroxyl (•OH), peroxyl (RO2
•), 
peroxynitrites (ONOO-•), and alkoxyl (RO•), as well as certain nonradicals that are either oxidizing 
agents and/or are easily converted into radicals such as hydrogen peroxide (H2O2), hypochlorous 
acid (HClO), and ozone (O3) [26]. Also, nitrogen-containing oxidants are defined as reactive 
nitrogen species [27]. The most distinctive feature of ROS is that there are unpaired electrons 
within the outer orbit. Most ROS exist transiently: for example, the half-life (t1/2) of superoxide 
anion (O2
-•) is only a few seconds. Superoxide anion (O2
-•) has a very low diffusion capacity due 
to its limited cellular membrane permeability. Therefore, the main place of its action is strictly 
confined in intracellular components [28]. However, H2O2 has a stronger cellular membrane 
permeability and survives longer than O2
-•, and hydroxyl (•OH) is the most reactive ROS formed 
by H2O2 via Fenton reactions, and its amount is negligible in normal conditions while accumulated 
in pathological circumstance to exert oxidative stress-associated cellular damage [25]. 
Both favorable and hazardous outcomes of ROS generation are reported in living 
organisms: On the one hand, ROS functions as the 2nd messengers to adjust the downstream 
regulatory ligands like Ang II, ET, PDGF, FGF-2, TNF-α, TGF-β1, and many others, and this 
process is defined as redox-signaling [25]. Then numerous downstream redox-sensitive protein 
kinases and transcription factors like activator protein 1 (AP-1), nuclear factor-κB (NF-κB), and 
hypoxia-inducible factor-1 (HIF-1) are activated to induce genotype and phenotype expression, 
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while the action of protein tyrosine phosphatases might get arrested. Those cascade activations 
stimulate normal cellular growth and proliferation, facilitating the survival of cells [29]. While on 
the other hand, when ROS levels are overwhelmingly exceeding the threshold that the cellular 
antioxidant defense system could cope with, the cellular membrane lipids, proteins, and nucleic 
acids are vulnerable to be directly attacked, leading to cellular dysfunction or even death. The 
reason behind is that one ROS radical production could generate several other ROS molecules 
through radical chain reactions since radicals attack their adjacent counterparts, creating multiple 
radicals that mainly consisted of lipid radicals. Those lipid radicals accumulate in the cellular 
membrane in this chain reaction, causing plasma leakage and membrane-bound receptors 
dysfunction. Furthermore, ROS may straightly cause DNA mutagenesis such as strand breaks, 
purine oxidation, and protein-DNA cross-linking, disturbing normal gene expression and 
denaturing protein functions [29]. 
To keep health, redundant ROS should be efficiently eliminated by both intrinsic enzymatic 
and non-enzymatic antioxidant defense systems such as superoxide dismutase (SOD), catalase 
(CAT), and glutathione (GSH) peroxidase enzymes. O2
−⋅ is rapidly converted to H2O2 in vivo under 
SOD with many isoforms like Cu/Zn SOD (SOD1) in cytosol, concentrated Mn SOD (SOD2) in 
mitochondria, and extracellular SOD (SOD3) within the plasma membrane or extracellularly-
compartments [30]. H2O2 level is strictly monitored by catalase and glutathione peroxidase, and 
H2O2 is scavenged with the final product of water and oxygen [31]. A series of antioxidants such 
as ubiquinone (Q10), lipoic acid, and ascorbic acid are catalyzed by thioredoxin reductase to fight 
against ROS. Glutathione is the reducing substrate for glutathione peroxidase in the enzymatic 
reaction. The major non-enzymatic anti-ROS mechanisms involve utilization of vitamins C & E, 
β-carotene (vitamin A precursor), and urate [29].  
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As for the relationship between ROS generation and cardiac hypertrophy, excessive ROS 
provoke a series of downstream signaling pathways such as protein kinases C (PKCs), protein 
kinase B (PKB or Akt), mitogen activated protein kinases (MAPKs), and the transcription factors 
of NFAT, GATA4, SRF, NF-κB, and AP-1 [29]. ROS impact cardiac hypertrophy relies on the 
fact that endogenously generated ROS directly or indirectly modulate various hypertrophy 
signaling kinases and transcription factors via intertwined intracellular signaling pathways 
regarding the redox status [26]. For direct modulation, cysteine and methionine thiols in 
macromolecules are the most susceptible targets. For indirect modulation, several mechanisms are 
involved: reactions between NO and ROS impair not only topical NO availability, but also the 
formation of cysteine oxidation with disulfide, nitrosylation and/or glutathiolation [25]. 
1.6. Autophagy in cardiac hypertrophy 
Autophagy is evolved from the Greek words auto (self) and phagy (eating) from the 
etymological aspect, indicating the lysosomal degradation of intracellular materials rather than the 
extracellular material degradation (heterophagy) [32]. Autophagy was initially identified in the 
1950s from studies on ultrastructural organelles as a self-degradative process in the 
lysosome/vacuole by electron microscopy of original single- and double- membrane vesicles with 
organelles and components at different degradation stages, and autophagy is a vital process for 
cells to fight against various types of harmful stress such as hypoxia, oxidative stress, pathogen 
infection, and most remarkably nutrient starvation [33]. This process is involved in the removal 
and recycling of pathogens, long-lived, redundant or damaged proteins, lipids, and dysfunctional 
cellular organelles, maintaining intracellular homeostasis, anti-oxidant defense, and cellular 
survival under various hazardous stimuli. Meanwhile, when it goes too far, superfluous autophagy 
without appropriate controlling mechanisms would cause vital cellular molecules and organelles 
exhaustion, leading to autophagic-induced cellular death as a two-bladed sword [34]. Besides, 
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autophagy may also occur in cellular organelle-specific manners within diversified intracellular 
places besides cytoplasm, e.g., selectively targeting at nucleus (nucleophagy), mitochondria 
(mitophagy), lipid droplets (lipophagy), ribosomes (ribophagy), peroxisomes (pexophagy), 
endoplasmic reticulum (reticulophagy), and microorganisms (xenophagy) [35]. 
The major course of autophagy consists of the following four steps: 1) Induction & 
Nucleation: A bilayer isolation membrane defined as phagepore is formed under various hazardous 
or pathological stimuli. When the phagepore is established, it directly targets to and then engulfs 
the cytosolic components including molecules and/or components to be degraded [36]. 2) 
Elongation & Expansion: the phagepore encompasses the cytosolic components to be degraded 
and creates an autophagosome. 3) Fusion: an autophagosome gets fused with a lysosome to 
establish an autolysosome in which lysosomal hydrolyases are present so as to digest those 
unwanted cellular organelles and macromolecules [37]. 4) Degradation: After the completion of 
digestion, the degraded components are transported back into the cytoplasm for further usage by 
intracellular recycling [38]. The processes of autophagy are shown in Figure 3. 
 
Figure 3: Autophagy flux process. Macroautophagy contains four steps as 1. Induction & 
nucleation, 2. Elongation & expansion, 3. Fusion, and 4. Degradation. A few autophagy-related 
(Atg) proteins are recruited to modify autophagy initiation and procedure within different steps 
[39]. 
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Over 30 intracellular regulatory components are reported to be involved in the supervision 
and arrangement of autophagy [40]. Some of those most essential regulators are: 1) Mammalian 
target of rapamycin (mTOR): this important autophagic regulator is influenced by the single or 
multiple combined hazardous factors such as shortage of amino acid or ATP supply, loss of growth 
factors, hypoxia [41, 42], etc. Those unfavorable conditions including accumulation of ROS make 
mTOR dissociate from lysosomes, activate autophagic-friendly components such as AMPK [43] 
or TSC1/2 [44], and inhibit autophagic-unfriendly components like Akt and Rheb [44], facilitating 
autophagy. It’s reported that mTOR is essential for animal survival as its gene knockout causes 
prenatal death during the embryonic stage in mice [45]. 2) Beclin-vacuolar protein sorting 34 (Bcl-
Vps34) complex: this is one of the downstream components of mTOR and monitored by nuclei 
transcripts such as NF-κB and E2F. Association of Belcin-1 with Class III PI3-kinase aids 
autophagosome nucleation via Vps34 phosphorylation. Alternative factors such as Rubicon, 
HMGB1, and NRBF2 also govern the binding between Beclin-1 and VPS34, assisting with 
subsequent autophagy [46, 47]. Activation of Beclin-1/Vps34 complex facilitates PIP production 
which is perceived by the downstream WIPIs with subsequent control by ATG9, promoting 
autophagy [48]. 3-methyladenine (3-MA) is an autophagic inhibitor by downregulation of 
Beclin/Vps34 activity [49]. 3) MAP-LC3 homologs: MAP refers to microtubule-associated 
proteins which have 4 groups to maintain cellular configuration, and LC means light chain. There 
are three light chains and one heavy chain within MAP1 family and LC3 is the tiniest among those 
three light chains [50]. After disposition by several regulatory proteins such as Atg 3 and Atg 4, 
those MAP-LC proteins are lipidated by phosphatidylethanolamine (PE) and enter 
autophagosomes to assist autophagy. The formation of MAP-LC3 II from MAP-LC3 I is the 
marker of autophagy initiation, and the larger LC3 II/LC3 I ratio indicates stronger autophagy [51, 
52]. 
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Autophagy is intricate but fundamental to keep the homeostasis of the cardiovascular 
system [53]. Convincing evidence shows that ROS generation, predominantly O2
-, is one of those 
initiating inducers that provoke autophagy in nutrient starvation by deprivation of nourishing 
materials such as glucose, glutamine, serum and/or pyruvate [54]. Thus, ROS may serve as an 
essential part of autophagic induction, and electrophilic antioxidants are useful to incompletely or 
thoroughly reverse this autophagic process [55]. 
Altogether, two most prominent roles of autophagy are: 1) as an alternative energy resource 
to supply with vital materials such as amino acids for intracellular protein synthesis and free fatty 
acids during organism exploitation; 2) as a vital part of the cellular means for quality control, 
assured by removal of abnormal proteins and organelles [56]. 
1.7. PI3-kinases in cardiac hypertrophy 
The family of lipid kinases termed as phosphoinositide 3-kinases (PI3Ks) was initially 
discovered in the 1980s. The main function of this type of kinases is to catalyze the formation of 
PIP3 which is an essential intracellular secondary messenger. This PI3-kinase pathway is highly 
conserved during the evolutionary process from yeast to mammalians as the downstream effector 
of receptor tyrosine kinases (RTKs) and G protein coupled receptors (GPCRs) [57]. An awful lot 
of cellular mechanisms such as metabolism, survival, proliferation, differentiation, migration, and 
apoptosis are under the regulation of PI3-kinase family in a context-dependent manner [57]. Three 
types of PI3-kinases have been identified as Class I (formation of PI(3,4,5)P3 from PI(4,5)P2), 
Class II (formation of PI(3,4)P2 from PI(4)P), and Class III (formation of PI(3)P from PIP) PI3-
kinases according to their varied functions, substrate specificity, and molecular structures [58]. Of 
note, the tumor suppressor kinase of PTEN (phosphatase and tensin homolog deleted from 
chromosome 10) is the most prominent negative regulator of the PI3-kinases signaling pathways 
since this kinase is able to reverse the process of PIP products formation with the opposing activity 
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of PI3-kinases. It is often observed that PTEN is mutated or even deleted in tumors [59]. The 
structures and functions of various PI3-kinases are shown in Figure 4. 
 
Figure 4: The structures and functions of PI3-kinases. A: Phosphoinositide 3-kinase (PI3K) 
family members are divided into Class IA (p110 catalytic subunit and p85 regulatory subunit, 
activated by RTKs), Class IB (heterodimer with a catalytic p110γ subunit and a p101 regulatory 
subunit exclusively activated by GPCRs), Class II (Begin with Ras binding domain (RasBD) from 
N-terminal, C2 domain, helical domain, and catalytic domain with PX and C2 domains at the C-
terminal), and Class III (single catalytic subunit Vps34) due to the structural characteristics and 
substrate specificity. B: The intracellular PIP3 level is modulated by Class I PI3-kinase [58]. 
PI3-kinases play fundamental roles in organ size control. In the cardiovascular system, 
abundant evidence suggests that only Class I and Class III PI3-kinase are expressed in the heart 
[60]. Class I PI3K/Akt signaling pathway is one of those well-studied signal transduction pathways 
that control cardiomyocyte survival and normal functions. Targeted overexpression of 
constitutively activate class I PI3-kinase in the heart results in increased organ size, which is 
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associated with a similar increase in cardiomyocyte size. While overexpression of dominant 
negative Class I PI3-kinase in the heart leads to smaller heart in mice, while dominant negative 
[61] treatment-induced inactivation of certain essential signaling transduction components such as 
p110 subunit inside Class I PI3-kinase in the heart attenuated cardiac hypertrophy in transgenic 
mice [62]. Oxidative stress-induced Class I PI3-kinase activation causes p70S6K1 activation and 
makes cardiomyocyte size growth, and this activation is associated with one 85-kDa regulatory 
subunit by tyrosine (TYR) phosphorylation and this hypertrophy was alleviated by wortmannin 
and rapamycin targeting at Class I PI3-kinase and mTOR respectively [63]. Also, inactivation of 
Class III PI3-kinase via deletion of the cardiac and hepatic Vps34/Pik3c3 component in Vps34f/f 
gene knockout mice provoked severe cardiac hypertrophy with impaired heart contractility and 
hepatomegaly with enhanced steatosis [64]. Therefore, the information demonstrates the 
importance of PI3-kinases in the progress of heart diseases. 
1.8. Overall hypothesis of the current study 
Heart failure means that the heart cannot meet the body’s metabolic demand since it is 
unable to pump enough blood to the peripheral organs and tissues, bringing about major health 
issues and threatening people’s well-beings in developed countries. In spite of significant 
therapeutic technical progresses, there are no sufficient advanced treatments for HF with an 
effective manner. Therefore, it is our primary concern to explore innovative clinical treatments for 
patients. 
The pathophysiology of CHF is complicated and multifactorial to compensate for the 
weakened cardiac contractility and pump enough blood. The most essential point is that this 
compensatory mechanism leads to increased Ang II secretion by activating renin angiotensin 
system [10]. Ang II exposure to heart tissue may activate intracellular ROS generation in 
cardiomyocytes, trigger several kinases and transcription factors, and lead to subsequent cardiac 
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remodeling like hypertrophy, perivascular fibrosis, and apoptosis, resulting in cardiac dysfunction 
and aggravated symptoms of CHF. Furthermore, overexcitation of RAS plays a pivotal role in the 
pathogenesis of heart failure. It seems that chronic exposure to high dosage of Ang II may also 
impair autophagy in cardiomyocytes, resulting in damaged mitochondria accumulation. It is well 
known that autophagy is a very important intracellular mechanism to protect cells from hazardous 
material accumulation by scavenging damaged mitochondria or proteins that produce reactive 
oxygen species (ROS). Accumulating evidence indicates the possible involvement of autophagy 
in the pathophysiology of Ang II-induced cardiac hypertrophy. However, the intracellular 
mechanisms involved in the accumulation of damaged mitochondria-derived ROS generation and 
how impaired autophagy contributes in Ang II-induced cardiac hypertrophy are still unclear. 
Recently, increasing evidence indicates the possible involvement of activated PI3-kinases 
in Ang II-induced heart failure. Besides previous literature reports, our preliminary data has also 
shown that the degree of autophagy was initially increased under lower dose of Ang II exposure 
and reached its peak at the Ang II concentration of 10-7 M, while autophagy became impaired as 
the dose of Ang II continued to rise. In addition, our preliminary data also indicated that under 
higher dosage of Ang II, pretreatment of Class I PI3-kinase inhibitor LY-294002 elevated 
autophagy, and attenuated ROS generation and hypertrophy, while pretreatment of Class III PI3-
kinase inhibitor 3-MA diminished autophagy, and potentiated ROS generation and hypertrophy. 
The preliminary data suggest the possible involvement of both PI3-kinases in Ang II-induced 
cardiac remodeling via autophagic alteration. All the background information and our preliminary 
data lead us to hypothesize that activation of Class I and Class III PI3-kinases in the heart is 
involved in Ang II-induced cardiac hypertrophy by ROS accumulation via an autophagic-
dependent mechanism. However, the role of the PI3-kinases in Ang II-induced cardiac 
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hypertrophy and the underlying intracellular mechanisms are still not fully clear. Thus, the current 
study was designed to test this hypothesis via the following specific aims: 
Aim 1. To determine the role of Class I PI3-kinase-dependent signaling pathways in Ang 
II-induced autophagy, ROS generation, and hypertrophy in primary cardiomyocytes. 
Aim 2. To examine the role of Class III PI3-kinase-dependent signaling pathways in Ang 
II-induced autophagy, ROS generation, and hypertrophy in primary cardiomyocytes. 
Aim 3. To validate the role of Class I PI3-kinase in autophagy, ROS generation, cardiac 
hypertrophy and perivascular fibrosis in chronic Ang II-perfused rats. 
Therefore, our major purpose of this current project was to provide evidences to evaluate 
the above-mentioned hypothesis. Furthermore, the main goal of this dissertation was to investigate 
the novel intracellular molecular mechanisms between the relationships of Ang II-induced cardiac 
hypertrophy and PI3-kinase activation-induced autophagic alteration. The combinations of in vitro 
and in vivo techniques with cellular, molecular and physiological approaches were used to realize 
this purpose. After the completion of those proposed aims, we believe a novel PI3-kinase-
dependent autophagic pathway will be identified in the development of Ang II-induced cardiac 
hypertrophy. It would be the first signaling pathway identified switching the heart function from 
compensation to decompensation by distinguishing two stages of hypertrophy. Thus, the data 
generated from this project would facilitate novel therapeutic approaches by specific targeting of 
PI3-kinase signaling pathway. 
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CHAPTER II. THE ROLE OF CLASS I PI3-KINASE-DEPENDENT SIGNALING 
PATHWAYS IN ANG II-INDUCED AUTOPHAGY, ROS GENERATION, AND 
HYPERTROPHY IN PRIMARY CARDIOMYOCYTES 
2.1. Introduction 
Among the physiological and pathological factors that cause cardiac hypertrophy, 
angiotensin II (Ang II) stimulation plays an essential role [65, 66]. It is universally recognized that 
Ang II, acting as a vasoconstrictor, mainly stimulates cardiomyocytes via triggering angiotensin 
receptors type 1 (AT1R) on the cellular surface membrane [67, 68]. It is well established that Ang 
II is involved in the initial physiological compensatory mechanism to keep the cardiac output by 
inducing cardiac hypertrophy. Elevated circulating Ang II levels are due to sympathetic activation-
induced renin release and reduced renal blood flow. At the initial stage, Ang II increases the 
preload and afterload to maintain normal cardiac function via compensatory mechanisms. In 
addition, long-term exposure and high level of Ang II contributes to the damaging effects on the 
heart and causes cardiac remodeling [69]. Accelerated protein synthesis takes place in 
cardiomyocytes and the molecular basis of myocardial fibers are restructured. As a result, cardiac 
hypertrophy shifts from compensatory to decompensatory, and cardiac output cannot meet the 
body metabolism in this stage, causing congestive heart failure [70]. 
Increasing information indicates that elevated ROS generation is involved in Ang II-
induced cardiac hypertrophy. ROS generation is induced by stimulating intracellular ROS-
producing enzymes such as NADPH oxidase (NOX, the main enzyme for ROS generation), 
xanthine oxidase (XO), uncoupled NO synthase (NOS), monoamine oxidase (MAO) and 
Cytochrome P450 oxidase. There might be a positive feedback relationship between Ang II 
receptor (ATR) and ROS generation, which means that Ang II-induced ROS generation would in 
turn, at least partially enhance the sensitivity of ATR, leading to elevated oxidative stress as a 
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vicious cycle [71]. ROS generation activates several cytosolic protein-synthesizing kinases like 
MAPK or Akt and intranuclear transcription factors like NFAT, GATA4 or NF-κB, and promote 
protein synthesis and subsequent hypertrophy [13, 26]. However, as is reported in recent literatures, 
genetic modification induced-inactivation of gp91phox subunit (a vital component of NADPH 
oxidase) in transgenic mice didn’t show significant beneficial effects to alleviate Ang II-induced 
hypertension or cardiac hypertrophy, suggesting there might be an alternative intracellular 
pathway to generate ROS in cardiomyocytes in prolonged period of Ang II administration [72]. 
Abundant evidence indicates that Ang II-triggered mitochondrial dysfunction in cardiomyocytes 
generates redundant ROS and such excessive oxidative stresses own a positive effect on 
hypertrophy and subsequent heart failure [73]. Thus, clarifying the origin of ROS generation is 
essential for us to seek appropriate approaches to combat Ang II-induced cardiac hypertrophy. 
Accumulation of ROS generation is a direct consequence of impaired autophagy. 
Autophagy, as a self-degradative process which removes and recycles damaged cellular organelles 
and proteins, keeps a homeostatic intracellular environment and the survival of cells [74]. For 
cardiomyocytes, though remarkably long-lived, they own a limited capacity of regeneration in 
adult hearts with a life-long activity of contractile action. Therefore, a constant procedure of 
cellular repair including elimination and substitution of impaired intracellular structures should be 
engaged [53]. Impaired autophagy in the heart could lead to the accumulation of defective 
mitochondria and proteins in cardiomyocytes, which may further lead to ROS generation [75]. 
Damaged mitochondria may continue generating greater levels of ROS that could stimulate stress-
related signaling pathway, cardiac hypertrophy, and cardiac damage if they are not instantly got 
rid of due to impaired autophagy (mitophagy) [71]. Besides, DNA within mitochondria (mtDNA) 
has proinflammatory unmethylated CpG motifs, and mtDNA gathering could induce a toll-like 
receptor (TLR) inflammatory response, leading to cardiac hypertrophy and heart failure [18]. 
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Class I PI3-kinase is one of those downstream signaling transduction kinases of Ang II 
receptor (AT) in cardiomyocytes with its downstream cascade components of Protein kinase B 
(Akt) and mammalian target of rapamycin (mTOR). Previous reports demonstrated that Class IA 
PI3-Kinass strongly provoke heart growth and cardiac hypertrophy, while nullification of this 
kinase by knocking out p85β subunit diminished heart size and alleviated cardiac hypertrophy [76] 
since Class I PI3-kinase negatively regulates autophagy via the Akt/mTOR-dependent mechanism. 
However, the role of Class I PI3-kinase in the progress Ang II-induced cardiac hypertrophy has 
not been fully investigated yet. Therefore, it is crucial to detect whether this kinase is involved in 
Ang II-induced cardiac hypertrophy. 
In this chapter, we have investigated the intracellular signaling pathway mediated by Class 
I PI3-kinase and the relevant participating components in primary cardiomyocytes from SD rats 
under Ang II exposure to verify our hypothesis that activation of Class I PI3-kinase is essential for 
Ang II-induced cardiac hypertrophy via autophagic impairment. More specifically, the role of 
Class I PI3-kinase was studied in the action of Ang II on autophagy, ROS generation, cardiac 
hypertrophy, and expression of relevant phosphorylated kinases in cardiomyocytes using various 
biochemical and pharmacological tools. 
2.2. Materials and methods 
2.2.1. Preparation of cardiomyocyte cultures 
Twelve-week-old male and female SD rats were obtained from Charles River Farms 
(Charles River Laboratories International, Wilmington, MA). Rats were housed at 25 ± 2°C on a 
12:12-h light-dark cycle and provided with food and water ad libitum. All animal protocols were 
approved by the North Dakota State University Institutional Animal Care and Use Committee. 
Primary cardiomyocytes were randomly divided into each group. Generally, dissociated neonatal 
rat primary cardiomyocytes were cultured for 5 days, and culture media was changed every other 
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day. Then cardiomyocytes were treated with relevant reagents: 10-9 M~10-5 M Angiotensin II (Ang 
II, Alfa Aesar, J60866, Reston, VA), 1 μM LY-294002 (LY, Sigma Aldrich, L9908, St. Louis, 
MO), 100 nM rapamycin (Rapa, Alfa Aesar, J62473, Reston, VA), 1 μM Losartan (Los, Sigma 
Aldrich, 61188, St. Louis, MO), 1 μM PD-123319 (PD, Sigma Aldrich, P186, St. Louis, MO), 1 
μM Mito-TEMPO (Mito, Santa Cruz Biotechnology, sc-221945, Santa Cruz, CA). All those 
reagents were administrated 30 minutes before Ang II stimulation in all experiments except dosage 
dependent-autophagy effect test of Ang II. After dosage-dependent effect test of Ang II, only 10-6 
M Ang II was administrated after the pretreatment of relevant reagents. HBSS was used as negative 
control in Ang II dosage-autophagy effect test while 0.1% DMSO vehicle control was used as 
negative control for other subsequent experiments. The total exposure duration of Ang II and other 
reagents was 24 hours for autophagy and hypertrophy determination. While for ROS generation 
determination, intracellular ROS levels were measured immediately after addition of Ang II or 
HBSS control by incubation with MitoSOX since superoxide is unstable and gradually neutralized 
by intracellular superoxide dismutase (SOD) as time elapses. 
2.2.2. Treatment protocol 
1~3 days old neonatal SD rats were anesthetized by sodium pentobarbital (200 mg/kg, i.p., 
Sigma, St. Louis, MO). Ventricle parts of the heart were quickly excised, minced into small pieces 
in cold HBSS and washed for several additional times. The minced tissue was digested with 0.1% 
trypsin in a 37oC water bath with shaking for 5-min rounds of tissue digestion (10-12 times). After 
each incubation, the supernatant was added to an equal volume of DMEM containing 10% FBS. 
Then, isolated cells were filtrated with 70 μm cellular sieve, centrifuged at 1,000 rpm for 10 min. 
Supernatants were discarded after centrifuge; and cellular pellets were suspended in DMEM 
composed of 10% FBS and 1% penicillin-streptomycin at 37℃ for 1.5 hr in a humidified 
atmosphere with 95% O2 and 5% CO2 to allow the most of non-myocyte cells, such as fibroblasts, 
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to attach on the plate bottom. Suspended cellular solution (final cellular density 5×105 cells/cm2) 
was transduction to a 24-well plate for morphological studies and to a 96-well plate for 
measurement of ROS levels. In the first three days, Brdu (100 μM) was added to suppress 
fibroblast growth. All of the manipulations were performed in culture hood to ensure an aseptic 
environment. After the primary cardiomyocyte cultures reached confluence (5 days on average) in 
an incubator filled with a humidified atmosphere of 5% CO2 at 37 °C, cardiomyocytes were used 
for in vitro experiments. 
2.2.3. Autophagy determination 
Cultured cardiomyocytes were treated with relevant reagents for 24 h. Each treatment was 
performed in triplicate wells. In brief, after treatment, cells were fixed in 4% PFA at 4℃ for 30 
min, and washed with fresh washing solution (0.1% Triton X-100 in PBS) three times. After pre-
incubation with 3% of bovine serum albumin (BSA) for 20 minutes, the cells were incubated with 
primary antibody of MAP-LC3 (Santa Cruz Biotechnology, sc-134226, Santa Cruz, CA), which 
was diluted to 1:100 with PBS containing 3% BSA, for overnight at 4℃. After three washings 
with the PBS solution, the cells were incubated with fluorescence-conjugated Alexa Fluor 488 
fluorescence-conjugated goat anti-rabbit IgG antibody (Molecular probes, A-11034, Waltham, MA) 
(1:1000 diluted in PBS) for 2 h at room temperature in dark. Photographic images of 
cardiomyocytes were taken with a fluorescence microscope (Olympus Microsystems, Waltham, 
MA). The MAP-LC3 antibody immunostaining positive images were analyzed, the puncta inside 
cardiomyocytes were counted and the average puncta number in each cell was calculated with at 
least 10 area of cells in each sample [77, 78]. The more average puncta in each cell indicates the 
larger degree of autophagy occurrence. HBSS negative control group was set as “1” and the results 
of each sample were expressed as “Fold vs Control”.  
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Immunostaining fluorescence was performed to evaluate the presence of LC3 II formation 
using anti-MAP-LC3 antibody which is one of the markers of autophagy. To further verify the 
cellular type in which LC3 II particles are present, we have co-stained primary cardiomyocyte 
cultures with an anti-α-actin antibody, a cardiomyocyte marker. Figure 5 shows that the LC3 II are 
abundantly expressed in primary cardiomyocytes. 
 
Figure 5: Identification of autophagy in primary cardiomyocytes. Immunofluorescence 
images showing autophagesomes marked with anti-MAP-LC3 antibody and cardiomyocyte-
marker alpha-actin antibody (red). MAP-LC3 localization on cultured primary cardiomyocytes. A, 
Microscopic image taken from primary cardiomyocytes in optical phase. B, Fluorescence image 
demonstrating localization of autophagesomes. C, same field of cells as in A,  immunostained with 
an anti-α-actin antibody. D, overlap of B and C, indicating that autophagesomes are localized 
within primary cardiomyocytes. 
2.2.4. ROS detection 
Mitochondrial ROS generation was determined using a superoxide-sensitive (O2∙-) 
fluorogenic probe of MitoSox (Thermo Fisher, M-36008, Rockford, IL). MitoSOX has a 
dihydroethidium (DHE) part linked to triphenylphosphoninum (TPP) component and yields red 
fluorescence when oxidized (excitation/emission wavelength: 510/580 nm). This compound is 
more concentrated in the mitochondria than in the cytosol since the former has more positively 
charged TPP [79] . Cultured cardiomyocytes were pretreated with relevant reagents except Ang II 
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for 30 minutes. Then the cardiomyocytes were treated with Ang II (10-6 M) or HBSS control. 
Intracellular mitochondrial ROS levels were measured immediately after the addition of Ang II or 
HBSS control by incubation with MitoSOX (5×10-6 M, 15 minutes). The intracellular ROS levels 
were measured using a fluorometric imaging plate reader (Spectra Max Gemini EM, Molecular 
Devices) to detect changes in fluorescence resulting from intracellular probe oxidation. The 
vehicle (DMSO, 0.1%) control group was set as 100% MitoSOX fluorescence. Fluorescent images 
were also acquired using a fluorescence microscope (Olympus) to visualize the strength of 
MitoSOX fluorescence in primary cardiomyocytes. 
2.2.5. Cardiac hypertrophy determination 
Cultured cardiomyocytes were treated with relevant reagents and Ang II for 24 h. Each 
treatment was performed in triplicate wells. Anti-α-actin antibody was used for cardiac 
hypertrophy via immunofluorescence staining. In brief, cells were fixed in 4% PFA at 4℃ for 30 
minutes, and washed with fresh washing solution (0.1% Triton X-100 in PBS) for three times. 
After pre-incubation with 3% of bovine serum albumin (BSA) for 20 minutes, the cells were 
incubated with primary antibody of sarcomeric α-actin (Santa Cruz Biotechnology, sc-53142, 
Santa Cruz, CA), which was diluted to 1:100 with PBS containing 3% BSA, overnight at 4℃. 
After three washings with the PBS solution, the cells were incubated with fluorescence-conjugated 
Alexa Fluor 594 goat anti-mouse IgG (Molecular probes, A-11032, Waltham, MA) (1:1000 diluted 
in PBS) for 2 h at room temperature in dark. Photographic images of cardiomyocytes were taken 
with a fluorescence microscope (Olympus Microsystems, Waltham, MA). The cellular surface area 
of positive image for α-actin staining cardiomyocytes was measured by the image analysis 
software (NIH Image J) [80]. Variations of cellular size were expressed as relative cellular surface 
area versus the control. The 0.1% DMSO negative control group was set as 100%. 
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2.2.6. Western blot analysis 
Akt and p-Akt protein levels in primary cardiomyocyte cultures were assessed by western 
blot analysis to determine the phosphorylation degree of those downstream components of Class I 
PI3-kinase. Briefly, after drug treatment for 24 hours, primary cardiomyocyte cultures were 
washed with ice-cold PBS and scraped into a lysis buffer containing 20 mM Tris HCl (pH 6.8), 
150 mM NaCl, 10% glycerol, 1% NP-40, and 8 µL/mL inhibitor cocktail (125 mM PMSF, 2.5 
mg/mL aprotinin, 2.5 mg/mL leupeptin, 2.5 mg/mL antipain, and 2.5 mg/mL chymostatin). The 
samples were sonicated twice for 5 s each and were centrifuged at 12,000 rpm for 10 min at 4°C. 
Supernatants were transferred into new tubes and stored in a -80°C freezer. The protein 
concentration was determined with a protein assay kit (Bio-Rad Laboratories, Hercules, CA). An 
aliquot of 30 µg of protein from each sample was separated on a 10% SDS-PAGE gel and was 
transferred onto nitrocellulose membranes for 2 h at 120 V. After a 10-min wash in TBST, 
membranes were blocked in PBST containing 10% milk for 1 h, followed by an overnight 
incubation in rabbit anti-Akt (Santa Cruz Biotechnology, sc-8312, Santa Cruz, CA), and anti-p-
Akt (Santa Cruz Biotechnology, sc-2448, Santa Cruz, CA) antibody (dilution 1:100) at 4 °C. After 
a 15-min wash in TBST, four 5-min washes in PBS-T will be carried out, and membranes will be 
then incubated for 2 h in an anti-rabbit peroxidase-conjugated antibody (dilution 1:15,000). 
Densitometry of p-Akt was normalized to total Akt, and immunoreactivity was detected by 
enhanced chemiluminescence autoradiography (ECL Western blotting detection kit, Amersham 
Pharmacia Biotechnology), and films were analyzed with Quantity One Software (Bio-Rad). 
2.2.7. Class I PI3-kinase activity assay 
After treatment of relevant reagents, primary cardiomyocytes from neonatal rats were 
rinsed with ice-cold PBS and Buffer A (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 1 mM CaCl2, 1 
mM MgCl2, and 1 mM Na3VO4) three times each. Then Buffer A was removed and the cells were 
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immediately lysed in lysis buffer Lysis Buffer (Buffer A plus 1% NP-40 and 1 mM PMSF) at 4°C 
for 20 minutes by rocking. The cells were scraped from dishes, transferred to 1.5 mL 
microcentrifuge tubes and centrifuged for 10 minutes to sediment insoluble material. Thereafter, 
supernatant was transferred to new tubes added with 5 μL of anti-PI3-Kinase antibody (Millipore 
Corp, 06-195, Billerica, MA) previously described [81] to each tube and incubated for one hour at 
4°C with gentle rotation. 60 μL of 50 % slurry of Protein A-agarose beads in PBS was added into 
each tube with gentle rotation for overnight, and tubes were centrifuged for 5 seconds for collection 
of immunoprecipitated enzymes. Sediments were washed three times with Buffer A plus 1% NP-
40, three times with 0.1 M pH 7.4 Tris-HCl with 5 mM LiCl and 1 mM Na3VO4, twice with TNE 
(10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA) containing 1 mM Na3VO4 and twice with 
KBZ Reaction Buffer. The last wash was aspirated completely and 30 μL of KBZ Reaction Buffer 
was added to cover the beads. Then the Class I PI3-kinase reactions were carried out using 
competitive enzyme-linked immunosorbent assay kit (Echelon Biosciences, K-1000s, Salt Lake 
City, UT) by exactly following the instructions provided by the manufacturer. A PIP3 standard 
curve (ranging from 4.4 nM to 1.08 μM) was simultaneously prepared and determined at 450 nm 
wavelength. Each assay was repeated at least 3 times. 
2.2.8. Data analysis  
All data are presented as means ± S.E.M. Statistical significance was evaluated by one- or 
two-way ANOVA, as appropriate, followed by either a Newman–Keuls or Bonferroni post hoc 
analysis when indicated. Differences will be considered significant at P<0.05, and individual 
probability values are noted in figures. 
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2.3. Results 
2.3.1. Dose-dependent effect of Ang II on autophagy, Class I PI3-kinase activity and 
phosphorylation of Akt 
Accumulating evidence indicates the possible involvement of autophagy in the 
pathophysiology of Ang II-induced cardiac hypertrophy [82]. Autophagy is an very important 
intracellular mechanism to protect cells from hazardous material accumulation by scavenging 
damaged mitochondria or proteins that produce reactive oxygen species (ROS). Intracellular ROS 
plays an important role in the pathogenesis of cardiac hypertrophy. Thus, we examined the effect 
of Ang II on autophagy in cardiomyocytes using immunofluorescence staining with antibodies 
against microtubule-associated protein light chain 3 (MAP-LC3), an autophagosome marker. The 
autophagesomes within cardiomyocytes are visualized as green fluorescent puncta, which are able 
to be counted under microscope. The results are presented in Figure 6, indicating that Ang II 
treatment produces a dose-dependent increases in autophagy with two phases; an increasing phase 
at lower dosages (autophagy degree 1.00 ± 0.05 in Ctrl vs. 3.81 ± 0.13 in 10-7 M Ang II, increased 
by 281% P < 0 .01 vs. HBSS Ctrl) and a decreasing phase at high dosages (autophagy degree 3.81 
± 0.13 in 10-7 M Ang II vs. 1.75 ± 0.08 in 10-5 M Ang II, decreased by 54.1 %, P < 0 .05 vs. HBSS 
Ctrl). Still, the degree of autophagy at the maximum concentration of 10-5 M Ang II was higher 
than the baseline of HBSS control, suggesting elevated autophagy under Ang II stimulation. Taken 
together, those results demonstrate that lower dosage Ang II exposure elevated while higher dosage 
Ang II impaired autophagy.  
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Figure 6: Dose-dependent effect of Ang II on autophagy in cardiomyocytes. Autophagy was 
examined in cardiomyocytes by immunostaining fluorescence with MAP-LC3 antibody 24 hours 
after treated with HBSS control or Ang II at dosages indicated in the figure. A-F: Representative 
fluorescence micrographs of cultured cardiomyocytes stained with MAP-LC3 antibody after the 
following treatments: HBSS control (A), 10-9 M Ang II (B), 10-8 M Ang II (C), 10-7 M Ang II (D), 
10-6 M Ang II (E), or 10-5 M Ang II (F). G: Bar graphs summarizing quantitative analysis of 
autophagic alterations in cardiomyocytes treated with HBSS control  or Ang II at different dosages 
(10-9 M - 10-5 M). The scale in the images is 25 μm. Data are presented as means ± SE and were 
derived from three experiments and at least triplicate wells in each experiment. *P < 0.05 vs. HBSS 
control. **P < 0.01 vs. HBSS control. 
Class I PI3-kinase activity was measured since we assume this kinase is involved in the 
impairment of autophagy under pathological higher Ang II concentration. For this reason, a 
measurement of PIP3 production is the indirect estimation of intracellular Class I PI3-kinase levels. 
PIP3 levels were measured 24 hours after treatment of Ang II with different dosages or HBSS 
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control. After Ang II treatment, the cardiomyocytes were lysed for PIP3 determination by the PIP3 
ELISA kit according to the manufacturer’s protocol. Results are shown in Figure 7. The results 
indicate that the activity of Class I PI3-kinase is slightly elevated with lower dosages of Ang II by 
80 % (PIP3 production (in pmol/μg of protein) 1.45 ± 0.09 in Ctrl vs. 2.61 ± 0.12 in 10-7 M Ang II, 
P <0 .01 vs. HBSS Ctrl), while a sharp increase of Class I PI3-kinase activity is witnessed when 
the Ang II concentration exceeds 10-7 M (PIP3 production (in pmol/μg of protein) 2.61 ± 0.12 in 
10-7 M Ang II vs. 3.35 ± 0.13 in 10-5 M Ang II, P <0 .01 vs. HBSS Ctrl), suggesting Class I PI3-
kinase is fully activated under higher dosage of Ang II exposure (exceeding 10-7 M Ang II). The 
dose-dependent stimulatory effect of Ang II on Class I PI3-kinase started at 10-8 M and reached to 
the peak at 10-6 M.  
 
Figure 7: Dose-dependent effect of Ang II on the activity of Class I PI3-kinase in 
cardiomyocytes. Bar graphs summarizing the activities of Class I PI3-kinases measured using 
PIP3 ELISA kits in cardiomyocytes as described in Methods. The Class I PI3-kinase activities are 
presented as the concentrations of PIP3 in per microgram protein 24 hours after treated with HBSS 
control or Ang II with different dosages. Data are presented as means ± SE, which were derived 
from three experiments and at least triplicate wells in each experiment. *P < 0.05, **P < 0.01, ***P 
< 0.001 as compared with cardiomyocytes treated with HBSS control. 
Akt is one of those direct downstream components of Class I PI3-kinase, and 
phosphorylation of Akt reflects the effect of Class I PI3-kinase. Thus, we measured the ratio of p-
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Akt/Total Akt by western blot in cardiomyocytes treated by Ang II with different dosages. The 
results are shown in Figure 8, indicating that the activity of Akt is slightly elevated under lower 
dosage of Ang II (p-Akt/Total Akt from 0.072 ± 0.005 in Ctrl to 0.134 ± 0.007 in 10-7 M Ang II, P 
<0 .01 vs. HBSS Ctrl), while an intense increase of Akt phosphorylation is observed when the Ang 
II concentration exceeds 10-7 M (p-Akt/Total Akt 0.134 ± 0.007 in 10-7 M Ang II vs. 0.181 ± 0.013 
in 10-5 M Ang II, P <0.001 vs. HBSS Ctrl), suggesting Akt is activated under higher dosage of Ang 
II exposure by phosphorylation and will activate its downstream components. 
 
Figure 8: Dose-dependent effect of Ang II on the phosphorylation of Akt in cardiomyocytes. 
A: Representative western blots of cardiomyocytes lysate probed for phosphorylated Akt (p-Akt) 
and total Akt in each group of Ang II dosages (from 10-9 M to 10-5 M) respectively for 24 h. B: 
Bar graphs summarizing the ratio of phosphorylated Akt vs. total Akt. Data are means ± SE of the 
ratio of p-Akt/Total Akt. Data are presented as means ± SE, which were derived from three 
experiments and at least triplicate wells in each experiment. *P < 0.05, **P < 0.01, ***P < 0.001  as 
compared with cardiomyocytes treated with HBSS control. 
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2.3.2. The effect of LY-294002, a Class I PI3-kinase inhibitor on autophagy, ROS generation, 
cardiac hypertrophy and Class I PI3-kinase activity 
To identify the intracellular mechanisms underlying Ang II-induced autophagy, the effect 
of high dose of Ang II on autophagy in cardiomyocytes was examined with and without presence 
of LY-294002 (LY, an inhibitor of Class I PI3-kinase). The results are presented in Figure 9 and 
demonstrated that Ang II (10-6 M) significantly induced an significant elevation in autophagy at 
the presence of vehicle by 161.0 % (DMSO, 0.1%, 1.00 ± 0.05 in control vs. 2.61 ± 0.12 in Ang II 
treatment, n=3 experiments, P < 0.01 vs. Vehicle Control). Preincubation of cardiomyocytes with 
LY-294002 (1 μM, 30 min) significantly potentiated Ang II-induced autophagy by 46.4% (1.06 ± 
0.07 in LY-294002 alone vs. 3.82 ± 0.13 in LY-294002 plus Ang II, n=3 experiments, P < 0.05 vs. 
Ang II). In addition, treatment with LY-294002 alone did not alter the basal autophagy in 
cardiomyocytes. Taken together, Class I PI3-kinase contributes to Ang II-induced impairment in 
autophagy via a Class I PI3-kinase-mediated inhibitory mechanism. 
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Figure 9: Effect of blockade of Class I PI3-kinase on Ang II-induced autophagy in 
cardiomyocytes. Autophagy was examined in cardiomyocytes by immunostaining fluorescence 
with MAP-LC3 antibody 24 hours after treated with Ang II (10-6 M) with or without the Class I 
PI3-kinase inhibitor, LY-294002 (LY, 1 μM, an inhibitor of Class I PI3-kinase). A: Representative 
fluorescence micrographs of cultured cardiomyocytes stained with MAP-LC3 antibody after the 
following treatments: Vehicle control, 1 μM LY-294002, an inhibitor of Class I PI3-kinase, 10-6 
M Ang II, or LY-294002 + Ang II. MAP-LC3 immunofluorescence staining shows LY-294002 
pretreatment elevates autophagy under 10-6 M Ang II exposure. B: Bar graphs demonstrating the 
effect of autophagy with the addition of LY-294002 under 10-6 M Ang II exposure. The scale in 
the images is 25 μm. Data are means ± SE and were derived from three experiments and at least 
triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes that treated with vehicle control. 
#P < 0.05 vs. cardiomyocytes that treated with Ang II. 
Accumulated evidence indicates that intracellular mitochondrial-ROS plays an important 
role in Ang II-induced cardiac hypertrophy [83] and that mitochondrial ROS is scavenged by 
autophagy [79]. Thus, we examined the role of Class I PI3-kinase in Ang II-induced mitochondrial 
ROS generation. The mitochondrial ROS generation was measured using the MitoSox 
fluorescence approach in cardiomyocytes treated by control or Ang II (10-6 M) with or without 
pretreatment with the Class I PI3-kinase inhibitor, LY-294002 (1 μM, 30 min). The results are 
presented in Figure 10, demonstrating that treatment of cardiomyocytes with Ang II significantly 
increased mitochondrial ROS generation at the presence of vehicle (DMSO, 0.1%) by 69.3 % as 
expected (100 ± 2.35 % in control vs 169.30 ± 3.60 % in Ang II, n=3 experiments, P < 0.01 vs. 
Vehicle Control). More interestingly, treatment with LY-294002 dramatically attenuated Ang II-
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induced increases in mitochondrial ROS accumulation by 31.7 % in cardiomyocytes (95.30 ± 2.20 % 
in LY-294002 alone vs. 115.60 ± 3.02 % in LY-294002 plus Ang II, n=3 experiments, P < 0.05 vs. 
Ang II). In addition, treatment with LY-294002 alone did not alter the basal mitochondrial ROS 
generation. Those data suggest that Class I PI3-kinase is involved in Ang II-induced mitochondrial 
ROS accumulation in cardiomyocytes through a Class I PI3-kinase-dependent stimulatory 
mechanism.  
 
Figure 10: Effect of blockade of Class I PI3-kinase on Ang II-induced mitochondrial ROS 
generation in cardiomyocytes. Mitochondrial ROS levels were determined using the oxidant-
sensitive fluorogenic probe MitoSOX in neonatal rat primary cardiomyocytes. Mitochondrial ROS 
levels were determined using the oxidant-sensitive fluorogenic probe MitoSOX in cardiomyocytes 
after treated with Ang II (10-6 M) with or without the Class I PI3-kinase inhibitor, LY-294002 (LY, 
1 μM, an inhibitor of Class I PI3-kinase) for 24 hours. A: Representative fluorescence micrographs 
of cultured cardiomyocytes loaded with MitoSOX after the following treatments: Vehicle  control, 
LY-294002 (LY, 1 μM), 10-6 M Ang II, or Ang II + LY. B: Bar graphs summarizing the effect on 
mitochondrial ROS production in cardiomyocytes treated with the conditions described in the 
above. The scale in the images is 25 μm. Data are presented as means ± SE, which were derived 
from three experiments and at least triplicate wells in each experiment. **P < 0.01 vs. 
cardiomyocytes treated with vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
After we measured the effect of blockade of Class I PI3-kinase on Ang II-induced ROS 
generation, we examined the role of Class I PI3-kinase in Ang II-induced cardiac hypertrophy. The 
cardiac hypertrophy in cardiomyocytes was measured using the α-actin immunofluorescence in 
cardiomyocytes treated by Vehicle control or Ang II (10-6 M) with or without pretreatment with 
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the Class I PI3-kinase inhibitor, LY-294002 (1 μM, 30 min). The results are presented in Figure 11, 
demonstrating that treatment of cardiomyocytes with Ang II significantly increased cardiac 
hypertrophy at the presence of vehicle (DMSO, 0.1%) by 104.6 % as expected (Relative cellular 
surface area 100 ± 4.7 % in control vs. 204.6 ± 8.5 % in Ang II, n=3 experiments, P < 0.01 vs. 
Vehicle Control). More interestingly, treatment with LY-294002 significantly attenuated Ang II-
induced increases in cardiac hypertrophy by 38.7 % in cardiomyocytes (95.3 ± 2.2 % in LY-294002 
alone vs. 125.2 ± 6.20 % in LY-294002 plus Ang II, n=3 experiments, P < 0.05 vs. Ang II). In 
addition, treatment with LY-294002 alone did not alter the basal hypertrophic state of 
cardiomyocytes. In summary, those data demonstrate that Class I PI3-kinases is involved in Ang 
II-induced cardiac hypertrophy in cardiomyocytes through a Class I PI3-kinase-dependent 
stimulatory mechanism. 
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Figure 11: Effect of blockade of Class I PI3-kinase on Ang II-induced cardiac hypertrophy 
in cardiomyocytes. Cardiac hypertrophy in cardiomyocytes was determined using 
immunofluorescent staining with α-sarcomeric actin antibody after treated with Ang II (10-6 M) 
with or without the Class I PI3-kinase inhibitor, LY-294002 (LY, 1 μM, an inhibitor of Class I 
PI3-kinase) for 24 hours. A: Representative fluorescence micrographs of cultured cardiomyocytes 
loaded with α-sarcomeric actin antibody after the following treatments: Vehicle control, LY-
294002 (1 μM, an inhibitor of Class I PI3-kinase), 10-6 M Ang II, or Ang II + LY. B: Bar graphs 
summarizing the effect on cardiac hypertrophy in cardiomyocytes treated with the conditions 
described in the above. The scale in the images is 25 μm. Data are presented as means ± SE, which 
were derived from three experiments and at least triplicate wells in each experiment. **P < 0.01 vs. 
cardiomyocytes treated with vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
Next, we measured the effect of blockade of Class I PI3-kinase on Ang II-induced Class I 
PI3-kinase activity. The Class I PI3-kinase activity was measured using the ELISA kit in 
cardiomyocytes treated by control or Ang II (10-6 M) with or without treatment with the Class I 
PI3-kinase inhibitor, LY-294002 (1 μM, 30 min). The results are presented in Figure 12, 
demonstrating that treatment of cardiomyocytes with Ang II significantly increased Class I PI3-
kinase activity at the presence of vehicle (DMSO, 0.1%) by 108.3 % as expected (PIP3 production 
(pmol/μg of protein) 1.45 ± 0.09 in control vs. 3.02 ± 0.08 in Ang II, n=3 experiments, P < 0.01 
vs. Vehicle Control). More surprisingly, treatment with LY-294002 dramatically attenuated Ang II-
induced increases in Class I PI3-kinase activity by 36.8% (PIP3 production (pmol/μg of protein) 
3.02 ± 0.08 in Ang II vs. 1.91 ± 0.12 in LY-294002 plus Ang II, n=3 experiments, P < 0.05 vs. Ang 
 39 
II). Besides, the addition of 1 μM LY-294002 alone did not affect the basal activity of Class I PI3-
kinase. 
 
Figure 12: Effect of blockade of Class I PI3-kinase on Ang II-induced Class I PI3-kinase 
activity in cardiomyocytes. Class I PI3-kinase activity in cardiomyocytes was determined using 
the ELISA kit after treated with Ang II (10-6 M) with or without the Class I PI3-kinase inhibitor, 
LY-294002 (LY, 1 μM) for 24 hours. Bar graphs summarizing the effect on Class I PI3-kinase 
activity in cardiomyocytes treated with Vehicle control, LY-294002 (LY, 1 μM, an inhibitor of 
Class I PI3-kinase), 10-6 M Ang II, or Ang II + LY. Data are presented as means ± SE, which were 
derived from three experiments and at least triplicate wells in each experiment. **P < 0.01 vs. 
cardiomyocytes treated with vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
2.3.3.  The effect of blocking different types of Ang II receptors on Ang II-induced autophagy, 
ROS generation, cardiac hypertrophy and Class I PI3-kinase activity 
After we determined the role of mTOR in Ang II-induced cardiac remodeling, we tested 
which type(s) of Ang II receptor is (are) responsible for Ang II-induced cardiac remodeling. The 
effect of high dose of Ang II on autophagy in cardiomyocytes was examined with and without 
presence of Losartan or PD-123319 to block Ang II receptor type 1 or 2 respectively. The results 
are presented in Figure 13, and preincubation of cardiomyocytes with Ang II receptor type 1 
antagonist of Losartan (Los, 1 μM, 30 min) significantly diminished Ang II-induced autophagy by 
59.7 % (0.95 ± 0.07 in Losartan alone vs. 1.05± 0.09 in Losartan plus Ang II, n=3 experiments, P 
< 0.05 vs. Ang II). In contrast, pretreatment with Ang II receptor type 2 antagonist of PD-123319 
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(PD, 1 μM, 30 min) did not significantly alter Ang II-induced autophagy (1.02 ± 0.07 in PD-
123319 alone vs. 2.57 ± 0.16 in PD-123319 plus Ang II, n=3 experiments, P > 0.05 vs. Ang II). In 
addition, treatment with Losartan or PD-123319 alone did not alter the basal autophagy in 
cardiomyocytes. Taken together, the results demonstrate that Ang II-induced autophagic alteration 
in cardiomyocytes is mainly mediated via Ang II receptor Type 1 activation. 
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Figure 13: Effect of blockade of Ang II receptor type 1 or type 2 on Ang II-induced 
autophagy in cardiomyocytes. Autophagy was examined in cardiomyocytes by immunostaining 
fluorescence with MAP-LC3 antibody 24 hours after treated with Ang II (10-6 M) with or without 
the Ang II receptor type 1 antagonist of Losartan (Los, 1 μM), or the Ang II receptor type 2 
antagonist of PD-123319 (PD, 1 μM). A: Representative fluorescence micrographs of cultured 
cardiomyocytes stained with MAP-LC3 antibody after the following treatments: vehicle control, 
Losartan, PD-123319, Ang II, Losartan + Ang II, or PD-123319 + Ang II. B: Bar graphs 
summarizing quantitative analysis of autophagic alterations in cardiomyocytes treated under the 
conditions described in the above. The scale in the images is 25 μm. Data are means ± SE and 
were derived from three experiments and at least triplicate wells in each experiment. **P < 0.01 vs. 
cardiomyocytes that treated with vehicle control. #P < 0.05 vs. cardiomyocytes that treated with 
Ang II. 
Next, we tested the effect of different Ang II receptor antagonists on ROS generation. The 
mitochondrial ROS production was measured using the MitoSox fluorescence in cardiomyocytes 
treated by control or Ang II (10-6 M) with or without pretreatment with the Ang II receptor type 1 
antagonist of Losartan (1 μM, 30 min) or the Ang II receptor type 2 antagonist of PD-123319 (1 
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μM, 30 min). The results are presented in Figure 14, demonstrating treatment with Losartan 
dramatically attenuated Ang II-induced increases in mitochondrial ROS accumulation by 32.4 % 
in cardiomyocytes (97.50 ± 2.66 % in Losartan alone vs. 114.40 ± 2.71 % in Losartan plus Ang II, 
n=3 experiments, P < 0.05 vs. Ang II). In contrast, treatment with PD-123319 did not significantly 
alter Ang II-induced elevations in mitochondrial ROS production in cardiomyocytes (103.20 ± 
3.25 % in PD-123319 alone vs. 159.2 ± 4.70 % in PD-123319 plus Ang II, n=3 experiments, P > 
0.05 vs. Ang II). In addition, treatment with Losartan or PD-123319 alone did not alter the basal 
mitochondrial ROS production. The results demonstrated that Ang II-induced ROS generation in 
cardiomyocytes is mainly mediated via Type 1 Ang II receptor activation. 
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Figure 14: Effect of blockade of Ang II receptor type 1 or type 2 on Ang II-induced ROS 
generation in cardiomyocytes. Mitochondrial ROS levels were determined using the oxidant-
sensitive fluorogenic probe MitoSOX in cardiomyocytes after treated with Ang II (10-6 M) with or 
without the Ang II receptor type 1 antagonist of Losartan (Los, 1 μM ) or the Ang II receptor type 
2 antagonist PD123319 (PD, 1 μM) for 24 hours. A: Representative fluorescence micrographs of 
cultured cardiomyocytes probed by MitoSOX after the following treatments: vehicle control, 
Losartan, PD-123319, Ang II, Losartan + Ang II, or PD-123319 + Ang II. B: Bar graphs 
summarizing the effect on mitochondrial ROS production in cardiomyocytes treated with the 
conditions described in the above. The scale in the images is 25 μm. Data are presented as means 
± SE, which were derived from three experiments and at least triplicate wells in each experiment. 
**P < 0.01 vs. cardiomyocytes treated vehicle control. #P < 0.05 vs. cardiomyocytes treated with 
Ang II. 
After the determination of blockade of AT1R or AT2R on Ang II-induced ROS generation, 
we measured the effect of different Ang II receptor antagonists on cardiac hypertrophy. The cardiac 
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hypertrophy in cardiomyocytes was measured using the α-actin immunofluorescence in 
cardiomyocytes treated by Vehicle control or Ang II (10-6 M) with or without pretreatment with 
the Ang II receptor type 1 antagonist of Losartan (1 μM, 30 min) or Ang II receptor type 2 
antagonist PD-123319 (1 μM, 30 min). The results are presented in Figure 15, demonstrating 
treatment with Losartan significantly attenuated Ang II-induced increases in cardiac hypertrophy 
by 37.8 % in cardiomyocytes (Relative cellular surface area 102.3 ± 4.12 % in Losartan alone vs. 
127.2 ± 3.92 % in Losartan plus Ang II, n=3 experiments, P < 0.05 vs. Ang II). In contrast, 
treatment with PD-123319 did not significantly alter Ang II-induced elevations in cardiac 
hypertrophy in cardiomyocytes (103.50 ± 4.60 % in PD-123319 alone vs. 185.6 ± 8.30 % in PD-
123319 plus Ang II, n=3 experiments, P > 0.05 vs. Ang II). In addition, treatment with Losartan 
or PD-123319 alone did not alter the basal cellular surface area. The results demonstrated that Ang 
II-induced cardiac hypertrophy in cardiomyocytes is mainly mediated via Ang II receptor Type 1. 
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Figure 15: Effect of blockade of Ang II receptor type 1 or type 2 on Ang II-induced cardiac 
hypertrophy in cardiomyocytes. Cardiac hypertrophy levels were determined using the α-actin 
immunofluorescence staining in cardiomyocytes after treated with Ang II (10-6 M) with or without 
the Ang II receptor type 1 antagonist of Losartan (Los, 1 μM) or Ang II receptor type 2 antagonist 
of PD-123319 (PD, 1 μM) for 24 h. A: Representative fluorescence micrographs of cultured 
cardiomyocytes staining with α-sarcomeric actin antibody after the following treatments: Vehicle 
control, Losartan, PD-123319, Ang II, Ang II plus Losartan, or Ang II plus PD-123319. B: Bar 
graphs summarizing the effect on cardiac hypertrophy in cardiomyocytes treated with the 
conditions described in the above. The scale in the images is 25 μm. Data are presented as means 
± SE, which were derived from three experiments and at least triplicate wells in each experiment. 
**P < 0.01 vs. cardiomyocytes treated with vehicle control. #P < 0.05 vs. cardiomyocytes treated 
with Ang II. 
After the determination of blockade of AT1R or AT2R on Ang II-induced cardiac 
hypertrophy, we measured the effect of different Ang II receptor antagonists on Ang II-induced 
elevation of Class I PI3-kinase activity. The was measured using the ELISA kit in cardiomyocytes 
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treated by Vehicle control or Ang II (10-6 M) with or without pretreatment with the Ang II receptor 
type 1 antagonist of Losartan (1 μM, 30 min) or Ang II receptor type 2 antagonist PD-123319 (1 
μM, 30 min). The results are presented in Figure 16, demonstrating treatment with Losartan 
significantly attenuated Ang II-induced increases in Class I PI3-kinase activity by 41.7 % in 
cardiomyocytes (PIP3 production (pmol/μg of protein) 1.42 ± 0.11 in Losartan vs. 1.76 ± 0.12 in 
Losartan + Ang II, n=3 experiments, P < 0.05 vs. Ang II). In contrast, treatment with PD-123319 
did not significantly alter Ang II-induced elevations in Class I PI3-kinase in cardiomyocytes (PIP3 
production (pmol/μg of protein) 1.51 ± 0.11 in PD-123319 vs. 2.84 ± 0.14 in PD-123319+Ang II, 
P > 0.05 vs. Ang II). In addition, treatment with Losartan or PD-123319 alone did not alter the 
basal Class I PI3-kinase activity. The results demonstrated that Ang II-induced Class I PI3-kinase 
activity in cardiomyocytes is mainly mediated via Ang II receptor Type 1. 
 
Figure 16: Effect of blockade of Ang II Receptor Type 1 or Type 2 on Ang II-induced Class 
I PI3-kinase activity in cardiomyocytes. Class I PI3-kinase activity in cardiomyocytes was 
determined using the ELISA kit after treated with Ang II (10-6 M) with or without the Ang II 
receptor type 1 antagonist of Losartan or Ang II receptor type 2 antagonist of PD-123319  for 24 
h. Bar graphs summarizing the effect on Class I PI3-kinase activity in cardiomyocytes treated with 
the Vehicle control, Losartan (Los, 1 μM), PD-123319 (PD, 1 μM), Ang II, Ang II plus Losartan, 
or Ang II plus PD-123319. Data are presented as means ± SE, which were derived from three 
experiments and at least triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes treated 
with vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
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2.3.4. The effect of rapamycin, an mTOR inhibitor and autophagic inducer on Ang II-
induced ROS generation and cardiac hypertrophy 
Since autophagy is an effective tool to eliminate mitochondria-derived ROS, we examined 
the role of mTOR as a negative regulator of autophagy in Ang II-induced mitochondrial ROS 
generation. The mitochondrial ROS generation was measured using the MitoSox fluorescence 
approach in cardiomyocytes treated by control or Ang II (10-6 M) with or without pretreatment 
with the mTOR inhibitor, Rapamycin (100 nM, 30 min). The results are presented in Figure 17, 
demonstrating that treatment of cardiomyocytes with Rapamycin dramatically attenuated Ang II-
induced increases in mitochondrial ROS accumulation by 33.6 % in cardiomyocytes (ROS 
generation 98.30 ± 2.40 % in Rapamycin alone vs. 112.3 ± 3.20 % in Rapamycin plus Ang II, n=3 
experiments, P < 0.05 vs. Ang II). In addition, treatment with rapamycin alone did not alter the 
basal mitochondrial ROS generation. The results demonstrated that Ang II-induced ROS 
generation in cardiomyocytes is alleviated after the blockade mTOR and with enhanced autophagy.  
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Figure 17: Effect of blockade of mTOR on Ang II induced-ROS generation in 
cardiomyocytes. Mitochondrial ROS levels were determined using the oxidant-sensitive 
fluorogenic probe MitoSOX in cardiomyocytes after treated with Ang II (10-6 M) with or without 
the mTOR inhibitor of Rapamycin (Rapa, 100 nM) for 24 hours. Bar graphs summarizing the 
effect on mitochondrial ROS production in cardiomyocytes treated with the conditions described 
in the above. Data are presented as means ± SE, which were derived from three experiments and 
at least triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes treated with vehicle 
control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
After the determination of blockade of mTOR on Ang II-induced ROS generation, we 
tested the effect of rapamycin on cardiac hypertrophy. The cardiac hypertrophy in cardiomyocytes 
was measured using the α-actin immunofluorescence in cardiomyocytes treated by Vehicle control 
or Ang II (10-6 M) with or without pretreatment with the mTOR inhibitor, Rapamycin (100 nM, 
30 min). The results are presented in Figure 18, demonstrating treatment with rapamycin 
significantly attenuated Ang II-induced increases in cardiac hypertrophy by 38.7 % in 
cardiomyocytes (Relative cellular surface area 98.6 ± 5.4 % in Rapamycin alone vs. 125.2 ± 6.20 % 
in Rapamycin plus Ang II, n=3 experiments, P < 0.05 vs. Ang II). In addition, treatment with 
Rapamycin alone did not alter the basal hypertrophic state of cardiomyocytes. In summary, the 
results demonstrate that Ang II-induced cardiac hypertrophy in cardiomyocytes is alleviated by 
blockade of mTOR and promotion of autophagy in cardiomyocytes. 
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Figure 18: Effect of blockade of mTOR on Ang II induced-cardiac hypertrophy in 
cardiomyocytes. Cardiac hypertrophy levels were determined using the immunofluorescence 
staining in cardiomyocytes after treated with Ang II (10-6 M) with or without the mTOR inhibitor 
of Rapamycin (Rapa, 100 nM) for 24 hours. Bar graphs summarizing the effect on mitochondrial 
ROS production in cardiomyocytes treated with the conditions described in the above. Data are 
presented as means ± SE, which were derived from three experiments and at least triplicate wells 
in each experiment. **P < 0.01 vs. cardiomyocytes treated with vehicle control. #P < 0.05 vs. 
cardiomyocytes treated with Ang II. 
2.3.5. The effect of mito-TEMPO, a mitochondrial ROS scavenger on autophagy, ROS 
generation, and cardiac hypertrophy 
After we tested the effect of blockade of two different types of Ang II receptors on Ang II-
induced cardiac remodeling, scavengers targeting at ROS generation in damaged mitochondria 
were examined. The effect of high dose of Ang II on autophagy in cardiomyocytes was examined 
with and without presence of Mito-TEMPO (Mito, 1 μM, mitochondria-targeting ROS scavenger, 
especially for superoxide elimination) 30 minutes before exposure to 10-6 M Ang II. The results 
are presented in Figure 19, and preincubation of cardiomyocytes with mito-TEMPO significantly 
diminished Ang II-induced autophagy by 52.4 % (0.98 ± 0.06 in mito-TEMPO alone vs. 1.24 ± 
0.11 in mito-TEMPO plus Ang II, n=3 experiments, P < 0.05). The results demonstrated that Ang 
II-induced autophagic alteration in cardiomyocytes is due to the accumulation of damaged 
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mitochondria. Therefore, scavenging mitochondria-derived ROS generation by mito-TEMPO 
helps maintain the basal state of intracellular autophagy as a self-defense mechanism. 
 
Figure 19: Effect of scavenging mitochondrial ROS on Ang II-induced autophagy in 
cardiomyocytes. Autophagy was examined in cardiomyocytes by immunostaining fluorescence 
with MAP-LC3 antibody 24 hours after treated with Ang II (10-6 M) with or without the 
mitochondria-targeting ROS scavenger of Mito-TEMPO (Mito, 1 μM) for 24 h. Bar graphs 
summarizing quantitative analysis of autophagic alterations in cardiomyocytes treated under the 
conditions described in the above. Data are means ± SE and were derived from three experiments 
and at least triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes that treated with 
vehicle control. #P < 0.05 vs. cardiomyocytes that treated with Ang II. 
Next, the mitochondrial ROS production was measured using the MitoSox fluorescence in 
cardiomyocytes treated by control or Ang II (10-6 M) with or without pretreatment with the 
mitochondria-targeting ROS scavenger of Mito-TEMPO (1 μM, 30 min). The results are presented 
in Figure 20, demonstrating treatment with Mito-TEMPO pretreatment largely alleviated Ang II-
induced increases in mitochondrial ROS accumulation by 37.8 % in cardiomyocytes (98.20 ± 2.05 % 
in Mito-TEMPO alone vs. 105.5 ± 2.22 % in Mito-TEMPO plus Ang II, n=3 experiments, P < 
0.05 vs. Ang II). In addition, treatment with Mito-TEMPO alone did not alter the basal 
mitochondrial ROS production. The results demonstrated that Ang II-induced ROS generation in 
cardiomyocytes stems mainly from mitochondrial dysfunction. 
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Figure 20: Effect of scavenging mitochondrial ROS on Ang II-induced ROS generation in 
cardiomyocytes. Mitochondrial ROS levels were determined using the oxidant-sensitive 
fluorogenic probe MitoSOX in cardiomyocytes after treated with Ang II (10-6 M) with or without 
the mitochondria-targeting ROS scavenger of Mito-TEMPO (Mito, 1 μM) for 24 hours. Bar graphs 
summarizing the effect on mitochondrial ROS production in cardiomyocytes treated with the 
conditions described in the above. Data are presented as means ± SE, which were derived from 
three experiments and at least triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes 
treated vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
Thereafter, we tested the effect of different ROS scavengers on Ang II-induced cardiac 
hypertrophy. The cardiac hypertrophy in cardiomyocytes was measured using the α-actin 
immunofluorescence in cardiomyocytes treated by Vehicle control or Ang II (10-6 M) with or 
without pretreatment with the mitochondria-targeting ROS scavenger of Mito-TEMPO (1 μM, 30 
min). The results are presented in Figure 21, demonstrating treatment with Mito-TEMPO 
significantly attenuated Ang II-induced increases in cardiac hypertrophy by 40.2 % in 
cardiomyocytes (Relative cellular surface area 96.5 ± 3.97 % in Mito-TEMPO alone vs. 122.3 ± 
7.10 % in Mito-TEMPO plus Ang II, n=3 experiments, P < 0.05 vs. Ang II). In addition, treatment 
with Mito-TEMPO alone did not alter the basal cellular surface area. The results demonstrated that 
Ang II-induced cardiac hypertrophy in cardiomyocytes is mainly due to intracellular mitochondrial 
dysfunction induced-ROS generation. 
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Figure 21: Effect of scavenging mitochondrial ROS on Ang II-induced cardiac hypertrophy 
in cardiomyocytes. Cardiac hypertrophy levels were determined using the α-actin 
immunofluorescence staining in cardiomyocytes after treated with Ang II (10-6 M) with or without 
the mitochondria-targeting ROS scavenger of Mito-TEMPO (Mito, 1 μM) for 24 hours. Bar graphs 
summarizing the effect on cardiac hypertrophy in cardiomyocytes treated with the conditions 
described in the above. Data are presented as means ± SE, which were derived from three 
experiments and at least triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes treated 
with vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
2.4. Data summary and conclusion 
In the present chapter, we examined the role of Class I PI3-kinase in Ang II-induced cardiac 
remodeling via an autophagic-dependent pathway. The results demonstrated that Class I PI3-
kinase is activated under higher dosage Ang II exposure via interaction with AT1R, and this 
activation impairs autophagy, damages mitochondria, causes ROS generation, and ultimately 
promotes cardiac hypertrophy. This conclusion is supported by the following sets of evidence: 1) 
Class I PI3-kinase activity and Akt phosphorylation were significantly elevated under higher Ang 
II exposure in a dose-dependent manner and autophagy is decreased as the elevated Class I PI3-
kinase activity; 2) Pretreatment of LY-294002, a Class I PI3-kinase inhibitor diminished the 
activity of Class I PI3-kinase, restored autophagy, and alleviated Ang II-induced ROS generation, 
and cardiac hypertrophy; 3) Ang II-induced autophagic alteration, ROS generation, cardiac 
hypertrophy and Class I PI3-kinase activation are mainly mediated through AT1R; 4) Rapamycin, 
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a mTOR inhibitor and autophagic inducer, attenuated Ang II-induced ROS generation, and cardiac 
hypertrophy by enhancing autophagy; 5) The origin of Ang II-induced ROS generation that causes 
cardiac hypertrophy mainly comes from damaged mitochondria in cardiomyocytes. 
Previous evidence showed that the autophagic response to Ang II infusion may be both 
time and dose-dependent: Early and/or low dose of Ang II exposure promotes autophagy while 
chronic and/or high dose of Ang II exposure impairs autophagy. It is assumed that transient Ang 
II with lower concentration exposure would initially exert a quick autophagic response while 
prolonged Ang II exposure with higher concentration may induce decreased autophagy degree and 
subsequent cardiac remodeling aggravation [78]. In our results, corresponding outcomes are 
observed that Class I PI3-kinase are activated under high dosage Ang II exposure through the 
interaction of AT1R in the surface of cardiomyocytes. 
NADPH oxidase is thought to be the origin of ROS generation, and gp91phox (an essential 
subunit of NADPH oxidase) inactivation decelerate the speed of cardiac hypertrophy by Ang II 
infusion [84]. However, elimination of gp91phox in transgenic mice with active renin 
overexpression could not protect those individuals from cardiac hypertrophy [72]. Judging by this 
piece of information, mitochondria-derived ROS is considered as the major resource of Ang II-
induced ROS generation. Our results showed that pretreatment of Mito-TEMPO, a mitochondria-
derived ROS scavenger almost completely abolished the Ang II-induced ROS generation and 
cardiac hypertrophy, suggesting that Ang II-induced cardiac hypertrophy in primary 
cardiomyocytes is mainly due to the accumulation of damaged mitochondria. 
Taken together, the results from this chapter indicate an important role of Class I PI3-kinase 
in Ang II-induced cardiac remodeling, which means activation of this kinase under higher Ang II 
dosage impairs autophagy, causes ROS generation and cardiac hypertrophy. 
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CHAPTER III. THE ROLE OF CLASS III PI3-KINASE-DEPENDENT SIGNALING 
PATHWAYS IN ANG II-INDUCED AUTOPHAGY, ROS GENERATION, AND 
HYPERTROPHY IN PRIMARY CARDIOMYOCYTES 
3.1. Introduction 
In the previous chapter, we discovered that under higher dosage of Ang II-induced 
activation of Class I PI3-kinase inhibits autophagy, exacerbates ROS generation and severe cardiac 
hypertrophy. This phenomenon resembles the later stage of decompensatory cardiac hypertrophy 
and heart failure under chronic Ang II exposure. According to the relationship between Ang II 
dosage and autophagy shown in Chapter II, we found lower dosage of Ang II potentiated 
autophagy, and it is postulated that this autophagic increment is due to the activation of another 
signaling pathway other than Class I PI3-kinase. 
Since autophagy mainly degrades damaged intracellular components and maintains cardiac 
homeostasis, it is convinced that autophagy plays distinct roles at different stages of cardiac 
hypertrophy as a two-bladed sword and the underlining mechanism is complicated and intertwined 
because previous literatures reported contradictory outcomes regarding the relationship between 
autophagy and hypertrophy. In general, basal autophagy keeps cardiac structure and functions via 
energy preparation, clearance of accumulated ROS and structural misfolding protein. Also, 
autophagic upregulation protects cardiomyocytes from hemodynamic stress which is detrimental 
to cardiomyocytes [53]. Thus, it is universally recognized that elevation of autophagy under 
various noxious stimuli at the initial exposure prevents cardiomyocytes from further protein 
synthesis and resultant cardiac hypertrophy. Furthermore, it is commonly accepted that mitophagic 
induction helps reduce oxidative stress-induced mitochondrial damage. Failure to remove those 
damaged mitochondria causes their accumulation, and generates higher levels of ROS, resulting 
in protein, lipid, and DNA damage [85]. Increased ROS level results in a potential reduction and 
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leakage in mitochondrial membranes, and subsequent activation of Parkin-dependent mitophagy 
gets obstructed, leading to higher level of ROS generation [86]. Therefore, autophagic 
deterioration in mitochondria (obstruction of mitophagy) by Class III PI3-kinase blockade may 
exacerbate Ang II-induced ROS generation and cardiac hypertrophy. The underlining mechanism 
might rely on the discovery that ATG4 activity inhibition via an essential cysteine residue 
oxidation, blocking PE cleavage from PE-conjugated LC3 and subsequent impairment of 
autophagy as stated before [87]. 
It is reported that among those PI3-kinases, only Class I and Class III PI3-kinases are 
expressed in the heart [60]. Contrary to the effect of Class I PI3-kinase, Class III PI3-kinase 
pathway activation facilitates autophagy with sequential activations of its relevant components of 
Class III PI3-kinase→Beclin-I→Vps34 [88]. Activation of Class III PI3-kinase pathway is also 
involved in autophagic alteration in several cell-lines including H9C2 cell line which is an analog 
of cardiomyocytes. 3-MA, a Class III PI3-kinase inhibitor, by specifically inactivating Vps34 in 
Class III PI3-kinase [64], suppresses autophagosome formation in starvation-induced autophagy 
in rat cardiomyocyte-derived H9C2 [89]. Therefore, it is also of vital importance to examine the 
role of Class III PI3-kinase in Ang II-induced autophagy, ROS generation, and cardiac hypertrophy. 
We assume that Class III PI3-kinase is continuously activated under a very small amount of Ang 
II exposure and this activation, in turn, initiates the elevation of autophagy to counteract the 
hypertrophic effect of Ang II. Therefore, it is necessary to detect the influence of Class III PI3-
kinase with its relevant blocker of 3-MA.  
3.2. Materials and methods 
3.2.1. Preparation of cardiomyocyte cultures 
Twelve-week-old male and female SD rats were obtained from Charles River Farms 
(Charles River Laboratories International, Wilmington, MA). Rats were housed at 25 ± 2°C on a 
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12:12-h light-dark cycle and provided with food and water ad libitum. All animal protocols were 
approved by the North Dakota State University Institutional Animal Care and Use Committee. 
Primary cardiomyocytes were randomly divided into each group. Generally, dissociated neonatal 
rat primary cardiomyocytes were cultured for 5 days, and culture media was changed every other 
day. Then those cardiomyocytes were treated with relevant reagents: 10-10~10-5 M Angiotensin II 
(Ang II, Alfa Aesar, J60866, Reston, VA), 1 μM 3-Methyladeninie (3-MA, BioVision, 2249-100), 
1 μM Losartan (Los, Sigma Aldrich, 61188, St. Louis, MO), and 1 μM PD-123319 (PD, Sigma 
Aldrich, P186, St. Louis, MO). All of those reagents were administrated 30 minutes before Ang II 
stimulation in all experiments except dosage dependent-autophagy effect test of Ang II. 0.1% 
DMSO vehicle was used as negative control for other subsequent experiments. The total exposure 
duration of Ang II and other reagents was 24 hours for autophagy and hypertrophy determination. 
While for ROS generation determination, intracellular ROS levels were measured immediately 
after addition of Ang II or HBSS control by incubation with MitoSOX since superoxide is unstable 
and could be gradually neutralized by intracellular superoxide dismutase (SOD) as time elapses. 
3.2.2. Treatment protocol 
1~3 days old neonatal SD rats were anesthetized by sodium pentobarbital (200 mg/kg, i.p., 
Sigma, St. Louis, MO). Ventricles of the heart were quickly excised, minced into small pieces in 
cold HBSS and washed for several additional times. The minced tissue was digested with 0.1% 
trypsin in a 37oC water bath with shaking for 5-min rounds of tissue digestion (10-12 times). After 
each incubation, the supernatant was added to an equal volume of DMEM containing 10% FBS. 
Then, isolated cells were filtrated with 70 μm cellular sieve, centrifuged at 1,000 rpm for 10 min. 
Supernatants were discarded after centrifuge; and cellular pellets were suspended in DMEM 
composed of 10% FBS and 1% penicillin-streptomycin at 37℃ for 1.5 hr in a humidified 
atmosphere with 95% O2 and 5% CO2 to allow the most of non-myocyte cells, such as fibroblasts, 
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to attach on the plate bottom. Suspended cellular solution (final cellular density 5×105 cells/cm2) 
was transduction to a 24-well plate for morphological studies and to a 96-well plate for 
measurement of ROS levels. In the first three days, Brdu (10-4 M) was added to suppress fibroblast 
growth. All of the manipulations were performed in culture hood to ensure an aseptic environment. 
After the cell cultures reached confluence (5 days on average) in an incubator filled with a 
humidified atmosphere of 5% CO2 at 37 °C, cardiomyocytes were used for in vitro experiments. 
3.2.3. Autophagy determination 
Cultured cardiomyocytes were treated with relevant reagents for 24 h. Each treatment was 
performed in triplicate wells. In brief, after treatment, cells were fixed in 4% PFA at 4℃ for 30 
min, and washed with fresh washing solution (0.1% Triton X-100 in PBS) three times. After pre-
incubation with 3% of bovine serum albumin (BSA) for 20 minutes, the cells were incubated with 
primary antibody of MAP-LC3 (Santa Cruz Biotechnology, sc-134226, Santa Cruz, CA), which 
was diluted to 1:100 with PBS containing 3% BSA, for overnight at 4℃. After three washings 
with the PBS solution, the cells were incubated with fluorescence-conjugated Alexa Fluor 488 
fluorescence-conjugated goat anti-rabbit IgG antibody (Molecular probes, A-11034, Waltham, MA) 
(1:1000 diluted in PBS) for 2 h at room temperature in dark. Photographic images of 
cardiomyocytes were taken with a fluorescence microscope (Olympus Microsystems, Waltham, 
MA). The MAP-LC3 antibody immunostaining positive images were analyzed, the puncta inside 
cardiomyocytes were counted and the average puncta number in each cell was calculated with at 
least 10 area of cells in each sample [77, 78]. The more average puncta in each cell indicates the 
larger degree of autophagy occurrence. HBSS negative control group was set as “1” and the results 
of each sample were expressed as “Fold vs. Control”. 
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3.2.4. ROS detection 
Mitochondrial ROS generation was determined using a superoxide-sensitive (O2∙-) 
fluorogenic probe of MitoSox (Thermo Fisher, M-36008, Rockford, IL). MitoSOX has a 
dihydroethidium (DHE) part linked to triphenylphosphoninum (TPP) component and yields red 
fluorescence when oxidized (excitation/emission wavelength: 510/580 nm). This compound is 
more concentrated in the mitochondria than in the cytosol since the former has more positively 
charged TPP [79]. Cultured cardiomyocytes were pretreated with relevant reagents except Ang II 
for 30 minutes. Then the cardiomyocytes were treated with Ang II (10-6 M) or HBSS control. 
Intracellular mitochondrial ROS levels were measured immediately after the addition of Ang II or 
HBSS control by incubation with MitoSOX (5×10-6 M, 15 minutes). The intracellular ROS levels 
were measured using a fluorometric imaging plate reader (Spectra Max Gemini EM, Molecular 
Devices) to detect changes in fluorescence resulting from intracellular probe oxidation. The 
vehicle (DMSO, 0.1%) control group was set as 100% MitoSOX fluorescence. Fluorescent images 
were also acquired using a fluorescence microscope (Olympus, Microsystems, Waltham, MA) to 
visualize the strength of MitoSOX fluorescence in primary cardiomyocytes. 
3.2.5. Cardiac hypertrophy determination 
Cultured cardiomyocytes were treated with relevant reagents and Ang II for 24 h. Each 
treatment was performed in triplicate wells. Anti-α-actin antibody was used for cardiac 
hypertrophy via immunofluorescence staining. In brief, cells were fixed in 4% PFA at 4℃ for 30 
minutes, and washed with fresh washing solution (0.1% Triton X-100 in PBS) for three times. 
After pre-incubation with 3% of bovine serum albumin (BSA) for 20 minutes, the cells were 
incubated with primary antibody of sarcomeric α-actin (Santa Cruz Biotechnology, sc-53142, 
Santa Cruz, CA), which was diluted to 1:100 with PBS containing 3% BSA, overnight at 4℃. 
After three washings with the PBS solution, the cells were incubated with fluorescence-conjugated 
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Alexa Fluor 594 goat anti-mouse IgG (Molecular probes, A-11032, Waltham, MA) (1:1000 diluted 
in PBS) for 2 h at room temperature in dark. Photographic images of cardiomyocytes were taken 
with a fluorescence microscope (Olympus Microsystems, Waltham, MA). The cellular surface area 
of positive image for α-actin staining cardiomyocytes was measured by the image analysis 
software (NIH Image J) [80]. Variations of cellular size were expressed as relative cellular surface 
area versus the control. The 0.1% DMSO negative control group was set as 100%. 
3.2.6. Class III PI3-kinase activity assay 
After treatment of relevant reagents, primary cardiomyocytes from neonatal rats were 
rinsed with ice-cold PBS and Buffer A (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 1 mM CaCl2, 1 
mM MgCl2, and 1 mM Na3VO4) three times each. Then Buffer A was removed and the cells were 
immediately lysed in lysis buffer Lysis Buffer (Buffer A plus 1% NP-40, 10% glycerol, and 1 mM 
PMSF) at 4°C for 20 minutes by rocking. The cells were scraped from dishes, transferred to 1.5 
mL microcentrifuge tubes and centrifuged for 10 minutes at 13,000 g to sediment insoluble 
material. Thereafter, supernatant was transferred to new tubes added with 5 μL of anti-hVps34 IP 
antibody (Echelon Biosciences, Z-R015, Salt Lake City, UT) and the samples were 
immunoprecipitated as described previously [90].  to each tube and incubated for one hour at 4°C 
with gentle rotation. 60 μL of 50 % slurry of Protein A- Sepharose beads in PBS was added into 
each tube with gentle rotation for overnight, and tubes were centrifuged for 5 seconds for collection 
of immunoprecipitated enzymes. Sediments were washed three times with Buffer A plus 1% NP-
40, three times with 0.1 M pH 7.4 Tris-HCl with 5 mM LiCl and 1 mM Na3VO4, twice with TNE 
(10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA) containing 1 mM Na3VO4 and twice with 
Vps34 kinase reaction buffer (10 mM Tris pH 8, 100 mM NaCl, 1 mM EDTA, 10 mM MnCl2, and 
50 μM ATP). The last wash was aspirated completely. A PIP standard curve (ranging from 9.8 nM 
to 10 μM) was simultaneously prepared and determined at 450 nm wavelength. Each assay was 
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repeated at least 3 times. Then Class III PI3-kinase assay was performed using competitive 
enzyme-linked immunosorbent assay kit (K-3000, Echelon Biosciences, Salt Lake City, UT) by 
exactly following the instruction provided by the manufacturer. Each assay was repeated at least 
3 times. 
3.2.7. Data analysis 
All data are presented as means ± SE. Statistical significance was evaluated by one- or two-
way ANOVA, as appropriate, followed by either a Newman–Keuls or Bonferroni post hoc analysis 
when indicated. Differences will be considered significant at P<0.05, and individual probability 
values are noted in figures. 
3.3. Results 
3.3.1. Dose-dependent effect of Ang II on Class III PI3-kinase activity 
Class III PI3-kinase activity was measured since we assume this kinase is involved in both 
physiological and pathological higher Ang II concentration. For this reason, a measurement of PIP 
production is the indirect estimation of intracellular Class III PI3-kinase levels. PIP levels were 
measured 24 hours after treatment of Ang II with different dosages or HBSS control. After Ang II 
treatment, the cardiomyocytes were lysed for determination of PIP by the ELISA kit according to 
the manufacturer’s protocol. Results are shown in Figure 22, demonstrating that the activity of 
Class III PI3-kinase is enhanced under lower dosage of Ang II (PIP production (in pmol/μg of 
protein) 1.25 ± 0.09 in HBSS control vs. 2.93±0.09 in 10-7 M Ang II, increase by 134.4 %, P <0.01 
vs. HBSS control), while the activity reaches the plateau when the Ang II concentration exceeds 
10-7 M (PIP production (in pmol/μg of protein) 2.93 ± 0.09 in 10-7 M Ang II vs. 3.15 ± 0.12 in 10-
5 M Ang II, P > 0.05 vs. 10-7 M Ang II), suggesting Class III PI3-kinase is activated under lower 
dosage of Ang II exposure at the initial stage. In contrast of the dose-dependent stimulatory effect 
of Ang II on Class I PI3-kinase, the dose-dependent stimulatory effect of Ang II on Class III PI3-
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kinase started at 10-9 M and reached to the peak at 10-7 M. These results indicate that Class III PI3-
kinase are more sensitive to Ang II as compared with Class I PI3-kinase in cardiomyocytes. 
 
Figure 22: Dose-dependent effect of Ang II on the activities of Class III PI3-kinase in 
cardiomyocytes. Bar graphs summarizing the activities of Class III PI3-kinases measured using 
PIP ELISA kits in cardiomyocytes as described in Methods. The Class III PI3-kinase activities are 
presented as the concentrations of PIP in per microgram protein 24 hours after treated with HBSS 
control or Ang II with different dosages. Data are presented as means ± SE, which were derived 
from three experiments and at least triplicate wells in each experiment. *P < 0.05, **P < 0.01, ***P 
< 0.001 as compared with cardiomyocytes treated with HBSS control. 
3.3.2. The effect of 3-MA, a Class III PI3-kinase inhibitor on Ang II-induced autophagy, 
ROS generation, cardiac hypertrophy, and Class III PI3-kinase activity 
Next, we identified the involvement of Class III PI3-kinase in Ang II-induced autophagy, 
the effect of high dose of Ang II on cardiomyocyte autophagy was examined with and without 
presence of 3-MA (MA, an inhibitor of Class III PI3-kinase). The results are presented in Figure 
23 and demonstrated that pretreatment with 3-MA (1 μM, 30 min) dramatically attenuated Ang II-
induced autophagy by 52.1 % (0.87 ± 0.07 in 3-MA alone vs. 1.25 ± 0.08 in 3-MA plus Ang II, 
n=3 experiments, P < 0.05 vs. Ang II). In addition, treatment with 3-MA alone did not alter the 
basal autophagy in cardiomyocytes. Therefore, Class III PI3-kinases contribute to Ang II-induced 
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elevation in autophagy. Taken together, both Class I and Class III PI3-kinases contribute to Ang 
II-induced elevation in autophagy via a Class III PI3-kinase-mediated stimulatory mechanism and 
a Class I PI3-kinase-mediated inhibitory mechanism. 
 
Figure 23: Effect of blockade of Class III PI3-kinase on Ang II-induced autophagy in 
cardiomyocytes. Autophagy was examined in cardiomyocytes by immunostaining fluorescence 
with MAP-LC3 antibody 24 hours after treated with Ang II (10-6 M) with or without the Class III 
PI3-kinase inhibitor, 3-MA (MA, 1 μM). A: Representative fluorescence micrographs of cultured 
cardiomyocytes stained with MAP-LC3 antibody after the following treatments: Vehicle control, 
1 μM 3-MA, an inhibitor of Class III PI3-kinase, 10-6 M Ang II, or 3-MA + Ang II. B: Bar graphs 
demonstrating the effect of autophagy with the addition of 3-MA under 10-6 M Ang II exposure. 
The scale in the images is 25 μm. Data are means ± SE and were derived from three experiments 
and at least triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes that treated with 
vehicle control. #P < 0.05 vs. cardiomyocytes that treated with Ang II. 
Next, we examined the role of Class III PI3-kinase in Ang II-induced mitochondrial ROS 
generation. The mitochondrial ROS generation was measured using the MitoSox fluorescence 
approach in cardiomyocytes treated by control or Ang II (10-6 M) with or without pretreatment 
with the Class III PI3-kinase inhibitor, 3-MA (1 μM, 30 min). The results are presented in Figure 
24, demonstrating that treatment with 3-MA dramatically promoted Ang II-induced elevations in 
mitochondrial ROS production in cardiomyocytes by 17.3 % (105.2 ± 5.32 % in 3-MA alone vs. 
198.6 ± 4.52 % in 3-MA plus Ang II, n=3 experiments, P < 0.05 vs. Ang II). In addition, treatment 
with 3-MA alone did not alter the basal mitochondrial ROS production. In summary, those data 
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suggest that Class III PI3-kinase is involved in Ang II-induced mitochondrial ROS accumulation 
in cardiomyocytes through a Class III PI3-kinase-dependent stimulatory mechanism. 
 
Figure 24: Effect of blockade of Class III PI3-kinase on Ang II-induced mitochondrial ROS 
generation in cardiomyocytes. Mitochondrial ROS levels were determined using the oxidant-
sensitive fluorogenic probe MitoSOX in neonatal rat primary cardiomyocytes. Mitochondrial ROS 
levels were determined using the oxidant-sensitive fluorogenic probe MitoSOX in cardiomyocytes 
after treated with Ang II (10-6 M) with or without the Class III PI3-kinase inhibitor, 3-MA (MA, 1 
μM) for 24 hours. A: Representative fluorescence micrographs of cultured cardiomyocytes loaded 
with MitoSOX after the following treatments: Vehicle control, 3-MA (1 μM, an inhibitor of Class 
III PI3-kinase), 10-6 M Ang II, or 3-MA + Ang II. B: Bar graphs summarizing the effect on 
mitochondrial ROS production in cardiomyocytes treated with the conditions described in the 
above. The scale in the images is 25 μm. Data are presented as means ± SE, which were derived 
from three experiments and at least triplicate wells in each experiment. **P < 0.01 vs. 
cardiomyocytes treated with vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
Thereafter, we examined the role of Class III PI3-kinase in Ang II-induced cardiac 
hypertrophy. The cardiac hypertrophy in cardiomyocytes was measured using the α-actin 
immunofluorescence in cardiomyocytes treated by Vehicle control or Ang II (10-6 M) with or 
without pretreatment with the Class III PI3-kinase inhibitor, 3-MA (1 μM, 30 min). The results are 
presented in Figure 25, demonstrating that treatment with 3-MA significantly attenuated Ang II-
induced increases in cardiac hypertrophy by 29.9 % in cardiomyocytes (128.4 ± 6.28% in 3-MA 
alone vs. 265.4 ± 10.38 % in 3-MA % in 3-MA plus Ang II, n=3 experiments, P < 0.05 vs. Ang 
II). In addition, treatment with 3-MA alone slightly elevated the basal hypertrophic state of 
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cardiomyocytes. In summary, those data demonstrate that Class III PI3-kinases is involved in Ang 
II-induced cardiac hypertrophy in cardiomyocytes through a Class III PI3-kinase-dependent 
inhibitory mechanism. 
 
Figure 25: Effect of blockade of Class III PI3-kinase on Ang II-induced cardiac hypertrophy 
in cardiomyocytes. Cardiac hypertrophy in cardiomyocytes was determined using 
immunofluorescent staining with α-sarcomeric actin antibody after treated with Ang II (10-6 M) 
with or without the Class III PI3-kinase inhibitor, 3-MA (MA, 1 μM) for 24 hours. A: 
Representative fluorescence micrographs of cultured cardiomyocytes loaded with α-sarcomeric 
actin antibody after the following treatments: Vehicle control, 3-MA (1 μM, an inhibitor of Class 
III PI3-kinase), 10-6 M Ang II, or Ang II + 3-MA. B: Bar graphs summarizing the effect on cardiac 
hypertrophy in cardiomyocytes treated with the conditions described in the above. The scale in the 
images is 25 μm. Data are presented as means ± SE, which were derived from three experiments 
and at least triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes treated with vehicle 
control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
Next, we measured the effect of blockade of Class III PI3-kinase on Ang II-induced Class 
III PI3-kinase activity. The Class III PI3-kinase activity was measured using the ELISA kit in 
cardiomyocytes treated by control or Ang II (10-6 M) with or without treatment with the Class III 
PI3-kinase inhibitor, 3-MA (1 μM, 30 min). The results are presented in Figure 26, demonstrating 
that treatment of cardiomyocytes with Ang II significantly increased Class III PI3-kinase activity 
at the presence of vehicle (DMSO, 0.1%) as expected (PIP production (pmol/μg of protein) 1.25 ± 
0.09 in control vs. 3.06 ± 0.12 in Ang II, n=3 experiments, P <0.01). More surprisingly, treatment 
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with 3-MA dramatically attenuated Ang II-induced increases in Class III PI3-kinase activity by 
(PIP production (pmol/μg of protein) 1.17 ± 0.10 in 3-MA vs. 1.46 ± 0.08 in 3-MA plus Ang II, 
n=3 experiments, P < 0.05 vs. Ang II). Besides, the addition of 1 μM 3-MA alone did not affect 
the basal activity of Class III PI3-kinase. 
 
Figure 26: Effect of blockade of Class III PI3-kinase on Ang II-induced Class III PI3-kinase 
activity in cardiomyocytes. Class III PI3-kinase activity in cardiomyocytes was determined using 
the ELISA kit after treated with Ang II (10-6 M) with or without the Class III PI3-kinase inhibitor, 
3-MA (MA, 1 μM) for 24 hours. Bar graphs summarizing the effect on Class III PI3-kinase activity 
in cardiomyocytes treated with Vehicle control, 3-MA (1 μM, an inhibitor of Class III PI3-kinase), 
10-6 M Ang II, or Ang II + 3-MA. Data are presented as means ± SE, which were derived from 
three experiments and at least triplicate wells in each experiment. **P < 0.01 vs. cardiomyocytes 
treated with vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
3.3.3. The effect of blockade of different Ang II receptor types on Class III PI3-kinase activity 
At last, we measured the effect of different Ang II receptor antagonists on Ang II-induced 
elevation of Class III PI3-kinase activity using the ELISA kit in cardiomyocytes treated by Vehicle 
control or Ang II (10-6 M) with or without pretreatment with the Ang II receptor type 1 antagonist 
of Losartan (1 μM, 30 min) or Ang II receptor type 2 antagonist PD-123319 (1 μM, 30 min). The 
results are presented in Figure 27, showing treatment with Losartan significantly attenuated Ang 
II-induced increases in Class III PI3-kinase activity by 63.3 % in cardiomyocytes (PIP production 
(pmol/μg of protein) 1.12 ± 0.06 in Losartan vs. 1.51 ± 0.07 in Losartan + Ang II, n=3 experiments, 
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P < 0.05 vs. Ang II). In contrast, treatment with PD-123319 did not significantly alter Ang II-
induced elevations in Class III PI3-kinase in cardiomyocytes (PIP production (pmol/μg of protein) 
1.35 ± 0.06 in PD-123319 vs. 2.97 ± 0.13 in PD-123319+Ang II, P > 0.05 vs. Ang II). In addition, 
treatment with Losartan or PD-123319 alone did not alter the basal Class III PI3-kinase activity. 
The results demonstrated that Ang II-induced Class III PI3-kinase activity in cardiomyocytes is 
mainly mediated via Ang II receptor Type 1. 
 
Figure 27: Effect of blockade of Ang II Receptor Type 1 or Type 2 on Ang II-induced Class 
III PI3-kinase activity in cardiomyocytes. Class III PI3-kinase activity in cardiomyocytes was 
determined using the ELISA kit after treated with Ang II (10-6 M) with or without the Ang II 
receptor type 1 antagonist of Losartan (Los, 1 μM) or Ang II receptor type 2 antagonist of PD-
123319 (PD, 1 μM) for 24 h. Bar graphs summarizing the effect on Class III PI3-kinase activity in 
cardiomyocytes treated with the Vehicle control, Losartan (Los, 1 μM), PD-123319 (PD, 1 μM), 
Ang II, Ang II plus Losartan, or Ang II plus PD-123319. Data are presented as means ± SE, which 
were derived from three experiments and at least triplicate wells in each experiment. **P < 0.01 vs. 
cardiomyocytes treated with vehicle control. #P < 0.05 vs. cardiomyocytes treated with Ang II. 
3.4. Data summary and conclusion 
The purpose of this part is to examine the role of Class III PI3-kinase in Ang II-induced 
cardiac remodeling via an autophagic-dependent pathway. This was achieved by observing and 
evaluating the effects of the relevant blocker of Class III PI3-kinase of 3-MA on autophagy, ROS 
generation, cardiac hypertrophy, and Class III PI3-kinase activity. The results demonstrated that 
Class III PI3-kinase is activated under lower Ang II dosage, facilitates autophagy, and protects 
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cardiomyocytes from ROS generation, and cardiac hypertrophy. This conclusion is supported by 
the following evidence: 1) Class III PI3-kinase activity was elevated at lower Ang II dosages with 
more sensitivity than that of Class I PI3-kinase, and autophagy was promoted as the elevated Class 
III PI3-kinase activity; 2) Pretreatment of 3-MA, a Class III PI3-kinase inhibitor lowered Class III 
PI3-kinase activity, diminished Ang II-induced autophagy, and exacerbated Ang II-induced ROS 
generation and cardiac hypertrophy; 3) Ang II-induced Class III PI3-kinase activation is also 
mainly mediated through AT1R instead of AT2R. 
The main function of Class III PI3-kinase is to serve PI as substrate and convert it into PIP. 
Effector proteins consisting of FYVE or PX domains are adopted by localized PIP production, and 
facilitate docking and fusion process in the membrane when internal vesicles are established [91]. 
3-methyladenine (3-MA) is a potent autophagic inhibitor by suppressing autophagosome 
formation and autophagic/lysosomal fusion in starvation-induced autophagy via glucose 
deprivation in rat cardiomyocyte-derived H9C2 cell lines via a Class III PI3-kinase-dependent 
pathway [89]. Therefore, 3-MA is widely adopted to examine the role of autophagy in various 
research areas such as tumorigenesis and cancer therapy, and previous studies found that this 
reagent might be useful to destroy cancer cells [92].  
In the current study, we used 3-MA to inhibit Class III PI3-kinase, and further obstruct 
autophagy. Our results indicated that autophagic decrement caused elevated ROS generation and 
cardiac hypertrophy, suggesting autophagic induction would be an effective initiative to prevent 
cardiac remodeling and facilitate cardiomyocyte to survive. Vps34 is the only conserved 
component of PI3-kinase family in all eukaryotes, playing essential regulatory roles in 
physiological membrane trafficking such as endosome-lysosome formation, endocytosis, and 
autophagosome formation/flux, etc [93]. Nucleation takes place after induction within the whole 
process of autophagy, and Vps34 is one of those components within the Beclin1-Atg14-Vps34-
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Vps15 complex which are essential for nucleation [94]. Thus, Vps34 is a vital component of Class 
III PI3-kinase that generates PIP, and this component is essential for the vacuolar protein delivery 
which is the very first step of autophagy. 3-MA is potent to inhibit the activity of Vps34 and 
terminate autophagy in the nucleation process Once Vps34 component is inactivated by 3-MA, the 
process of autophagy is totally blocked [95]. Overall, autophagic impairment by Class III PI3-
kinase inhibition caused severe ROS generation and cardiac hypertrophy in primary 
cardiomyocytes under Ang II exposure. 
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CHAPTER IV. VALIDATION OF THE ROLE OF CLASS I PI3-KINASE, 
AUTOPHAGY, AND ROS GENERATION IN ANG II-INDUCED CARDIAC 
HYPERTROPHY IN CHRONIC ANG II-PERFUSED VERSUS CONTROL RATS 
4.1. Introduction 
In the previous chapters, we have examined the effects of both Class I and Class III PI3-
kinases on autophagy, ROS generation, cardiac hypertrophy and the activities of relevant PI3-
kinases in cultured primary cardiomyocytes from neonatal SD rats. Although in vitro studies 
provide a convenient, stable and reliable environment, they cannot perfectly mimic the real 
physiological condition in living bodies in the presence of hormone secretion and hemodynamic 
factors such as blood pressure, heart beat and contraction. To make up for this flaw, we performed 
in vivo study in adult rat hearts in this chapter to further identify the roles that Class I PI3-kinase 
play in Ang II-induced cardiac remodeling in adult rats. 
It is well known that Ang II stimulates the cardiomyocytes by increasing their contractility 
and cardiac remodeling via stimulation of angiotensin receptor type I (AT1R). Accumulating 
evidences indicate that PI3-kinases are involved in the intracellular downstream signaling 
transduction pathways of AT1 receptors in cardiomyocytes [67, 68]. PI3-kinases are divided into 
three subclasses as Class I, II, III due to the specificity of substrates, varied molecular structures 
and diversified physiological functions, and only Class I & Class III PI3-kinases are expressed in 
the heart [60]. It’s also reported that targeted overexpression of Class I PI3-kinase increases heart 
size, resulting in cardiac hypertrophy in the in vivo studies [62]. However, it is still unclear whether 
and how those PI3-kinases mediate Ang II-induced cardiac remodeling in living animals. 
Therefore, to elucidate the underlying mechanisms of Ang II-induced cardiac hypertrophy, it is 
crucial to adopt in vivo studies in an authentic physiological environment as a useful tool for 
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understanding the mechanisms of Ang II-induced cardiac remodeling via an autophagic-dependent 
manner. 
In the previous chapters, application of ordinary chemical reagents relevant to the activity 
of PI3-kinases and mTOR were chosen to determine the role of PI3-kinase in Ang II-induced 
cardiac hypertrophy. Nevertheless, some shortcomings of the utilization of those chemical reagents 
in living animals should be paid attention to: 1). Their poor solubility in aqueous solvent makes it 
difficult to prepare a solution with desirable concentrations, while DMSO is a toxic solvent for 
living animals despite its higher solubility of those chemical reagents; 2). The actions of those 
drugs on living animals might be quite transient, while adaptations and drug resistance emerges as 
their prolonged exposure, losing sensitivity gradually; 3). The specificity of some reagents to their 
target molecules is not ideal. Thus, it is obliged for us to explore novel approaches to affect the 
activity of PI3-kinases without the usage of chemical reagents. 
In recent years, gene delivery to overexpress or knockout of certain proteins is attractive 
and regarded as hot spot areas of study. The vectors that carry genes have various forms such as 
inorganic complex, organic polymers and bioactive viral vectors. To name a few, bioactive viral 
vectors are a new star for their high transfection efficiency and their ability to accomplish the 
process of adsorption, infusion and propagation spontaneously while the non-viral vectors don’t 
own this privilege. Our lab has successfully delivered AAV2-apelin viral vector into the RVLM 
region of rat brains to enhance the apelin level and we learned its relationship with the MAP [96]. 
Previously, we also successfully delivered Lv-DNp85 and Lv-GFP into both primary neuron 
cultures and brain NTS region in WKY and SHR rats to inhibit the activity of Class I PI3-kinase 
[81]. Thus, we have competitive expertise to carry out this viral delivery technique in living 
animals. 
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Therefore, in the present chapter, we performed in vivo studies with lenti-viral vector gene 
transduction into adult rat hearts to consolidate our hypothesis that activated Class I PI3-kinase 
and impaired autophagy mediate Ang II-induced cardiac hypertrophy via a ROS-dependent 
mechanism. We have detected the physiological parameters such as blood pressure (BP), heart rate 
(HR), left ventricular contractile functions (dP/dt Max) to measure the heart functions in living 
adult rats by chronic blockade of Class I PI3-kinase. Further, we performed molecular biology and 
morphological studies to tell the effectiveness of blockade of Class I PI3-kinase with relevant 
lentiviral vectors. 
4.2. Materials and methods 
4.2.1. Animals 
Twelve-week-old male SD rats were obtained from Charles River Farms (Charles River 
Laboratories International, Wilmington, MA). Rats were housed at 25 ± 2°C on a 12:12-h light-
dark cycle and provided with food and water ad libitum. All animal protocols were approved by 
the North Dakota State University Institutional Animal Care and Use Committee. 
4.2.2. Myocardial in vivo gene delivery 
The lentiviral vectors containing dominant negative Class I PI3-kinase p85α subunit (Lv-
DNp85) and negative control viral vector Lv-GFP were constructed and titered as previously 
described (80). The dominant negative construct of the p85α subunit of the Class I PI3-kinase 
(DNp85α) was delivered in vivo in a lentiviral vector driven by EF1 promoter (LV-EF1-DNp85α-
IRES-eGFP). The titer was 2×1010 transducing units per milliliter, which was shown to be efficient 
in central cardiac transduction. For cardiac gene transfer, Lv-DNp85 and Lv-GFP were delivered 
into the heart via routine intra-aortic root injection. Briefly, adult male SD rats were anesthetized 
with a mixture of oxygen (1 L/min) and isoflurane (3%) delivered through their nose cones. Left 
anterior thoracotomy was carried out in the left second intercostal space. For arterial occlusion, 
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ligatures were looped around the main pulmonary arteries and the ascending aorta followed by a 
ligature occlusion. Then a PE-50 catheter insertion through the right carotid artery into the aortic 
root was made just above the aortic valve and below the occlusion ligature loop to determine blood 
pressure and exert injections in coronary arteria. Ice packs were used after the anesthesia to create 
a general hypothermia environment for the rats to cool their body temperatures below 26 ℃ and 
followed by injection of cardioplegic solution (2 µL/g body weight) containing (in mM): NaCl 
110, KCl 20, MgCl2 16, NaHCO3 10, and CaCl2 1.2 via the arterial catheter. Substance P was also 
added into the cardioplegic solution with the final concentration of 25 μg/mL to enhance the 
permeability of coronary artery wall and let the viral vectors pass through. Thereafter, 200 μL 
2×1010 TU/mL of Lv-GFP or Lv-DNp85 in the cardioplegic solution with Substance P was injected 
through the same catheter. Both occlusions were loosed 90 seconds after lenti-viral vectors 
injection, and dobutamine (12 μg/kg, 50 μL) was administered to make the heart beat again. and 
rat body temperature was heated back to normal with a heating pad. The chest was then closed by 
suture and the intrathoracic air was evacuated by syringe suction. 
4.2.3. Ang II subcutaneous infusion and blood pressure (BP) recording 
After cardiac injection of either Lv-DNp85 or Lv-GFP into the heart, Alzet osmotic pumps 
(Reservoir volume 200 μL) were implanted under the back skin of the rats for subcutaneous 
infusion of Ang II (200 ng/kg/min) or normal saline (NS). A four week-period was allowed for 
recovery from surgery and gene expression in the heart. The rats were then anaesthetized with 3% 
pentobarbital (50 mg/kg), and BP was recorded using PE-10 catheters fused to PE-50 catheters. 
The vascular catheters were prefilled with heparinized saline (100 IU/mL) and inserted into the 
right femoral artery. Left ventricular pressure (dp/dt Max) was recorded via right carotid artery 
catheterization. The vascular catheters were connected to a BP transducer and a bridge amplifier 
(AD instrument, Colorado Springs, CO, USA). The BP, heart rate (HR), and left ventricular dP/dt 
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Max were recorded and analyzed with PowerLab software (AD instrument). At the end of 
recording, hearts were harvested for subsequent morphologic measurements and protein 
expression investigation. 
4.2.4. Measurement of cardiac hypertrophy 
The hearts of each group were collected after BP and HR measurement and washed with 
saline. After heart weight and cardiac morphology were determined, they were transversely 
sectioned with a microtome (Leica). Hearts were fixed in 10% formalin/PBS and embedded in 
paraffin. Heart sections (10 μm) were cut using a cryo-microtome and placed on a slide. Paraffin 
sections were deparaffinized and rehydrated by incubating in 3 × 3 minutes in xylene, 3 × 3 minutes 
in 100% ethanol, 1 x 3 minutes in 95% ethanol, 1 × 3 minutes in 80% ethanol, and 1 × 5 minutes 
in deionized H2O. Rehydrated tissues were stained by incubating with hematoxylin for three 
minutes. Excessive and unbound stain was removed by running tap water over the section. Slides 
were washed by dipping in Acid-ethanol followed by deionized water. Excessive water was 
removed by blot paper and air-dried. Air dried slides were incubated in eosin stain for 45 seconds 
and washed for 3 × 5 minutes in 95% ethanol, 3 × 5 minutes and 3 × 15 minutes in xylene. Slides 
were covered with a cover slip using a mounting medium. The cross-sectional diameter of single 
myocytes was measured by the cellular diameter crossing the nuclei using were evaluated by using 
Image Pro Plus 6.0 (Media Cybernetics, Bethesda, MD) and the outline of 100-200 
cardiomyocytes were traced in each group. 
4.2.5. Assessment of perivascular fibrosis 
Interstitial perivascular fibrosis is a hallmark for cardiac remodeling during heart failure. 
Sirius Red solution known as F3B staining is the most accepted technique for studying interstitial 
perivascular fibrosis via evaluation of the extent of perivascular fibrosis, which was expressed as 
the percentage of perivascular fibrotic area in the total area of the whole artery cross-section plus 
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the perivascular fibrotic area. In brief, after four weeks of cardiac gene transfer, the animals were 
anesthetized by i.p injection of 200 mg/kg sodium pentobarbital and euthanized by decapitation. 
Hearts were removed. After the heart weight and cardiac morphology were examined, hearts were 
fixed in 10 % formalin/PBS and embedded in paraffin. Heart sections (10 μm) were cut using a 
cryo-microtome stained and placed on a slide. Sections were incubated in clearing agent 3 × for 5 
minutes by changing the clearing agent after every 5 minutes. Slides were incubated in 100% 
ethanol for 3 times for 3 minutes each, in 95% ethanol for 3 times for 3 minutes each, in 80% 
alcohol for 3 minutes and finally wash tap water for 3 minutes. 0.1% Sirius Red was added and 
incubated for 60 minutes. The slide was washed with acidified water and air-dried. After drying, 
the slides were washed for 1 minute in 80% alcohol, 2 minutes in 95% ethanol, 2 times in 100% 
ethanol for 10 minutes each time, and finally 3 times for 3 minutes in clearing solution. were 
covered with a cover slip. The histology, morphology, and cross-sectional area of cardiomyocytes 
were examined and analyzed by the image analysis software (Image Pro Plus 6.0, Media 
Cybernetics, Bethesda, MD). The external diameter of the arteries measured was no more than 100 
μm and the number of arterial cross-sections measured was more than 50, from five rats in each 
group.  
4.2.6. Western blots analysis 
Akt, p-Akt, mTOR, p-mTOR, β-actin, and LC3 (including LC3-I and LC3-II) protein 
levels in adult rat heart tissue were assessed by western blot analysis to determine the 
phosphorylation degree of those downstream components of Class I PI3-kinase. Briefly, after 
sacrificing those four group of rats, their heart tissues were washed with ice-cold PBS and scraped 
into a lysis buffer containing 20 mM Tris HCl (pH 6.8), 150 mM NaCl, 10% glycerol, 1% NP-40, 
and 8 µL/mL inhibitor cocktail (125 mM PMSF, 2.5 mg/mL aprotinin, 2.5 mg/mL leupeptin, 2.5 
mg/mL antipain, and 2.5 mg/mL chymostatin). The samples were sonicated twice for 5 s each and 
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were centrifuged at 12,000 rpm for 10 min at 4°C. Supernatants were transferred into new tubes 
and stored in a -80°C freezer. The protein concentration was determined with a protein assay kit 
(Bio-Rad Laboratories, Hercules, CA). An aliquot of 30 µg of protein from each sample was 
separated on a 10% SDS-PAGE gel and was transferred onto nitrocellulose membranes for 2 h at 
120 V. After a 10-min wash in TBST, membranes were blocked in PBST containing 10% milk for 
1 h, followed by an overnight incubation in rabbit anti-Akt (Santa Cruz Biotechnology, sc-8312, 
Santa Cruz, CA), anti-p-Akt (Santa Cruz Biotechnology, sc-2448, Santa Cruz, CA), anti-mTOR 
(Santa Cruz Biotechnology, sc-1549, Santa Cruz, CA), anti-p-mTOR (Santa Cruz Biotechnology, 
sc-101738, Santa Cruz, CA), LC3 (Santa Cruz Biotechnology, sc-134226, Santa Cruz, CA) and 
mouse anti-β-actin (Santa Cruz Biotechnology, sc-47778, Santa Cruz, CA) (dilution 1:100) at 4 °C. 
After a 15-min wash in TBST, four 5-min washes in PBS-T will be carried out, and membranes 
will be then incubated for 2 h in an anti-rabbit peroxidase-conjugated antibody (dilution 1:15,000). 
Densitometry of p-Akt was normalized to total Akt, p-mTOR normalized to total mTOR, LC3 II 
to β-actin ratio and p85 protein to β-actin ratio. Immunoreactivity was detected by enhanced 
chemiluminescence autoradiography (ECL Western blotting detection kit, Amersham Pharmacia 
Biotechnology), and films were analyzed with Quantity One Software (Bio-Rad). 
4.2.7. Immunofluorescence staining of heart tissue 
The immunofluorescence staining of heart sections was performed to evaluate the 
successful cardiac gene transfer of Lv-GFP. In brief, the transverse heart sections were fixed with 
4% PFA at 4℃ for 30 minutes, and cellular membranes were penetrated with 0.1% Triton X-100 
in PBS for 30 minutes. After pre-incubation with 3% of bovine serum albumin (BSA) for 60 
minutes, the cells were then incubated with primary antibodies of mouse sarcomeric α-actin (Santa 
Cruz Biotechnology, sc-53142, Santa Cruz, CA) and rabbit anti-GFP (Santa Cruz Biotechnology, 
sc-8334, Santa Cruz, CA), which was diluted to 1:100 with PBS containing 3% BSA, overnight at 
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4℃. After three washings with the PBS solution, the cells were incubated with fluorescence-
conjugated Alexa Fluor 594 fluorescence-conjugated goat anti-mouse IgG antibody (Molecular 
probes, A-11032, Waltham, MA) and Alexa Fluor 488 fluorescence-conjugated goat anti-rabbit 
IgG antibody (Molecular probes, A-11034, Waltham, MA) (1:1000 diluted in PBS each) for 2 h at 
room temperature in dark. Photographic images of heart tissue were taken with a fluorescence 
microscope (Olympus Microsystems, Waltham, MA). 
4.2.8. Class I PI3-kinase activity assay 
After a four-week treatment, rat heart tissues from those four groups were rinsed with ice-
cold PBS and Buffer A (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, and 
1 mM Na3VO4) three times each. Then Buffer A was removed and the cells were immediately 
lysed in lysis buffer Lysis Buffer (Buffer A plus 1% NP-40 and 1 mM PMSF) at 4°C for 20 minutes. 
The cells were scraped from dishes, transferred to 1.5 mL microcentrifuge tubes and centrifuged 
for 10 minutes to sediment insoluble material. Thereafter, supernatant was transferred to new tubes 
added with 5 μL of anti-PI3-Kinase antibody (Millipore Corp, 06-195, Billerica, MA) previously 
described [81] to each tube and incubated for one hour at 4°C with gentle rotation. 60 μL of 50% 
slurry of Protein A-agarose beads in PBS was added into each tube with gentle rotation for 
overnight, and tubes were centrifuged for 5 seconds for collection of immunoprecipitated enzymes. 
Sediments were washed three times with Buffer A plus 1% NP-40, three times with 0.1 M pH 7.4 
Tris-HCl with 5 mM LiCl and 1 mM Na3VO4, twice with TNE (10 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 5 mM EDTA) containing 1 mM Na3VO4 and twice with KBZ Reaction Buffer. The 
last wash was aspirated completely and 30 μL of KBZ Reaction Buffer was added to cover the 
beads. Then the Class I PI3-kinase reactions were carried out using competitive enzyme-linked 
immunosorbent assay kit (Echelon Biosciences, K-1000s, Salt Lake City, UT) by exactly 
following the instructions provided by the manufacturer. A PIP3 standard curve (ranging from 4.4 
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nM to 1.08 μM) was simultaneously prepared and determined at 450 nm wavelength. Each assay 
was repeated at least 3 times. 
4.2.9. Reactive Oxygen Species (ROS) generation assay in heart tissues 
ROS generation in heart tissue was determined using a fluorogenic probe, MitoSOX 
(Thermo Fisher, M-36008, Rockford, IL). MitoSOX is a superoxide-sensitive (O2
∙-) fluorogenic 
probe, and it yields red fluorescence when oxidized in mitochondria (excitation/emission 
wavelength: 510/580 nm). Heart sections were embedded in a freezing medium of OTC 
immediately after harvest, and transverse sections (20 μm) of frozen tissue were obtained using a 
cryostat microtome sectioning machine, collected on glass sides, and equilibrated for 10 min in 
Hanks’ solution. Heart sections were loaded with 5 μM MitoSOX for 30 min at 37℃ in dark room. 
Thereafter, the incubated heart sections were rinsed with 37℃ HBSS three times and five minutes 
for each time. Fluorescence images of cardiomyocytes in heart tissue were captured by a 
fluorescence microscope (Olympus), and the mean fluorescence intensity of cardiomyocytes was 
analyzed and quantified in 50 randomly selected fields in each section with Image J. 
4.2.10. Data analysis 
All data are presented as means ± SE. Data were statistically analyzed by GraphPad Prism 
5.0 (GraphPad Software, San Diego, CA). Statistical significance was evaluated by one- or two-
way ANOVA, as appropriate, followed by either a Newman–Keuls or Bonferroni’s post hoc 
analysis when indicated. Differences were considered significant at P < 0.05, and individual 
probability values are noted in the figure legends. 
4.3. Results 
4.3.1. Identification of Lv-GFP delivery into the cardiomyocytes in adult rat hearts 
We examined the efficacy of cardiac transfer of lentiviral vectors before we performed 
gene expression modification-induced inactivation of Class I PI3-kinase. Cardiac transfer of Lv-
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GFP was adopted to investigate the successful delivery of lentiviral vectors into adult rat hearts 
and served as the negative control of Lv-DNp85. The results are presented in Figure 28, cardiac 
micro-injection of Lv-GFP (2 x 1010 TU/mL, 200 μL) significantly increased GFP expression in 
cardiomyocytes after four weeks, emitting green fluorescence and overlapped with α-actin 
generating red fluorescence as a cardiomyocytes marker. The results demonstrated that we have 
successfully transduced lentiviral vector-mediated GFP (Lv-GFP) gene into cardiomyocytes with 
desirable specificity for in adult rat hearts. 
 
Figure 28: Effect of cardiac transfer of Lv-GFP in adult rat hearts. Immunofluorescence 
images showing GFP expression in cardiomyocytes in adult rat heart tissues that received Lv-GFP 
microinjection. A: Fluorescence micrograph demonstrating localization of green fluorescence 
protein (GFP, green). B: The same field of heart tissue as in A which is immunostained with anti-
α-actin (red) as a cardiomyocyte marker. C: Merge of A and B, indicating successful lentiviral 
vector-mediated GFP gene transduction into cardiomyocytes. Scale bar: 250 μm. 
4.3.2. Effect of cardiac transfer of Lv-DNp85 into adult rat hearts on Ang II-induced Class I 
PI3-kinase activity 
The effects of Ang II infusion and Lv-DNp85 cardiac transduction on Class I PI3-kinase 
activity were evaluated to confirm lentiviral vector-mediated overexpression of a dominant 
negative subunit p85α of Class I PI3-kinase (Lv-DNp85) and PIP3 production. The results are 
presented in Figure 29, PIP3 production was significantly elevated by Ang II infusion by 100.21 % 
(PIP3 production (in pmol/μg of protein) 1.75 ± 0.24 in the Saline+Lv-GFP group vs. 3.52 ± 0.33 
in the Ang II+Lv-GFP group, n = 6, P < 0.05 vs. Saline+Lv-GFP) and this increase in Class I PI3-
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kinase activity was mitigated by cardiac transduction of Lv-DNp85 by 41.76 % (PIP3 production 
(in pmol/μg of protein) 3.52 ± 0.33 in the Ang II+Lv-GFP group vs. 2.05 ± 0.25 in the Ang II+Lv-
DNp85 group, n = 6, P < 0.05 vs. Ang II+Lv-GFP). The results demonstrate that cardiac transfer 
of Lv-DNp85 increases p85α subunits expression and decreases Class I PI3-kinase activity in the 
heart. 
 
Figure 29: Effect of Ang II and cardiac transfer of Lv-DNp85 on Class I PI3-kinase activity 
in adult rat hearts. Production of PIP3 were examined 4 weeks after subcutaneous infusion of 
Ang II or normal saline (NS) with cardiac transduction of Lv-DNp85 or Lv-GFP.: Bar graphs 
summarizing Class I PI3-kinase activity measured with PIP3 ELISA kit in the heart tissues from 
these rats treated under the conditions described in the above. Data are means ± SE (n = 6 rats).  
*P < 0.05 vs. rats that received Saline + Lv-GFP. #P < 0.05 vs. rats that received Ang II + Lv-GFP. 
4.3.3. Effect of blockade of Class I PI3-kinase on Ang II-induced cardiac function changes 
in adult rats 
Then, we determined several physiological parameters to evaluate the effect of Ang II and 
Class I PI3-kinase on heart function in living rats. The results are presented in Figure 30A and B, 
and cardiac transfer of neither Lv-GFP nor Lv-DNp85 altered the mean arterial pressure (MAP) 
or heart rate (HR) in rats infused with saline. While chronic subcutaneous Ang II infusion 
considerably elevated MAP by about 48 %, which was not attenuated by cardiac transfer of either 
Lv-GFP or Lv-DNp85 (132.35 ± 7.96 mmHg in Ang II + Lv-GFP and 127.83 ± 6.84 mmHg in the 
Ang II + Lv-DNp85 group respectively, n = 6, P < 0.05 vs. Rats that received Saline). Besides, 
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none of those four groups showed significant Heart Rate (HR) change. Thus, we conclude that 
neither the basal MAP nor the pressor response to subcutaneous Ang II infusion was altered by 
cardiac transfer of Lv-DNp85. The results demonstrated that blockade of cardiac Class I PI3-
kinase has no noticeable effect on peripheral blood pressure. Taken together, those outcomes 
indicate that neither basal blood pressure nor Ang II-induced pressor effect is altered by cardiac 
transfer of Lv-DNp85. 
Heart contractility was also determined by left ventricular catheterization in those four rat 
groups. The larger value of dP/dt Max indicates stronger cardiac contractility. The results are 
presented in Figure 30 C, and chronic subcutaneous infusion of Ang II significantly reduced 
cardiac contractility by 8.12 % (dP/dt Max 7400 ± 360 mmHg/s in the Saline+Lv-GFP group vs. 
6850 ± 210 mmHg/s in the Ang II+Lv-GFP group, n = 6, P < 0.05 vs. Saline+Lv-GFP) due to the 
possible occurrence of Ang II-induced decompensated hypertrophy and perivascular fibrosis. 
Blockade of Class I PI3-kinase considerably attenuated Ang II-induced reduction in cardiac 
contractility by 13.8 % (dP/dt Max of 6850 ± 210 mmHg/s in the Ang II + Lv-GFP group vs. 
7800±430 mmHg/s in the Ang II + Lv-DNp85 group, n = 6, P < 0.05 vs. Ang II + Lv-GFP) of left 
ventricle, indicating that blockade of Class I PI3-kinase remarkably restores chronic Ang II 
infusion-induced cardiac dysfunction. 
All those results demonstrate Ang II infusion elevated blood pressure and undermined heart 
functions. While Lv-DNp85 overexpression in cardiomyocytes attenuated Ang II-induced  
contractility decline without alteration of blood pressure or hear rate. 
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Figure 30: Effect of Ang II and cardiac transfer of Lv-DNp85 on MAP, HR and dp/dt Max 
in adult rats. Hemodynamic indexes were recorded to examine cardiac function in living adult 
rats 4 weeks after subcutaneous infusion of either Ang II or normal saline (NS) with cardiac 
transduction of Lv-DNp85 or Lv-GFP. Bar graphs summarizing MAP (A) and Heart rate (HR) (B) 
recorded via femoral arterial cannulation; and dP/dt Max (C) was recorded via the left ventricular 
catheterization through the right carotid artery. Data are means ± SE (n = 6 rats). *P < 0.05 vs. rats 
that received Saline + Lv-GFP. #P < 0.05 vs. rats that received Ang II + Lv-GFP. 
4.3.4. Effect of blockade of Class I PI3-kinase on Ang II-induced cardiac hypertrophy 
Cardiac hypertrophy was identified by calculating the ratio of heart weight to body weight 
(HW/BW) in rats infused with normal saline or Ang II and cardiac transduction of Lv-GFP or Lv-
DNp85. The results are presented in Figure 31, and no significant body weight alterations were 
observed in any of those four groups (BW: 344 ± 13 g in the Saline + Lv-GFP group; 339 ± 12 g 
in the Saline+ Lv-DNp85 group; 337 ± 14 g in the Ang II + Lv-GFP group; 342 ± 11 g in the Ang 
II + Lv-DNp85 group, n = 6, P > 0.05 vs. Saline+Lv-GFP). Whereas subcutaneous infusion of 
Ang II (200ng/kg/min for 4 weeks) significantly elevated HW/BW by 51.40 % (HW/BW ratio 
3.05±0.15 mg/g in the Saline+Lv-GFP group vs. 4.62 ± 0.18 mg/g in the Ang II+Lv-GFP group, 
n = 6, P < 0.05 vs. Saline+Lv-GFP). Cardiac transfer of Lv-DNp85 significantly attenuated Ang 
II-induced elevation of HW/BW ratio by 27.05 % (HW/BW ratio of 4.62 ± 0.18 mg/g in the Ang 
II + Lv-GFP group vs. 3.37 ± 0.17 mg/g in the Ang II+Lv-DNp85 group, n = 6, P < 0.05 vs. Ang 
II + Lv-GFP). 
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Figure 31: Effect of Ang II and Lv-DNp85 on HW/BW ratio and cardiac morphology. Cardiac 
morphological alterations were examined 4 weeks after subcutaneous infusion of Ang II or saline 
by cardiac transduction of Lv-DNp85 or Lv-GFP, as described in Methods. A-D: Graphs showing 
representative heart sections stained with hematoxylin/eosin in rats that received subcutaneous 
infusion of saline (A and B) or Ang II (C and D) with cardiac transduction of Lv-GFP (A and C) 
or Lv-DNp85 (B and D). E: Bar graphs summarizing heart weight/body weight ratios (HW/BW) 
under the conditions indicated. Scale bar: 2 mm. Data are means ± SE (n = 6 rats). *P < 0.05 vs. 
rats that received Saline + Lv-GFP. #P < 0.05 vs. rats that received Ang II + Lv-GFP. 
Cardiac morphology identification was also observed to further confirm the results of 
cardiac hypertrophy. The effects of Ang II infusion and Lv-DNp85 cardiac transduction on cardiac 
hypertrophy were evaluated in these four groups of rats by examination the dimensional size of 
cardiac myocytes on the heart sections using H&E staining in these four groups of rats. The results 
are presented in Figure 32, demonstrating that Ang II infusion greatly increased the average 
diameter of cardiomyocytes inducing severe cardiac hypertrophy by 45.62 % (15.5 ± 0.5 μm in 
the Saline + Lv-GFP group vs. 22.5 ± 1.2 μm in the Ang II + Lv-GFP group, n = 6, P < 0.05 vs. 
Saline+Lv-GFP). Ang II-induced increases in cardiomyocyte diameter were significantly 
attenuated by cardiac transduction of Lv-DNp85 by 21.77 % (22.5 ± 1.2 μm in the Ang II + Lv-
GFP group vs. 17.6 ± 1.1 μm in the Ang II + Lv-DNp85 group, n = 6, P < 0.05 vs. Ang II + Lv-
GFP). The results demonstrate blockade of Class I PI3-kinase attenuates chronic Ang II infusion-
induced cardiac hypertrophy. 
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Figure 32: Effect of Ang II and Lv-DNp85 on cardiac histology. Cardiomyocyte diameters 
were examined 4 weeks after subcutaneous infusion of Ang II or normal saline (NS) with cardiac 
transduction of Lv-DNp85 or Lv-GFP. A-D: Micrographs showing representative heart sections 
stained with hematoxylin/eosin in rats that received subcutaneous infusion of NS (A and B) or 
Ang II (C and D) with cardiac transfer of Lv-GFP (A and C) or Lv-DNp85 (B and D). E: Bar 
graphs summarizing cross-sectional areas of cardiomyocytes from transverse cardiac sections of 
each group of rats. Cross-sectional areas of 100 cells per rat were observed randomly per group. 
Scale bar: 50 μm. Data are means ± SE (n = 6 rats). *P < 0.05 vs. rats that received NS + Lv-GFP. 
#P < 0.05 vs. rats that received Ang II + Lv-GFP. 
4.3.5. Effect of blockade of Class I PI3-kinase on Ang II-induced perivascular fibrosis 
Fibroblast proliferation, perivascular fibrosis and cardiomyocyte apoptosis characterize the 
late stage of cardiac remodeling. Therefore, we determined the effect of Ang II infusion and Class 
I PI3-kinase inactivation on perivascular fibrosis in rats received cardiac transfer of Lv-GFP or 
Lv-DNp85 and subcutaneous infusion of Saline or Ang II for 4 weeks. The results are presented 
in Figure 33, perivascular collagen deposition in the heart was remarkably promoted by chronic 
subcutaneous infusion of Ang II by 96.4 % (Perivascular fibrosis area of 31.4 ± 3.2 % in the 
Saline+Lv-GFP group vs. 67.2±10.0 % in the Ang II+Lv-GFP group, n = 6, P < 0.05 vs. 
Saline+Lv-GFP), while cardiac transfer of Lv-DNp85 considerably alleviated Ang II-induced 
perivascular fibrosis by blockade of Class I PI3-kinase by 41.81 % (Perivascular fibrosis area of 
67.2 ± 10.0 % in the Ang II+Lv-GFP group vs. 39.1 ± 3.1 % in the Ang II+Lv-DNp85 group, n = 
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6, P < 0.05 vs. Ang II + Lv-GFP). The results demonstrate that chronic blockade of Class I PI3-
kinase by Lv-DNp85 may attenuate Ang II-induced perivascular fibrosis in adult rats. 
 
Figure  33: Effect of Ang II and Lv-DNp85 on cardiac perivascular fibrosis. Perivascular 
fibrosis was examined 4 weeks after subcutaneous infusion of Ang II or normal saline (NS) with 
cardiac transduction of Lv-DNp85 or Lv-GFP. A-D: Representative microscopic images showing 
myocardial perivascular collagen deposition (red) in rats 4 weeks after subcutaneous infusion of 
Saline (A and B) or Ang II (C and D) with cardiac transduction of Lv-GFP (A and C) or Lv-
DNp85 (B and D). E: Bar graphs summarizing the quantitative analysis of perivascular fibrosis, 
expressed as the ratio of perivascular collagen area to vessel cross-sectional area of the coronary 
arteries. Data are means ± SE (n = 6 rats). Scale bar: 100 μm. *P < 0.05 vs. rats that received NS 
+ Lv-GFP. #P < 0.05 vs. rats that received Ang II + Lv-GFP. 
4.3.6. Effect of blockade of Class I PI3-kinase on Ang II-induced oxidant stress 
Autophagy is a useful tool to protect cells, tissues and organs from impairment by 
eliminating and scavenging damaged mitochondria and other organelles & proteins producing 
reactive oxygen species (ROS). Thus, we measured ROS generation levels in the heart of rats 
receiving cardiac transfer of Lv-GFP or Lv-DNp85 along with subcutaneous infusion of saline or 
Ang II for 4 weeks. MitoSOX staining technique was adopted as the fluorogenic probe to measure 
ROS generation on heart sections. The results are presented in Figure 34, chronic Ang II infusion 
significantly elevated ROS generation in the heart by 91.51 % (MitoSOX Fluorescence of 100.0 ± 
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7.5 % in the Saline+Lv-GFP group vs. 191.5 ± 14.5 % in the Ang II+Lv-GFP group, n = 6, P < 
0.05 vs. Saline+Lv-GFP). while cardiac transduction of Lv-DNp85 greatly attenuated ROS 
generation elevation (MitoSOX Fluorescence of 191.5 ± 14.5 % in the Ang II+Lv-GFP group vs. 
115.3 ± 9.3 % in the Ang II+Lv-DNp85 group, n = 6, P < 0.05 vs. Ang II + Lv-GFP). The results 
demonstrate Ang II-induced elevation of ROS generation is attenuated by cardiac transfer of Lv-
DNp85 to inactivate Class I PI3-kinase. 
 
Figure 34: Effect of Ang II and Lv-DNp85 on ROS generation in adult rat hearts. ROS 
generation in heart tissue was examined 4 weeks after subcutaneous infusion of Ang II or normal 
saline (NS) with cardiac transduction of Lv-DNp85 or Lv-GFP. A-D: Representative microscopic 
images showing the ROS fluorescence (red staining) in rats 4 weeks after subcutaneous infusion 
of saline (A and B) or Ang II (C and D) with cardiac transduction of Lv-GFP (A and C) or Lv-
DNp85 (B and D). E: Bar graphs summarizing the quantitative analysis of ROS generation levels 
measured with the fluorescent probe of MitoSOX, expressed as the percentage of MitoSOX 
Fluorescence. Scale bar: 50 μm. Data are means ± SE (n = 6 rats). *P < 0.05 vs. rats that received 
Saline + Lv-GFP. #P < 0.05 vs. rats that received Ang II + Lv-GFP. 
4.3.7. Effect blockade of Class I PI3-kinase on Ang II-induced autophagic impairment 
Accumulating evidence indicates the possible involvement of autophagic alteration in the 
pathogenesis of cardiac hypertrophy and cardiomyocyte death. Thus, it is obliged to examine the 
chronic effect of Ang II and blockade of Class I PI3-kinase on cardiac autophagy by examining 
the abundance of microtubule-associated protein light chain 3 (MAP-LC3), an autophagosome 
 86 
marker with two forms known as LC3-I and LC3-II. LC3-I (18kD) is converted to LC3-II (16KD) 
during autophagy via Atg protein-facilitated conjugation with Phosphatidyl-ethanolamine (PE), 
and LC3-II is recruited by autophagosomes. Enhanced LC3-II/β-actin ratio indicates stronger 
occurrence of autophagy. After cardiac transfer of Lv-GFP or Lv-DNp85 along with subcutaneous 
infusion of Saline or Ang II for 4 weeks. The results are presented in Figure 35, chronic Ang II 
infusion in Lv-GFP group reduced cardiac autophagy by 40 % (LC3 II/β-actin of 0.25 ± 0.02 in 
the Saline+Lv-GFP group vs. 0.15 ± 0.016 in the Ang II+Lv-GFP group, n = 6, P < 0.05 vs. 
Saline+Lv-GFP), while this Ang II-induced reduction in autophagy was mitigated by cardiac 
transduction of Lv-DNp85 by 53.33 % (LC3 II/β-actin ratio of 0.15 ± 0.016 in the Ang II + Lv-
GFP group vs. 0.23 ± 0.016 in the Ang II+Lv-DNp85 group, n = 6, P < 0.05 vs. Ang II + Lv-GFP). 
The results demonstrate that chronic blockade of PI3-kinase attenuates Ang II-induced impairment 
of autophagy in the heart tissue. 
 
Figure 35: Effect of Ang II and Lv-DNp85 on autophagy in adult rat hearts. Autophagy in 
heart tissue was examined 4 weeks after subcutaneous infusion of Ang II or normal saline (NS) 
with cardiac transduction of Lv-DNp85 or Lv-GFP. A: Representative western blots of heart lysate 
for LC3 protein and β-actin. B: Bar graphs summarizing the ratio of LC3 II/β-actin in hearts of 
rats that received chronic subcutaneous infusion of Ang II or saline with cardiac transfer of Lv-
DNp85 or Lv-GFP for four weeks. Data are means ± SE (n = 6 rats). *P < 0.05 vs. rats that received 
Saline + Lv-GFP. #P < 0.05 vs. rats that received Ang II + Lv-GFP. 
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4.3.8. Effect of blockade of Class I PI3-kinase on Ang II-induced Akt and mTOR 
phosphorylation 
Akt, the alias of protein kinase B, is one of the downstream components of Class I PI3-
kinase, and mTOR is one of the downstream effectors of Akt in intracellular signal transduction 
pathways. Activation of mTOR impairs autophagy, and this signaling transduction pathway is via 
the cascade of AT1R→Class I PI3-kinase→Akt→mTOR. The cardiac tissue were collected to 
detect Akt and mTOR phosphorylation using conventional Western Blots with antibodies against 
phosphorylated Akt or mTOR and total Akt or mTOR. The results are presented in Figure 36 and 
Figure 37, indicating that 4-week infusion of Ang II significantly increased the ratio of 
phosphorylation of Akt by 55.26 % and mTOR by 145.16 % (p-Akt/Total Akt: 0.38 ± 0.07 in the 
in Saline+Lv-GFP group vs. 0.59 ± 0.12 in the Ang II + Lv-GFP group, p-mTOR/Total mTOR of 
0.31 ± 0.06 in the Saline + Lv-GFP group vs. 0.76 ± 0.12 in the Ang II+Lv-GFP group, n = 6, P < 
0.05 vs. Saline+Lv-GFP), suggesting a chronic stimulatory effect of Ang II on Class I PI3-kinase. 
Cardiac transduction of Lv-DNp85 successfully attenuated Ang II infusion-induced 
phosphorylation of Akt by 63.81 % and mTOR by 68.33 % (p-Akt/Total Akt: 0.59 ± 0.12 in the 
Ang II + Lv-GFP group vs. 0.36 ± 0.06 in the Ang II+Lv-DNp85 group, p-mTOR/Total mTOR: 
0.76 ± 0.12 in the Ang II+Lv-GFP group vs. 0.35 ± 0.05 in the Ang II+Lv-DNp85 group, n = 6, P 
< 0.05 vs. Ang II + Lv-GFP). The results demonstrate that cardiac transduction of Lv-DNp85 
attenuates Ang II-induced activation of Class I PI3-kinase. These results demonstrate that Akt and 
mTOR phosphorylation are involved in the downstream signaling of Class I PI3-kinase in Ang II-
induced impairment of autophagy in the heart. 
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Figure 36: Effect of Ang II and Lv-DNp85 on Akt phosphorylation in adult rat hearts. Akt 
phosphorylation in heart tissue was examined 4 weeks after subcutaneous infusion of Ang II or 
normal saline (NS) with cardiac transduction of Lv-DNp85 or Lv-GFP. A: Representative western 
blots of heart lysate probed for phosphorylated Akt (p-Akt) and total Akt in each group of rats. B: 
Bar graphs summarizing the ratio of phosphorylated Akt vs. total Akt. Data are presented as means 
± SE (n = 6 rats). *P < 0.05 vs. rats that received Lv-GFP. #P < 0.05 vs. rats that received Ang II + 
Lv-GFP. 
 
Figure 37: Effect of Ang II and Lv-DNp85 on mTOR phosphorylation in adult rat hearts. 
mTOR phosphorylation in heart tissue was examined 4 weeks after subcutaneous infusion of Ang 
II or normal saline (NS) with cardiac transduction of Lv-DNp85 or Lv-GFP. A: Representative 
western blots of heart lysate for phosphorylated mTOR (p-mTOR) and total mTOR. B: Bar graphs 
summarizing the ratio of phosphorylated mTOR vs. Total mTOR. Data are presented as means ± 
SE (n = 6 rats). *P < 0.05 vs. rats that received Lv-GFP. #P < 0.05 vs. rats that received Ang II+Lv-
GFP. 
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4.4. Data summary and conclusion 
In this chapter, we examined the role of Class I PI3-kinase in Ang II-induced cardiac 
remodeling in adult rat hearts. The results verified our initial hypothesis that chronic administration 
of Ang II caused cardiac remodeling via an autophagic-dependent manner in living animal hearts. 
This conclusion is supported by those following findings: 1) Chronic subcutaneous infusion of 
Ang II remarkably elevated the activity of Class I PI3-kinase, generating increasing amount of 
PIP3 as the final product. Chronic Ang II administration also enhanced the phosphorylation of Akt 
and mTOR which are two essential downstream components of Class I PI3-kinase. Activation of 
mTOR by phosphorylation impaired autophagy and this autophagic impairment exacerbated ROS 
generation accumulation, perivascular fibrosis, cardiac hypertrophy and contractile dysfunction in 
adult rat hearts. 2) Lentiviral vectors of Lv-GFP and Lv-DNp85 were successfully delivered into 
the heart of adult rats via cardiac coronary artery microinjection. Those Ang II-induced 
pathophysiological alterations in the adult rat hearts were greatly attenuated by blockade of Class 
I PI3-kinase using cardiac transfer of dominant negative PI3-kinase p85 subunit (Lv-DNp85) while 
administration of negative control lenti-viral vector of Lv-GFP did not alter Ang II-induced 
pathophysiological actions. 
Lenti-viral vectors are adopted as a novel gene delivery technique. Bioactive viral vectors 
are mainly divided into two categories: adeno-viral vectors and lenti-viral vectors. The advantage 
of the adeno-viral vectors is their larger capacity of gene fragments as large as 8k while the lenti-
viral vectors have a relatively smaller capacity to accommodate the gene fragments (~2k). 
Nevertheless, it has been proved that the lenti-viral vectors could be successfully administrated 
into several non-dividing cell lines like primary and stem cells which are difficult to be transfected 
by conventional vectors [97]. Thus, we used lenti-viral vector in this part to testify our hypothesis. 
Dominant negative treatment is a novel and effective method to perform gene therapy. Unlike the 
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conventional gene knockout or RNA silencing method, the dominant negative mutation treatment 
conserves the whole intact protein without losing any subunits. However, not only does the mutant 
protein lose the biological functions itself, but also the mutant protein inhibits or even abolishes 
the function of adjacent wild type protein subunits, losing the whole function [98]. Known as the 
adapter protein of Class Ia PI3-kinase, p85α subunit was over-expressed after cardiac transfer of 
Lv-DNp85. Western blot analysis showed elevated p85 subunit expression in dominant negative 
lenti-viral vector treatment while other approaches proved the loss of the protein function in 
signaling transduction. The underlying mechanism is the formation of the protein dimer or polymer 
which has no signal transduction function, thereafter the function of adjacent wild type protein has 
also been inhibited. There are reports of marketed dominant negative viral vector forms of DNp85 
for Class Ia PI3-kinase [99] and DNVps34p for Class III PI3-kinase [100]. Thus, the usage of lenti-
viral vectors could further prove the function of Class I PI3-kinase by disabling the relevant 
signaling transduction functions of this kinase. 
Our initial aim is to make successful delivery of lenti-viral vectors into the cardiomyocytes 
of living adult rat hearts to exert certain physiological effects since chemical compounds such as 
LY-294002 and wortmannin neither have the desirable blockade specificity on Class I PI3-kinase 
nor could be used in a heart-specific manner in chronic in vivo studies. Therefore, it is obliged to 
use lenti-viral vectors in our chronic in vivo studies. We performed coronary artery microinjection 
technique, and four weeks later, the overlap of GFP and α-actin under fluorescence microscope 
indicates we have successfully delivered lenti-viral vectors. Also, diminished PIP3 production in 
heart tissue mean successful delivery of Lv-DNp85 into cardiomyocytes. 
The next objective after successful cardiac delivery of lenti-viral vectors is to compare the 
physiological parameters relevant to Ang II-induced cardiac remodeling. First, we determined 
blood pressure and heart rate, it is found that the elevation of blood pressure in Ang II group is not 
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altered by Lv-DNp85 administration, and the heart rate in all four groups remained identical. The 
plausible explanation is that Ang II constricts the blood vessels, increasing the peripheral 
resistance, and the blood pressure gets elevated prior to the occurrence of cardiac remodeling. For 
the steady heart rate in all those four groups, it is possible that the elevated blood pressure might 
cause the heart to beat slower so as to preserve the total cardiac output, while Ang II could direct 
stimulate the α1 receptor in the heart, accelerating the heart rate. Thus, those two contradictory 
chronotropic factors compensate for each other, keeping the heart rate within a steady value. 
Then, we determined the pathophysiological indexes relevant to cardiac remodeling such 
as cardiomyocyte diameter, HW/BW ratio, perivascular fibrosis and dP/dt Max. We found Lv-
DNp85 administration strongly attenuated Ang II-induced cardiac remodeling by ameliorating 
above-mentioned pathophysiological parameters, suggesting preserved heart function under the 
presence of Ang II. To determine the possible route of the effect of Lv-DNp85 and Class I PI3-
kinase in attenuating cardiac remodeling, we detect the phosphorylation degree of Akt and mTOR, 
ROS generation and the degree of autophagy since evidence showed that the specific knockout of 
autophagy related protein (Atg) in the heart provoked cardiac hypertrophy and dysfunction [101]. 
The results demonstrated that diminished degree of Akt and mTOR phosphorylation, ROS 
generation and restored autophagy were observed in Ang II+ Lv-DNp85 group when compared 
with Ang II+ Lv-GFP group, suggesting Ang II-induced cardiac remodeling might be mediated 
via the Class I PI3-kinase/Akt/mTOR pathway via impairing autophagy. 
In summary, all of those results indicate that selective inactivation of Class I PI3-kinase by 
Lv-DNp85 cardiac transfection in the heart restores autophagy, ameliorates left ventricular 
contractility which has been deteriorated by Ang II infusion, and alleviates Ang II-induced Akt 
and mTOR phosphorylation, ROS generation, perivascular fibrosis and cardiac hypertrophy, 
which are the most ordinary pathophysiological alterations in HF. Those evidences strongly 
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support the hypothesis that elevated action of Class I PI3-kinase in the heart contributes to the 
development of Ang II-induced cardiac injury and heart failure via autophagic impairment. 
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CHAPTER V. OVERALL DISCUSSION 
This present study examined the possible involvement of different PI3-kinases in both 
primary neonatal and living adult cardiomyocytes from SD rats in Ang II-induced cardiac 
remodeling with both in vitro and in vivo approaches. Furthermore, the fundamental goal in this 
ongoing project was to identify the intracellular signaling mechanisms underlying PI3-kinases 
using various biochemical, molecular biological, pharmacological and morphological techniques. 
The most notable and prominent discoveries of this study is the involvement of only Class III PI3-
kinase activation under lower dosage of Ang II exposure initially, while both Class I and Class III 
PI3-kinases are activated under higher dosage of Ang II exposure or in a chronic manner, 
representing different stages of compensatory and decompensatory cardiac hypertrophy. The 
results demonstrate that both Class I and Class III PI3-kinases are involved at different stages in 
Ang II-induced cardiac remodeling via an autophagic-dependent mechanism, and impaired 
autophagy results in the loss of capability to scavenge the damaged mitochondria accumulation-
induced ROS generation, contributing to the emergence and progression of cardiac remodeling 
and subsequent heart dysfunction. 
5.1. Intracellular mechanisms for the heart switching from compensation to decompensation 
Intense exercise was accompanied with enhanced aldosterone, renin, K+, and vasopressin 
in plasma. Among those factors, Renin-Angiotensin System is an essential hormonal pathway for 
cellular growth via mechanical stretch in cardiomyocytes. There are two major separate sources of 
RAS that produce Ang II: one source is the systemic RAS converting hepatocyte-generated 
angiotensinogen to Ang I by kidney-released renin, while the other source is local RAS which 
responds to local stimuli and produces Ang II in an autocrine or paracrine manner [65]. The normal 
Ang II concentration in plasma ranges from 0.4 to 0.8 nM, and exercise training-produced Ang II 
concentration is very tiny (within nanomolar scale) [102]. During exercise training-induced 
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hemodynamic overload, physiological cardiac hypertrophy in the left ventricle occurs in a 
compensatory mechanism without perivascular fibrosis or apoptosis as an effective approach to 
adapt to this hemodynamic overload by elongation of cardiomyocytes in a parallel manner, 
enhancing the ventricular stroke volume and stimulating cardiac output with ameliorated aerobic 
capacity [13, 103]. Thus, exercise training is a safe and a most effective non-pharmacological 
therapeutic approach to combat cardiac remodeling, cardiac apoptosis, and perivascular fibrosis 
with normal heart structure, preserved or ameliorated heart function, and very tiny alterations of 
gene expression pattern in cardiomyocytes [104]. Generally speaking, aerobic exercise dilates the 
peripheral vessels to maintain more blood flow in the skeletal muscles. In this process, the renal 
blood pressure become lowered due to the rise of peripheral blood flow, resulting in the rise of 
circulating renin level soon after acute exercise. Meanwhile, lactic acid produced in skeletal 
muscle begins to accumulate and suppress angiotensinases that degrade Ang I and II, leading to 
vasoconstriction and cardiac hypertrophy [105] . 
Exercise-induced cardiac hypertrophy are divided into two categories: concentric and 
eccentric hypertrophy. Concentric hypertrophy refers to the addition of cardiac sarcomeres in a 
parallel manner (myocyte width increase), and it is the result of static or isometric physical exercise 
like weight lifting with little or no movement. Nevertheless, isotonic and aerobic exercises such as 
swimming and running lead to eccentric hypertrophy which means the cardiac sarcomeres are 
added in a series pattern with the increased chamber volume (myocyte length increase), and the 
cardiac output are increased with elevated skeletal muscle effectiveness and decreased peripheral 
vascular resistance [103, 106]. Both types of exercise-induced cardiac hypertrophy are losartan 
preventable, suggesting the participation of AT1R [107]. It is found swimming training starting 
from very young age successfully prevented hypertension in spontaneous hypertensive rats (SHR) 
even though they are genetically programmed to develop elevated blood pressure level with 
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decreased plasma Ang II concentration, which is similar to the treatment of ACE inhibitors like 
captopril, or AT1R antagonists like losartan [108]. In this process, local Renin-Angiotensin System 
is activated mainly due to hemodynamic overload with elevated circulating Ang II levels, while 
slight elevation of local cardiac Ang II is not a direct factor that is associated with cardiac 
hypertrophy [109]. Under physiological conditions in the health body, rapid internalization and 
desensitization of Ang II receptor type 1 (AT1R) were observed in the heart in spite of the rising 
dosage of cardiac Ang II level to avoid pathological cardiac hypertrophy. It is also postulated 
AT1R might enlarge the cornary artery to maintain the cardiac blood flow [110], serving as a 
protective mechanism to protect heart from pathological cardiac hypertrophy. Swimming training-
induced physiological hypertrophy in Wistar rats didn’t show significant manifestations of 
pathological cardiac markers. Simultaneously, enhanced ACE2 and Ang (1-7) levels as well as 
decreased ACE and Ang II amounts were observed in such aerobic exercise training [111]. Thus, 
exercise training might have the preferential ACE2/Ang (1-7)/MAS Receptor axis over general 
RAS (ACE/Ang II/AT1R) axis. Ang (1-7) is generated from Ang II via ACE2 cleavage, and it is 
a potent vasodilator with anti-hypertrophic and anti-fibrotic effects to lower down the blood 
pressure and prevent the heart from cardiac hypertrophy. Our lab has already proved the cardiac 
protective role of Ang (1-7) both in cardiomyocytes and adult rat hearts [79, 112]. It is also reported 
that aerobic exercise decreased Ang II levels and increased AT2R expression in the normal heart. 
Convincing evidence indicates the physiological effects of AT2R are vasodilation due to the 
stimulation of NO and bradykinin release [113], which just counteracts AT1R as a powerful 
vasopressor and aldosterone secretion stimulator. Thus, regulation of the activities of AT2R 
expression and Ang (1-7) production within the RAS is an important method to keep 
cardiovascular homeostasis. Recently, microRNAs such as miR-195, miR-21, miR-133 and miR-
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1 are also discovered to have contribution to regulate physiological cardiac hypertrophy through 
varied signaling pathways, which is a novel field worth further investigation [107]. 
Unlike exercise-induced physiological cardiac hypertrophy, pathological cardiac 
hypertrophy means the enlargement of the heart accompanied with preexisting morbid states such 
as heart attack, hypertension, cardiomyopathy, diabetes and unhealthy living habits. The most 
distinctive consequence of pathological cardiac hypertrophy is cardiac remodeling, including 
unbalances of extracellular matrix homeostasis, perivascular fibrosis, autophagic defect, 
mitochondrial dysfunction, abnormal metabolism, impaired ATP generation and gene expression 
modifications [114]. Cardiac remodeling makes the cardiomyocytes stiffen and reduce the 
elasticity and the ability to efficiently pump blood of the heart, resulting in contractile dysfunction, 
ventricular dilation, and heart failure [115]. Heart failure at the initial stage is compensatory since 
cardiomyocytes are able to beat faster and squeeze harder to compensate for both stroke volume 
and heart rate to restore the loss of blood supply. However, chronic hemodynamic overload with 
more demand of oxygen lets the cardiomyocytes die off, causing worsening heart failure with a 
vicious cycle, and this stage of heart failure is decompensatory [116]. During this vicious cycle, 
Ang II is continuously released and reaches a relatively higher level in both plasma and heart, 
resulting in severer symptoms of heart failure. The major difference between compensatory and 
decompensatory cardiac hypertrophy is that the former has no significant heart failure symptoms. 
However, as time goes by, the benefits of the initial compensatory cardiac hypertrophy progress 
into decompensatory stage, suggesting the process of cardiac remodeling either lose the 
effectiveness in a concerted manner or reaches the threshold that is detrimental to normal heart 
function [117]. 
The intracellular mechanisms in decompensatory cardiac hypertrophy are quite complex 
and intertwined besides those involved in compensatory cardiac hypertrophy. Generally speaking, 
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the initiation of the signaling usually occurs at the cellular membrane, and the ligand could be 
catecholamines, ET-1, Ang II and IGF-I, interacting with G-protein-coupled receptors (GPCR) 
and generates DAG and PIP3. Meanwhile, receptors of tyrosine kinase or with Ser/Thr domains 
are also regarded as mediators. Internal stretch-sensitive receptors are activated when 
hemodynamic overload is encountered. Essential mediators of cardiac hypertrophy could stem 
from cytoplasmic signaling pathways such as ERK/MAPK, calcineurin-NFAT and IGF-
I/PI3K/Akt/mTOR, nuclear transcription factors such as CDK7 and CDK9, or from HDACs 
shuttling regulated by kinase [13]. Finally, those receptors converge on a limited number of 
intercellular signal-transduction circuits and regulate cardiac growth via gene expression change, 
accelerating the translation & synthesis rate and decelerating the degradation speed of cytoplasmic 
protein. Those above-mentioned components are discovered in physiological cardiac hypertrophy 
with an adaptive manner. However, excessive extracellular stimuli like Ang II, TNF-α and 
catecholamines are associated with c-Jun, N-terminal kinase and p38 as essential upstream 
activators to induce fibrosis and apoptosis in cardiomyocytes which are only present during 
exercise-induced pathological hypertrophy [118]. Of note, mitochondria plays a crucial role in 
Ang II-induced decompensatory cardiac hypertrophy and heart failure: in physiological 
hypertrophy, mitochondrial biogenesis is enhanced with mitochondrial oxidative capacity, 
facilitating oxygen consumption, ATP generation and antioxidant defense. However, in 
pathological cardiac hypertrophy and decompensatory heart failure, disturbance of signaling 
pathways occur and lead to mitochondrial dysfunction with decreased mitochondrial biogenesis, 
oxidative capacity, and mitochondrial DNA transcription, resulting in impaired oxygen 
consumption, ATP generation, antioxidant defense and mitochondrial biogenesis, along with 
elevated fatty acid uptake and lipotoxicity [119]. In this process, constitutive activation of Akt 
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might suppress normal mitochondrial function and induce ROS accumulation due to excessive 
oxidative stress although Akt activation is present in physiological cardiac hypertrophy [120]. 
5.2. Role of Ang II in cardiac remodeling 
Cardiac remodeling, including cardiac hypertrophy, perivascular fibrosis, apoptosis and 
changes in metabolism, is the direct source of heart failure. Ang II is one of those major effector 
hormones in renin-angiotensin-aldosterone-system (RAAS), interacting with various AT receptors 
in both central and peripheral cardio-regulatory regions. As a peptide product of RAAS, Ang II 
plays a crucial role in cardiovascular physiology and pathology and causes pressor effect via 
vasoconstriction, resulting in deleterious sequelae like cardiac and vascular hypertrophy or renal 
dysfunction. Nevertheless, we cannot easily distinguish the mechanisms of Ang II in cardiac 
hypertrophy. In general, this peptide elevates the overall cardiac workload by its vascular-
constricting effect, and cardiac hypertrophy is secondary to cardiac hemodynamic overload. 
However, recently researchers found that Ang II also directly stimulates the growth of 
cardiomyocytes including the acceleration of transmission speed of sympathetic nerves, 
enhancement of cardiac contractility, and initiation of cardiac structural remodeling [19]. This 
viewpoint was verified through investigation of heart explants in heart failure patients [121]. Thus, 
a shortcoming in the determination of in vivo effects of Ang II is that this peptide exerts both 
growth-promoting effects to the cardiomyocytes and generalized elevations in hemodynamic 
workload. So it’s obliged for us to figure out the possible intracellular mechanisms of cardiac 
remodeling induced by direct Ang II exposure.  
In this project, we have overcome this shortcoming through two approaches: 1. We adopted 
primary cardiomyocytes culture in our in vitro experiment. The physiological parameters such as 
blood pressure, heart rate and cardiac contractility are totally absent, facilitating the investigation 
of direct effect of Ang II on cardiomyocytes without any generalized influence. 2. We used 
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selective inactivation of Class I PI3-kinase in the heart by cardiac transfer of Lv-DNp85. The 
application of Lv-DNp85 together with subcutaneous Ang II infusion did not attenuate the blood 
pressure elevation, enabling us to rule out the peripheral impacts of Ang II on cardiac remodeling 
since hemodynamic workload in both Ang II + Lv-DNp85 group and Ang II + Lv-GFP group 
remain comparable. Thus, the general systemic effect of Ang II chronic administration as 
hemodynamic overload still exists, meanwhile, the circulating Ang II level remains stable. Thus, 
our approach first manifests the in vivo targeting of Ang II as a biological active peptide in a heart-
specific manner, and distinguishes the impact of Ang II on the heart between local (direct) and 
systemic (indirect). Therefore, congestive heart failure rat models were successfully established 
by using chronic subcutaneous Ang II infusion for four weeks. Cardiac function was determined 
by cannulation of cardiac catheter inserted through the left carotid artery. Results indicated the 
heart weight and body weight ratio was significantly elevated in Ang II vs. Saline rats in Lv-GFP 
group, suggesting the occurrence of cardiac hypertrophy. It is also observed dP/dt Max were 
dramatically diminished in Ang II+ Lv-GFP rats when compared with Saline+ Lv-GFP rats, 
indicating chronic infusion of Ang II induces severe left ventricular dysfunction which has a 
positive relationship with cardiac hypertrophy as one of those forms of cardiac remodeling. 
The normal physiological concentration of plasma Ang II in mammals is about 0.5 nM, 
while in the pathological states such as heart failure, stroke and myocardial infarction, the scale of 
plasma Ang II concentration elevation would be up to ~200 fold [102, 118]. This process might 
take place in a chronical manner within several months or even years. To shorten the study duration 
and eliminate the internal physiological modulation that exists in the in vivo experiments, primary 
culture of cardiomyocytes were adopted and 24-hour Ang II treatment with different 
concentrations with a ten-fold gradient was carried out. These in vitro experiments show quick 
outcomes and give us a reliable vision of the dose-dependent effect of Ang II. Our dose-dependent 
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effect of 24-hour treatment of Ang II caused significant elevations of ROS generation and cardiac 
hypertrophy in cultured cardiomyocytes when the concentration of Ang II was above 10-7 M, and 
cardiomyocytes began to die with abnormal and deformed nuclei above this Ang II concentration 
(data not shown). Therefore, 10-7 M Ang II is regarded as the watershed of the higher and lower 
Ang II concentration in our in vitro experiments. Lower concentration of Ang II such as 10-8 M 
didn’t present significant ROS generation and cardiac hypertrophy in primary cardiomyocytes, 
while higher concentration of Ang II such as 10-6 M prominently caused notable ROS generation 
and cardiac hypertrophy. 
It is universally recognized that ROS generation plays an essential role in Ang II-induced 
cardiac remodeling. To confirm the possible involvement of elevated ROS generation in Ang II-
induced cardiac remodeling, we performed both in vitro and in vivo experiments. After treatment 
of primary cardiomyocytes for 24 hours or adult rats for 4 weeks with Ang II, relevant 
pathophysiological parameters were measured to prove the effect of Ang II on cardiac remodeling. 
Our morphological analysis of both primary cardiomyocytes and adult rat heart slices confirmed 
cellular size enlargement after chronic Ang II exposure. In addition, we noticed elevated ROS 
generation along with enhanced degree of cardiac remodeling in both in vitro and in vivo 
experiments, suggesting elevated ROS generation as one of those intracellular mechanisms might 
contribute to cardiac remodeling. 
It is universally accepted that Ang II-stimulated ROS generation majorly stems from 
activation of NADPH oxidase by phosphorylation via MAPK or PI3-kinase. Nevertheless, our lab 
has recently identified that both protection of mitochondria from injury and scavenging excessive 
ROS generation derived from damaged mitochondria are two effective ways to alleviate Ang II-
induced cardiac remodeling [79]. Other report also excludes the involvement of NADPH oxidase 
in Ang II-induced ROS generation since elimination of gp91phox, an essential part inside NADPH 
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oxidase, did not efficiently prevent hypertension and cardiac hypertrophy in transgenic mice 
overexpressing active renin [72]. Thus, damaged mitochondria accumulation is proposed as 
another source of ROS generation in cardiomyocytes, and this hypothesis is supported as the 
mitochondrial ROS scavenger Mito-TEMPO remarkably attenuated Ang II-induced ROS 
generation and cardiac hypertrophy. Those pieces of evidence prove ROS generation derived from 
damaged mitochondria is the major source in chronic Ang II-induced cardiac remodeling. Despite 
the viewpoint that mitochondria-derived ROS generation come mainly from mitochondrial 
respiratory chain, we cannot completely rule out the potential contribution of ROS generation from 
other cytosolic sources like xanthine oxidase (XO) and NADPH oxidase (NOX). 
5.3. Autophagic alterations in Ang II-induced cardiac remodeling 
From the previous information, we found that Ang II-induced ROS generation in 
cardiomyocytes mainly comes from the accumulation of damaged mitochondria, and elimination 
of the ROS generation by mito-TEMPO as a mitochondria-derived ROS scavenger almost 
abolished the Ang II-induced ROS generation in primary cardiomyocytes. Mitochondria serve as 
both sources and attacking targets for ROS. Once the damaged mitochondria get accumulated and 
failed to be efficiently degraded, a vicious cycle takes place: the ROS generation from damaged 
mitochondria further do harm to healthy mitochondria, producing aggravated ROS generation as 
a positive feedback cascade. Gradually, the whole heart tissue are affected and continuous 
enhancement of ROS generation eventually causes cardiac remodeling. 
To combat the accumulation of the damaged mitochondria and maintain cellular 
hemostasis, there should be at least one intracellular mechanism to wipe out those damaged 
mitochondria. Thus, autophagy has just come into our mind. Autophagy, known as the process of 
as self-digestion, refers to the intracellular recycling and degrading aged and damaged organelles 
and proteins to keep a homeostatic intracellular environment. Abnormal regulation of autophagy 
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in cardiovascular system results in various heart diseases. Thus, our subsequent focus is to study 
the alteration of autophagy in Ang II-induced cardiac remodeling in both in vitro and in vivo 
models. We detected autophagy in cardiomyocytes in our in vitro experiments with 
immunocytochemistry in primary cardiomyocytes and in our in vivo experiments with western blot 
in adult rat heart tissues. 
In our in vitro study of Ang II-induced autophagy in cardiomyocytes, the initial phase of 
autophagic elevation (beginning from 10-9 M and peaking at 10-7 M Ang II) represents the 
compensatory stage of cardiac hypertrophy, where enhanced autophagy enables the degradation 
of redundant proteins; while the subsequent phase of autophagic impairment under higher Ang II 
dosage (exceeding 10-7 M and reached nadir at 10-5 M Ang II) represents the decompensatory stage 
of cardiac hypertrophy, where excessive protein synthesis occur due to higher dosage of Ang II 
stimulation and insufficient autophagy, leading to heart failure. This initial rising and subsequent 
falling degree of autophagy under different concentration of Ang II exposure was also reported in 
the HL-1 cardiomyocyte cell lines. Unfavorable condition such as hypoxia in HL-1 cardiomyocyte 
cell lines also showed the same autophagic alteration trend at different hypoxia durations [78]. The 
plausible explanation of this event is that primary cardiomyocytes swift from initial compensatory 
state under lower dosage of Ang II to the final decompensatory state under lower dosage of Ang 
II. The cardiomyocytes respond very early after exposure to tissue injury mediators, while 
continuous hazardous stimuli may make the primary cardiomyocyte exhaust their endogenous 
defense, and the continuous ROS generation simulates the protein synthesis and cellular damage, 
eventually manifesting cardiac hypertrophy. It’s also observed that 10-5 M Ang II-induced 
autophagy is still higher than the basal level, and the plausible explanation may be that the injury 
caused by autophagy from cellular level extends to subsequent tissue damage [78].  
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Although similar autophagic degree was observed between 10-5 M & 10-9 M Ang II or 
between 10-6 M & 10-8 M Ang II in our in vitro results in cardiomyocytes, the amount of Ang II-
induced accumulation of damaged mitochondria (degree of ROS generation) and the speed of Ang 
II-induced protein synthesis (degree of cardiac hypertrophy) in cardiomyocytes are totally different 
between those higher and lower Ang II concentrations (higher Ang II concentration causes 
elevated accumulation of damaged mitochondria and accelerates the speed of protein synthesis). 
Therefore, it’s prudent to conclude a shift of the cardiomyocytes from compensation to 
decompensation when the concentration of Ang II is above 10-7 M according to the dose-dependent 
result of Ang II on ROS generation and cardiac hypertrophy in cardiomyocytes (data not shown). 
10-8 M Ang II exposure is an example of compensation heart since no significant ROS generation 
and cardiac hypertrophy happen in this Ang II concentration, while  10-6 M Ang II is an example 
of decompensation heart for significant ROS generation and cardiac hypertrophy take place. 
Nowadays, ROS generation are considered not only as one of potential toxic origins under 
various hazardous stimulations, but also as constituent components of signaling transduction 
pathways at physiological levels. Thus, it is believed excessive intracellular ROS might activate 
autophagy, and scavenging of the ROS in cardiomyocytes by antioxidants reduces overt toxicity 
as well as inhibit autophagy induced by chronic Ang II exposure. From our results, we observed 
the usage of mito-TEMPO (mitochondria-derived ROS scavenger) almost abolished autophagic 
increment. Furthermore, Ang II-induced ROS generation and cardiac hypertrophy were alleviated 
by mito-TEMPO in cardiomyocytes. All those factors prove that ROS generation from damaged 
mitochondria is the major source in Ang II-induced cardiac remodeling. 
To further consolidate the role of autophagy in Ang II-induced cardiac remodeling, 
autophagic blockers of Bafilomycin A1 (Baf A1) or Chloroquine Phosphate (CQ) can be used in 
primary cardiomyocytes to directly block Ang II-induced autophagy. Baf A1 inhibits the fusion of 
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autophagosome with lysosome, obstructing the formation of autolysosome as the final step of 
autophagy [122]. The alkaline characteristic of CQ enables the neutralization of the acidic 
environment in the lysosomes and autolysosomes [123]. We then assume combined usage of 
autophagic inhibitors with Ang II would exacerbate Ang II-induced ROS generation and cardiac 
hypertrophy, suggesting impaired autophagy contributes to the cardiac remodeling under 
hazardous stimuli.  
As for the in vivo experiments, we also determined autophagic alterations in the heart tissue 
after chronic Ang II subcutaneous infusion. Autophagic impairment was observed as decreased 
LC3-II/LC3-I ratio in Ang II+ Lv-GFP group when compared with Saline+ Lv-GFP group by 
means of western blot technique. Interpretations of the discrepancy between in vitro and in vivo 
studies are not definitely elucidated, but may be due to the different test sample origins as neonatal 
primary cardiomyocytes and adult rat heart tissues. Also, distinct PI3-kinases may be involved at 
different stages of Ang II-induced cardiac remodeling, and the duration of Ang II administration 
is also different in our in vitro neonatal primary cardiomyocytes (24 hours) and in vivo adult rat 
heart tissues (4 weeks) experiments. Taken together with our in vitro and in vivo results of 
autophagic alteration, we conclude that autophagy is enhanced in the initial exposure or lower 
dosage of Ang II, while prolonged exposure or higher dosage of Ang II causes autophagic 
impairment. Autophagic impairment severely aggravate cardiac conditions of pressure overload 
or ischemia-reperfusion, and targeting at the intracellular signaling pathways of Ang II-induced 
autophagic impairment in the heart might be an effective approach to protect heart from stress-
induced damage. 
5.4. PI3-kinases-dependent autophagic alterations in Ang II-induced cardiac remodeling 
After determination and interpretation of Ang II-induced autophagic alteration, our next 
aim is to find out the underlying intracellular mechanisms that cause such autophagic alterations 
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in cardiomyocytes. Judging by the information illustrated above, one of those effective approaches 
to keep cardiomyocytes from Ang II-induced cardiac remodeling is mitochondria protection via 
scavenging ROS generation by enhancing mitophagy. This is a novel strategy to relief cardiac 
hypertrophy and relevant secondary pathological complications. In our in vitro study, we noticed 
the degree of autophagy in primary cardiomyocytes has a dose-dependent relationship with Ang 
II concentration. Previous studies showed the role of PI3-kinases in the enhanced chronotropic 
effect of Ang II in neurons [81] and targeted overexpression of Class I PI3-kinase resulted in 
cardiac hypertrophy in transgenic mice [62], so we hypothesize PI3-kinases might be responsible 
for Ang II-induced autophagic alterations in cardiomyocytes. 
One of those intracellular downstream components of PI3-kinases Class I that might be 
activated by membrane-translocated PIP3 formation is Protein kinase B (Akt) [124]. Akt has a 
central serine/threonine (Ser/Thr) catalytic domain with three isoforms as AKT1, AKT2 and AKT3 
which could be stimulated by PIP3-induced phosphorylation via conformational alterations [125]. 
Once phosphorylation and activation of Akt are completed, several downstream components such 
as GLUT (glucose transporter), GSK (glycogen synthase kinase)-3, FOXOs (the forkhead family 
of transcription factors) and mTOR (mammalian target of rapamycin) [126] are further activated. 
Among those downstream components activated by Akt, mTOR is the most worthwhile to be 
further elucidated. It is known mTOR is one of the direct downstream targets of Akt, and plays 
essential roles in cellular growth and proliferation by supervising whether nutrients are available 
or enough, the cell is in an environment of appropriate energy and oxygen levels in case, and 
whether mitogenic signals are present [127]. For mTOR, it is a 289kDa kinase with two discrete 
complexes named as mTORC1 (mTOR catalytic subunit, Raptor, PRAS40, and mLST8/GbL) and 
mTORC2 (mTOR, Rictor, mSIN1, and mLST8/GbL) [128], and this kinase has an evolutionary-
conserved Ser/Thr which could be activated by multiple factors. Activation of mTOR prevents 
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autophagy, and rapamycin, a specific inhibitor of mTOR, is a strong autophagic inducer [129]. 
mTOR is a sensitive biomolecular sensor and it regulates biogenesis based on the amount of 
available nutrients through activation of p70S6K by enhancing mRNA translation with 5'-
polypyrimidine tracts and suppressing the translational repressor of mRNAs with a 5’-cap named 
4E-BP1 [130]. 
We sought to investigate the possible involvement of PI3-kinases in Ang II-induced cardiac 
remodeling via autophagic-dependent mechanisms. By measuring PIP3 and PIP production as the 
respective final product of Class I and Class III PI3-kinase, we identified Ang II administration 
caused stronger activities of Class I and Class III PI3-kinases in primary cardiomyocytes. As for 
our in vivo study, it is also found that four weeks’ chronic Ang II administration caused hyper-
activity in Class I PI3-kinase, resulting in elevated PIP3 production as the final product. Results 
also indicated the activity of Class III PI3-kinase reached the plateau at lower Ang II concentration 
(10-7 M) than that of Class I PI3-kinase (10-5 M Ang II), suggesting the Class III PI3-kinase is 
earlier saturated in the dosage-activity response than Class I PI3-kinase via Ang II stimulation. 
As mentioned before, only Class I and Class III PI3-kinases are expressed in the heart [131] 
and activation of those two PI3-kinases presents contradictory effects on autophagy: activation of 
Class I PI3-kinase pathway with major components of Class I PI3-kinase→Akt 
→mTOR→GSK→S6K→FOXO3 suppresses autophagy [132], while Class III PI3-kinase 
pathway activation with the relevant components of PI3-K Class III→Beclin-I→Vps34 facilitates 
autophagy [88]. Under Ang II stimulation, autophagy initially increased and reached its peak under 
10-7 M Ang II, suggesting the major activation of Class III PI3-kinase. However, exposure of 
higher concentration of Ang II diminished autophagy and autophagy achieved the nadir at 10-5 M 
Ang II, suggesting the subsequent activation of Class I PI3-kinase and the saturated activation of 
Class III PI3-kinase. Those results correspond with the trend of autophagic result in HL-1 
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cardiomyocyte cell line under 24 hours of Ang II exposure with varied concentrations [78] and 
support our initial hypothesis that under lower concentrations of Ang II exposure, only Class III 
PI3-kinase is activated and autophagy is enhanced, while under higher concentration of Ang II 
exposure, both Class I and Class III PI3-kinase are activated, resulting in impaired autophagy. 
Thus, we have enough confidence to draw the conclusion that Class I and Class III PI3-kinases are 
both involved in autophagic regulatory, while small amount stimulation of harmful simulations 
like Ang II, lectin, hypoxia, and carbon monoxide might be beneficial to initiate tissue protective 
mechanisms [133]. From our results, we knew that both Class III and Class I PI3-kinases in 
cardiomyocytes were significantly activated by 10-6 M Ang II. Furthermore, most of the 
cardiomyocytes still remain alive at this 10-6 M Ang II concentration while large quantities of 
cardiomyocytes began to die out under 10-5 M Ang II exposure. Therefore, 10-6 M Ang II is chosen 
in our subsequent in vitro experiments since it mimics the decompensatory heart while this Ang II 
concentration still keeps the majority of cultured cardiomyocytes alive. Furthermore, we don’t 
need to detect the presence of Class I and Class III PI3-kinases additionally in cardiomyocytes by 
means of immunohistochemistry or polymerase chain reaction (PCR) since they are ubiquitously 
present in almost every type of eukaryotic cells. 
To further confirm the involvement of Class I and Class III PI3-kinases in Ang II-induced 
autophagic alteration in cardiomyocytes under 10-6 M Ang II exposure, we used certain approaches 
to inhibit those two kinases respectively or jointly. Akt and mTOR are two consecutive 
downstream signaling kinases in Class I PI3-kinase mediated signaling pathways in the 
physiological system. Protein abundance determination by western blot indicated treatment of Ang 
II significantly increased the ratio of p-Akt/total Akt and p-mTOR/total mTOR, suggesting the 
activation of Akt and mTOR by phosphorylation under Ang II. Combined usage of Ang II with 
LY-294002, an inhibitor Class I PI3-kinase in vitro, or with Lv-DNp85, a lenti-viral vector to 
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inhibit the Class I PI3-kinase in vivo resulted in considerable decrease in Ang II-induced PIP3 
production as well as p-Akt/total Akt and p-mTOR/total mTOR ratio, suggesting blockade of Class 
I PI3-kinase attenuated the effect of Ang II-induced autophagic impairment via inhibiting 
phosphorylation of Akt and mTOR, two essential downstream components of Class I PI3-kinase. 
Then we found pretreatment of 1 μM LY-294,002 under 10-6 M Ang II exposure elevated 
autophagy, attenuated ROS generation, and cardiac hypertrophy, so we are able to draw the 
conclusion that the activation of Class I PI3-kinase stimulates the mTOR component and reduces 
autophagy [135]. For the in vivo study, we used cardiac transfer of Lv-DNp85 protein to inactivate 
the Class I PI3-kinase, and similar results were observed as restored autophagy, attenuated ROS 
generation, cardiac hypertrophy and fibrosis as well as ameliorated cardiac functions in Ang 
II+Lv-DNp85 group when compared with Ang II+ Lv-GFP group. 
When it comes to the possible cross-inhibition effect of LY-294002 on Class III PI3-kinase 
and 3-MA on Class I PI3-kinase, preliminary experiments of the dose-dependent effect of those 
two reagents on Class I and Class III PI3-kinases were carried out to seek their appropriate 
concentrations as to minimize their cross-inhibition effect. The IC50 value of LY-294002 on Class 
I and Class III PI3-kinase is 0.51 μM and over 50 μM respectively [135]. Meanwhile, the IC50 
value of 3-MA on Class I and Class III PI3-kinase is 0.76 μM and over 100 μM respectively [64]. 
Therefore, the concentration of 1 μM LY-294002 or 3-MA was chosen to inhibit Class I and Class 
III PI3-kinase activity with a minimal interreference of inhibition to each other. In our preliminary 
results, the effects of cross-inhibition of 1 μM LY-294002 on Ang II-induced Class III PI3-kinase 
by measuring PIP production and 1 μM 3-MA on Ang II-induced Class I PI3-kinase by measuring 
PIP3 production are both less than 10 % (data not shown), indicating sufficient targeting specificity 
of LY-294002 on Class I PI3-kinase activity and 3-MA on Class III PI3-kinase activity at 1 μM 
concentration. 
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Moreover, straight inhibition of mTOR by rapamycin as an autophagic inducer showed 
remarkable attenuation of Ang II-induced ROS generation and cardiac hypertrophy in our in vitro 
study. Thus, we validated that Ang II-induced cardiac remodeling is mediated by Class I PI3-
kinase/Akt/mTOR signaling transduction pathway. Subsequent usage of different angiotensin II 
antagonists further verified this activation of Class I PI3-kinase-Akt-mTOR signaling transduction 
pathway is mediated through AT1R on the surface membrane of cardiomyocytes. 
On the other hand, Vps34 complex is essential for the autophagosomes formation due to 
its facilitation of the pre-autophagosomal structure establishment by recruiting autophagy-related 
(Atg) protein [136] and 3-MA, a blocker of Vps34 component in the Class III PI3-kinase pathway 
[137], reduces the degree of autophagy. The result that pretreatment of 1 μM 3-MA in 
cardiomyocytes under 10-6 M Ang II exposure diminished autophagy, exacerbated ROS generation, 
elevated cardiac hypertrophy further proves our hypothesis that activation of Class III PI3-kinase 
pathway facilitates the occurrence of autophagy under both lower and higher concentration of Ang 
II exposure.   
 110 
CHAPTER VI. CONCLUSION AND FUTURE DIRECTIONS 
6.1. Overall conclusions 
In the present study, we determined the effects of Ang II and its impact on the Class I and 
Class III PI3-kinases and further elucidated the signaling mechanisms underlying those actions of 
Ang II-induced cardiac remodeling using in vitro and in vivo SD rat models. The overall 
conclusions from the in vivo and in vitro studies are summarized as Figure 38: 
 
Figure 38: Diagram summarizing proposed Ang II-induced PI3-kinase-dependent pathways 
activation in cardiomyocytes. 
Taken together, all results indicate that both Class I and Class III PI3-kinases play essential 
roles in Ang II-induced cardiac remodeling. Activation of Class III PI3-kinase under lower dosage 
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of Ang II facilitates autophagy, representing the compensatory period of cardiac hypertrophy. 
Nevertheless, when the dosage of Ang II goes higher and the exposure duration is longer, Class I 
PI3-kinase is activated and the downstream component of Akt and mTOR are stimulated. 
Stimulation of mTOR inhibits autophagy, causes accumulation of damaged mitochondria and 
generates higher level of ROS. The enhanced ROS generation triggers several intracellular kinases 
and transcription factors, promoting protein synthesis and cardiac remodeling, which represents 
the decompensatory period of cardiac remodeling. 
6.1.1. In vitro studies on primary cardiomyocytes of neonatal SD rats 
1. Lower dosage Ang II increases autophagy while higher dosage Ang II decreases 
autophagy with two distinctive phases, while the degree of autophagy at the highest Ang II 
concentration of 10-5 M is still higher than basal level of autophagy. 
2. Ang II stimulation activates Class III PI3-kinase at lower dosage, and there is a shit 
activation of PI3-kinases from Class III to Class I at higher dosage Ang II. Smaller Ang II 
concentration saturates Class III PI3-kinase than that of Class I PI3-kinase. Detection of 
phosphorylation of Akt as the downstream component of Class I PI3-kinase by measuring p-
Akt/total Akt ratio also verifies dose-dependent relationship between Ang II and Class I PI3-kinase. 
3. Pretreatment of LY-294002 to inhibit Class I PI3-kinase greatly restores Ang II-induced 
autophagic impairment, and attenuates Ang II-induced Class I PI3-kinase activation, ROS 
generation, cardiac hypertrophy. 
4. Inhibition Class III PI3-kinase by pretreatment of 3-MA remarkably impairs Ang II-
induced autophagy and Class III PI3-kinase activity, and exacerbates Ang II-induced ROS 
generation and cardiac hypertrophy. 
 112 
5. Pretreatment of AT1R antagonist Losartan greatly diminishes Ang II-induced elevation 
of Class I & Class III PI3-kinase activities, autophagy, ROS generation and cardiac hypertrophy, 
while AT2R antagonist PD123319 does not show such effects. 
6. Pretreatment of mito-TEMPO as a mitochondrial-derived ROS scavenger considerably 
attenuates Ang II-induced autophagy, ROS generation and cardiac hypertrophy. 
7. Pretreatment of mTOR inhibitor of rapamycin as an autophagic inducer considerably 
attenuates Ang II-induced ROS generation and cardiac hypertrophy. 
6.1.2. In vivo study on adult SD rat hearts 
1. Lv-GFP is successfully delivered into the adult rat hearts as immunofluorescence show 
the overlap of GFP protein and α-actin. 
2. Cardiac transfer of Lv-DNp85 is successful, and this transfer greatly attenuates Ang II-
induced Class I PI3-kinase activity, ROS generation, cardiac hypertrophy, perivascular fibrosis 
and remarkably ameliorates Ang II-induced cardiac dysfunction in spite of the presence of Ang II-
induced hypertension. 
3. Cardiac delivery of Lv-DNp85 remarkably diminishes Ang II-induced increment of p-
Akt/total Akt and p-mTOR/total mTOR ratio, and considerably restores Ang II-induced 
autophagic impairment. 
To summarize, all results indicate that PI3-kinases play a crucial role in the progression of 
Ang II-induced cardiac remodeling. Activation of distinct types of PI3-kinases might be involved 
depending on the concentration and duration of Ang II exposure, leading to the shift of cardiac 
hypertrophy from compensatory stage to decompensatory stage, resulting in congestive heart 
failure. 
 113 
6.2. Future research directions 
These studies were primarily based on the use of pharmacological reagents to regulate the 
activity of PI3-kinases and their relevant downstream effectors via an autophagic-dependent 
mechanism, and we ought to be very prudent in data interpretation. In our in vivo study, we used 
Lv-DNp85 to inactivate Class I PI3-kinase, but due to the huge expense and limited time span of 
lenti-viral vector construction, we haven’t conducted Class III PI3-kinase inactivation in adult rat 
hearts. Thus, it would be more perfect to perform another cardiac transfer of Lv-DNVps34 to block 
the Class III PI3-kinase in the rat heart since this viral vector has already been delivered into 
neuroblastoma cells [100]. Also, cardiac transfer of Lv-Vps34 might also be used to exogenously 
activate Class III PI3-kinase via overexpression of Vps34 subunit in adult rat hearts and we can 
further confirm the protective roles of this kinase at the initial stage of Ang II-induced cardiac 
hypertrophy. Furthermore, we can seek the possible relationship between AT2R and Class III PI3-
kinase since they are the cascade components of intracellular signal transduction and both of them 
show protective effects to prevent cardiomyocytes from cardiac hypertrophy. Further, other similar 
treatments of hazardous stimuli such as hypoxia and/or norepinephrine might be adopted to 
cardiomyocytes at different exposure durations or concentrations to learn the impact on autophagy 
and cardiac remodeling. Recently our lab has conducted a series of researches of mitochondrial 
ROS-dependent mechanism on Ang II or 20-HETE-induced cardiac remodeling and apoptosis [79, 
138]. Therefore, this is a brand-new area to investigate Ang II-induced mitochondrial autophagy 
and morphological alterations via determination of mitochondrial membrane potential by JC1-
staining and mitophagy by Parkin staining. When it comes to both in vitro and in vivo autophagic 
measurement, it is inevitable to draw prejudiced judgements since only MAP-LC3 antibody 
detection is used. In order to gain a more thorough view, alternative autophagic detection 
approaches such as GFP-LC3 viral vector insertion, electron microscopy (EM), acridine orange 
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(AO) and monodansylcadaverine (MDC) fluorescence staining might also be employed to monitor 
the whole process of autophagy. 
Moreover, there are three major types of autophagy with varied modes of cargo delivery 
into lysosomes: 1) Macroautophagy: this type of autophagy is the most universal, essential and 
absolutely the best-investigated type with preferable competence (hereafter termed as autophagy) 
which is launched by membrane circling target proteins, organelles with desirable capacity to 
establish autophagosomes [40]. 2) Microautophagy: it is the process of straight extension and/or 
invagination of the limiting lysosomal/vacuole membranes to entrap the damaged proteins or 
organelles, and those substrates are directly segregated [61]. 3) Chaperone-mediated autophagy 
(CMA): the chaperone protein HSC70 is capable to identify the proteins with a unanimous 
sequence of KFERQ and engulf the proteins in succession to the LAMP-2A (lysosome-associated 
membrane protein 2A) receptor to convey those proteins into lysosomes for degradation. This type 
of autophagy is quite unique in mammalian cells via investigation of the protein co-incubated with 
isolated lysosomes or with chaperone, or lysosomal receptor with genetic modifications, while the 
other two types of autophagy could occur both in eukaryotes and yeasts [139]. Thus, we may 
further investigate which type(s) of autophagy is (are) involved in Ang II-induced cardiac 
remodeling by relevant approaches. 
6.3. Clinical significance 
This is the first study to demonstrate the possible involvement of cardiac Class I and Class 
III PI3-kinases that present contradictory roles in autophagic regulation at different stages of Ang 
II-induced cardiac remodeling and subsequent pathophysiology conditions of CHF from 
compensatory to decompensatory. Regarding the astonishing statistics for the worldwide 
prevalence for heart failure, novel targets need to be explored which could substitute or at least 
ameliorate the existing major therapeutic strategies of HF such as diuretics, inotropic agents, ACE 
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inhibitors and AT1R antagonists. This study showed targeting the cardiac PI3-kinases system by 
developing pharmacological agents or gene therapy in the patient with HF may attenuate the 
pathophysiological condition with beneficial compliance. Hence, future research should be carried 
out in developing targeting agents against PI3-kinases and mitochondrial ROS generation. 
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